var title_f28_57_29584="Megameatus intact prepuce";
var content_f28_57_29584=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Megameatus intact prepuce",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 390px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Megameatus intact prepuce is a hypospadias variant with a normal foreskin. After circumcision, the abnormal large urethral meatus at the coronal margin is apparent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Laurence Baskin.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_57_29584=[""].join("\n");
var outline_f28_57_29584=null;
var title_f28_57_29585="Med bronchogen cyst CXR IV";
var content_f28_57_29585=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Paratracheal bronchogenic cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph shows a right paratracheal mass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_57_29585=[""].join("\n");
var outline_f28_57_29585=null;
var title_f28_57_29586="Patient information: Epinephrine auto-injectors (The Basics)";
var content_f28_57_29586=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15917\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/41/7824\">",
"         Hives",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/44/11975\">",
"          Using an epinephrine auto-injector",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?32/30/33250\">",
"         Patient information: Anaphylaxis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/27/35250\">",
"         Patient information: Food allergy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/51/15155\">",
"         Patient information: Insect bites and stings (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/35/17971\">",
"         Patient information: Peanut allergy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?14/57/15250\">",
"         Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/14/41186\">",
"         Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/30/28134\">",
"         Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Epinephrine auto-injectors (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/epinephrine-auto-injectors-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H20996315\">",
"      <span class=\"h1\">",
"       What is an epinephrine auto-injector?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An epinephrine auto-injector is a device that gives a person a shot of a medicine called &ldquo;epinephrine.&rdquo; Epinephrine is used to treat a severe allergic reaction, also called &ldquo;anaphylaxis.&rdquo; A severe allergic reaction can happen after a person eats a food, takes a medicine, or is stung by an insect that he or she is allergic to.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20996322\">",
"      <span class=\"h1\">",
"       What are the symptoms of an allergic reaction?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms of an allergic reaction can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Hives &ndash; These are raised, red patches of skin that are very itchy (",
"        <a class=\"graphic graphic_picture graphicRef79242 \" href=\"UTD.htm?7/41/7824\">",
"         picture 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Puffiness of the face, eyelids, ears, mouth, hands, or feet",
"       </li>",
"       <li>",
"        Redness or itching of the skin (without hives)",
"       </li>",
"       <li>",
"        Runny nose or swelling of the tongue",
"       </li>",
"       <li>",
"        Wheezing or trouble breathing",
"       </li>",
"       <li>",
"        Vomiting or diarrhea",
"       </li>",
"       <li>",
"        Feeling dizzy or passing out",
"       </li>",
"       <li>",
"        Death (although this is rare)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20996329\">",
"      <span class=\"h1\">",
"       When should I use my epinephrine auto-injector?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse will tell you when you should use your auto-injector. Most doctors recommend that you use one right away when you have an allergic reaction and:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have trouble breathing or feel like your throat is tight",
"       </li>",
"       <li>",
"        Feel dizzy or like you are going to pass out",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your doctor prescribed an auto-injector for your child, use it right away when your child has an allergic reaction and:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Seems groggy or passes out",
"       </li>",
"       <li>",
"        Vomits a lot",
"       </li>",
"       <li>",
"        Coughs a lot",
"       </li>",
"       <li>",
"        Has hives all over his or her body",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Most doctors also recommend that you use an auto-injector right away if you or your child eats a food that caused a severe allergic reaction in the past.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20996336\">",
"      <span class=\"h1\">",
"       How do I use an epinephrine auto-injector?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your auto-injector will have directions that come with it. In general, you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Take the auto-injector out of its case",
"       </li>",
"       <li>",
"        Hold the auto-injector in your fist, making sure that your fingers aren&rsquo;t over either end",
"       </li>",
"       <li>",
"        Take off the safety cap or caps",
"       </li>",
"       <li>",
"        Press the tip firmly into the outer thigh &ndash; The needle in the auto-injector can go through clothes (",
"        <a class=\"graphic graphic_picture graphicRef75436 \" href=\"UTD.htm?11/44/11975\">",
"         picture 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Hold it in place and count to 10",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      After you use an auto-injector, call 9-1-1 or go to the hospital, because your symptoms can come back as the medicine wears off. In the hospital, doctors can give you other medicines and make sure that your symptoms don&rsquo;t return.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20996343\">",
"      <span class=\"h1\">",
"       What if the auto-injector doesn&rsquo;t stop my symptoms?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The medicine in the auto-injector should stop your symptoms within a few minutes. But if your symptoms don&rsquo;t improve, get worse, or return before you reach the hospital, you will need another dose.",
"     </p>",
"     <p>",
"      Some auto-injectors have 2 doses of medicine in them, but others have only 1 dose. If your auto-injector has only 1 dose of medicine, you will need to use a second auto-injector.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20996350\">",
"      <span class=\"h1\">",
"       Where should I keep my auto-injector?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Keep your auto-injector at room temperature &mdash; and not in places that get too hot or cold.",
"     </p>",
"     <p>",
"      You should carry at least 1 auto-injector with you at all times, because you never know when you&rsquo;ll need it. Let your family members know where you keep your auto-injector. That way, if you have an allergic reaction but can&rsquo;t get your auto-injector, another person can get it and use it on you.",
"     </p>",
"     <p>",
"      If your child has an auto-injector, be sure to bring it wherever he or she goes. You should also keep 1 at your child&rsquo;s school (if he or she goes to school).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20996357\">",
"      <span class=\"h1\">",
"       What are the side effects of epinephrine?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Epinephrine can cause short-term side effects, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fast or pounding heartbeat",
"       </li>",
"       <li>",
"        Feeling nervous, shaky, or dizzy",
"       </li>",
"       <li>",
"        Headache",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20996364\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/30/33250?source=see_link\">",
"       Patient information: Anaphylaxis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/27/35250?source=see_link\">",
"       Patient information: Food allergy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/51/15155?source=see_link\">",
"       Patient information: Insect bites and stings (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/35/17971?source=see_link\">",
"       Patient information: Peanut allergy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=see_link\">",
"       Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=see_link\">",
"       Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/14/41186?source=see_link\">",
"       Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?28/57/29586?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15917 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-CF9877BBA9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_57_29586=[""].join("\n");
var outline_f28_57_29586=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20996315\">",
"      What is an epinephrine auto-injector?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20996322\">",
"      What are the symptoms of an allergic reaction?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20996329\">",
"      When should I use my epinephrine auto-injector?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20996336\">",
"      How do I use an epinephrine auto-injector?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20996343\">",
"      What if the auto-injector doesn&rsquo;t stop my symptoms?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20996350\">",
"      Where should I keep my auto-injector?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20996357\">",
"      What are the side effects of epinephrine?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20996364\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15917\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/41/7824\">",
"      Hives",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/44/11975\">",
"       Using an epinephrine auto-injector",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/30/33250?source=related_link\">",
"      Patient information: Anaphylaxis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=related_link\">",
"      Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/14/41186?source=related_link\">",
"      Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/27/35250?source=related_link\">",
"      Patient information: Food allergy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/51/15155?source=related_link\">",
"      Patient information: Insect bites and stings (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/35/17971?source=related_link\">",
"      Patient information: Peanut allergy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=related_link\">",
"      Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_57_29587="Alpha-1 proteinase inhibitor: Patient drug information";
var content_f28_57_29587=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Alpha-1 proteinase inhibitor: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15076?source=see_link\">",
"     see \"Alpha-1 proteinase inhibitor: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F131976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aralast NP;",
"     </li>",
"     <li>",
"      Glassia&trade;;",
"     </li>",
"     <li>",
"      Prolastin&reg;-C;",
"     </li>",
"     <li>",
"      Zemaira&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F131977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Prolastin&reg;-C",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat alpha",
"       <sub>",
"        1",
"       </sub>",
"       -antitrypsin deficiency.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701470",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to alpha",
"       <sub>",
"        1",
"       </sub>",
"       -proteinase inhibitor or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701363",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a lack of immunoglobulin A.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11164 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.65.66-BC5B390E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_57_29587=[""].join("\n");
var outline_f28_57_29587=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131976\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131977\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012219\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012218\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012223\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012224\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012226\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012221\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012222\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012227\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012228\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15076?source=related_link\">",
"      Alpha-1 proteinase inhibitor: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_57_29588="Female perineum muscles";
var content_f28_57_29588=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F74060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F74060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Muscles of the female perineum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure illustrates the muscles of the female perineum. Note the location of the levator ani (iliococcygeus) muscles, the external anal sphincter, and the superficial transverse perineal muscle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_57_29588=[""].join("\n");
var outline_f28_57_29588=null;
var title_f28_57_29589="Acid-base and electrolyte abnormalities with diarrhea or ureteral diversion";
var content_f28_57_29589=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acid-base and electrolyte abnormalities with diarrhea or ureteral diversion",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/57/29589/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/57/29589/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/57/29589/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/57/29589/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/57/29589/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/57/29589/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/57/29589/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     DIARRHEA AND OTHER LOSSES OF INTESTINAL SECRETIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intestinal secretions below the stomach, including pancreatic and biliary secretions, are relatively alkaline with a total base concentration of 50 to 70",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29589/abstract/1\">",
"     1",
"    </a>",
"    ]. As a result, metabolic acidosis, frequently accompanied by hypokalemia, can be induced by diarrhea, a villous adenoma, or the removal of pancreatic, biliary, or intestinal secretions (by tube drainage, fistulas, or vomiting with intestinal obstruction). Patients who become volume depleted may also develop hypernatremia (if the free water losses are not replaced) or hyponatremia due to an inability to excrete ingested water because of the hypovolemic stimulus to the release of antidiuretic hormone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Laxative abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occult laxative abuse (a form of factitious diarrhea) should be suspected in any patient with an unexplained normal anion gap metabolic acidosis and hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29589/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Other findings that may be present include volume depletion and moderate to severe hypermagnesemia if a magnesium-containing cathartic is used (in some cases, the magnesium may be taken inadvertently with antacids or food supplements) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29589/abstract/3,5\">",
"     3,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For reasons that are not well understood, many patients with laxative abuse present with metabolic alkalosis rather than the expected metabolic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29589/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. It has been speculated that the alkalosis may be due in part to hypokalemia impairing the intestinal reabsorption of chloride, thereby diminishing bicarbonate secretion into the intestinal lumen via chloride-bicarbonate exchange. Loss of a high-chloride, low-bicarbonate solution can raise the serum bicarbonate concentration, and both volume depletion and hypokalemia then prevent excretion of the excess bicarbonate in the urine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10692?source=see_link\">",
"     \"Pathogenesis of metabolic alkalosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Confirming the diagnosis of laxative abuse depends upon the laxative ingested. A number of over-the-counter laxatives used to contain phenolphthalein, which was reclassified because of carcinogenic effects in animals and is no longer available over-the-counter in the United States. The presence of phenolphthalein in the stool can be indirectly demonstrated by the diarrheal fluid turning a red or purple color after the addition of alkali (such as sodium or potassium hydroxide); another laxative, bisacodyl, turns purple-blue in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29589/abstract/4\">",
"     4",
"    </a>",
"    ]. Screening of stool water or urine by thin layer chromatography (TLC) can also be performed if the index of suspicion is high.",
"   </p>",
"   <p>",
"    These tests will not detect magnesium-containing cathartics, which requires measurement of the magnesium concentration in the diarrheal fluid. A value above 108",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (45",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    or 90",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    suggests magnesium-induced diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29589/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6246?source=see_link\">",
"     \"Factitious diarrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Renal response and urine pH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the urine pH and urine anion gap will usually distinguish any form of diarrheal losses from the metabolic acidosis induced by renal tubular acidosis. The renal response to metabolic acidosis is to increase acid excretion as ammonium. Normal subjects given an acid load can increase ammonium excretion from the baseline level of approximately 40 meq per day to over 150",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29589/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12762?source=see_link&amp;anchor=H10#H10\">",
"     \"Chapter 11A: Renal hydrogen excretion\", section on 'Ammonium excretion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, marked diarrheal losses are required to induce metabolic acidosis if renal function is normal. However, the tendency to become acidotic will be enhanced if there is renal failure or some other cause of impaired acidification. The most likely cause of the latter is volume depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29589/abstract/7\">",
"     7",
"    </a>",
"    ]. In this setting, both a decline in glomerular filtration rate (GFR) and increased proximal reabsorption (mediated in part by angiotensin II) contribute to an appropriate reduction in the urine sodium concentration to below 25",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    The associated decrease in delivery of sodium chloride to the collecting tubules limits the excretion of ammonium as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25411?source=see_link\">",
"     ammonium chloride",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Urine pH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increase in acid excretion in metabolic acidosis should be associated with a urine pH that is below 5.5, with higher values being suggestive of underlying renal tubular acidosis. There are, however, two mechanisms by which an elevated urine pH can be seen with diarrhea (or other cause of loss of lower intestinal secretions). First, distal acidification is transiently impaired by volume depletion as mentioned in the preceding section. Second, concurrent hypokalemia (due to intestinal potassium loss) can indirectly raise the urine pH without interfering with acid excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29589/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypokalemia is a stimulus to renal ammonia production, an effect that may be mediated by a transcellular cation shift. The loss of potassium from the extracellular fluid will induce potassium movement out of the cells in an attempt to replete the extracellular stores. Electroneutrality is in part maintained in this setting by the movement of extracellular hydrogen (and sodium) into the cells; the ensuing intracellular acidosis will stimulate ammonia production via a signal that may be similar to that in metabolic acidosis.",
"   </p>",
"   <p>",
"    Diffusion of this ammonia into the tubular lumen will drive the following reaction to the right:",
"   </p>",
"   <p>",
"    &nbsp;NH3 &nbsp;+ &nbsp;H+ &nbsp; &lt;&mdash;&gt; &nbsp; NH4+",
"   </p>",
"   <p>",
"    Thus, acid excretion as ammonium will appropriately increase but the urine pH will rise due to the fall in the free hydrogen ion concentration. The correct diagnosis of diarrhea rather than renal tubular acidosis can be established both by the history and by calculation of the urine anion gap. The urine anion gap &nbsp;&mdash; &nbsp;([Na] &nbsp;+ &nbsp;[K]) &nbsp;- &nbsp;[Cl] &nbsp;&mdash; &nbsp;will have a positive value in renal tubular acidosis, but will be negative with diarrhea since ammonium excretion will be increased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11558?source=see_link\">",
"     \"Urine anion and osmolal gaps in metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurement of urinary potassium excretion also may be helpful in distinguishing between diarrhea and renal tubular acidosis in patients who are also hypokalemic. A value below 25",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in the presence of hypokalemia suggests appropriate potassium conservation and an extrarenal source of potassium loss. The hypokalemia in renal tubular acidosis, on the other hand, is due to urinary potassium wasting and should be associated with a higher urine potassium concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link\">",
"     \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\"",
"    </a>",
"    .) The urine potassium concentration may be less helpful if the patient is volume depleted with secondary hyperaldosteronism. In this setting, the urine sodium concentration should be below 25",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    the urine potassium concentration may be higher than expected, but total urinary potassium excretion will be appropriately low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Serum anion gap",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with diarrhea tend to develop a normal anion gap or hyperchloremic acidosis due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    loss in the stool followed by renal sodium chloride retention to preserve the extracellular fluid volume. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link\">",
"     \"Approach to the adult with metabolic acidosis\"",
"    </a>",
"    .) If the fluid losses are severe, however, a high anion gap acidosis can be seen due to the triad of hemoconcentration (leading to hyperalbuminemia), lactic acidosis (due to hypoperfusion), and hyperphosphatemia (resulting from an acidemia-induced release of phosphate from the cells) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29589/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. This combination of a &nbsp;normal and high anion gap acidosis can be suspected clinically by comparing the change in anion gap to the change in the serum bicarbonate concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=see_link\">",
"     \"The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Observing the response to therapy also may be helpful. The anion gap normalizes with rehydration with saline but that component of the acidosis due to bicarbonate loss in the diarrhea will initially persist unless alkali therapy is given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic approach to the patient with diarrhea and metabolic acidosis depends upon the severity of the two disturbances. Alkali administration is not necessary with mild to moderate reductions in the serum bicarbonate concentration if the diarrhea can be controlled (thereby minimizing further bicarbonate loss) and renal function is normal (thereby allowing acid excretion to increase). Some patients, however, will require",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link\">",
"     \"Approach to the adult with metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although generally well tolerated, alkali therapy should be temporarily withheld in patients with marked hypokalemia since raising the systemic pH will drive potassium into the cells, further reducing the serum potassium concentration. In this setting,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    should be given first to partially replete potassium stores; this can then be followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     URETERAL DIVERSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Implantation of the ureters into the sigmoid colon or a short loop of ileum that opens at the abdominal wall (ureteroileostomy) has been used to treat patients with obstructive uropathy due to locally invasive tumor, surgical removal of the bladder for carcinoma, or less often neurologic bladder dysfunction. A number of metabolic complications can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29589/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Metabolic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hyperchloremic metabolic acidosis occurs in up to 80 percent of patients with a ureterosigmoidostomy and is due to two factors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29589/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The colon has an anion exchange pump with luminal chloride being reabsorbed as bicarbonate is secreted. Thus, when chloride enters the colon (in this case from the urine) and is absorbed, the associated secretion of bicarbonate will result in bicarbonate loss.",
"     </li>",
"     <li>",
"      The colon can also absorb ammonium, which is derived both from the urine and from urea-splitting bacteria in the colon [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29589/abstract/1,11\">",
"       1,11",
"      </a>",
"      ]. How this occurs in incompletely understood, but cotransport with absorbed sodium may be involved (as the favorable inward gradient for sodium absorption drives the active transport of ammonium) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29589/abstract/10\">",
"       10",
"      </a>",
"      ]. Absorbed ammonium is converted to ammonia and a hydrogen ion in the liver. The ammonia is normally detoxified to urea but hyperammonemic encephalopathy can occur in patients with severe hepatic disease or with a marked ammonia load due to a urinary tract infection with a urea-splitting organism [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29589/abstract/11,14\">",
"       11,14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Metabolic acidosis is much less likely with a ureteroileostomy, since rapid drainage of urine into an ileostomy bag means that contact time between the urine and intestine is normally too short for significant changes in urinary composition to occur. However, metabolic acidosis can be seen if contact time is increased because of malfunction of the loop (most often due to stomal [anastomotic] stenosis). Thus, a loopogram should be performed when an otherwise unexplained metabolic acidosis develops in a patient with a ureteroileostomy. Reabsorption of urinary ammonium appears to be a more important to the fall in the serum bicarbonate concentration in this setting than is secretion of bicarbonate in the ileum [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29589/abstract/11,15\">",
"     11,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Effects on mineral metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with metabolic acidosis, some of the retained acid is buffered in bone, resulting in the release of bone calcium. The combination of metabolic acidosis and loss of bone calcium can lead both to bone demineralization (with possible rickets or osteomalacia) and to hypercalciuria, hypocitraturia, and kidney stones [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29589/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    .) However, a more common mechanism of stone formation is infection in the loop with a urease-producing organism, leading to struvite stones [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29589/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40802?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of struvite stones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolic acidosis associated with a ureteral diversion can usually be corrected by the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    or sodium citrate&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29589/abstract/10\">",
"     10",
"    </a>",
"    ]. With an ileal loop, however, a more appropriate long-term approach is to reverse the loop malfunction so that contact time is reduced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Changes in serum potassium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of urinary diversion on potassium balance vary with the site of the diversion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29589/abstract/12,17\">",
"     12,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypokalemia is common with sigmoid loops due to potassium secretion by the colon. Why this occurs is not clear. One possibility is that secretion is unmasked because urinary ammonium competes with potassium for reabsorption.",
"     </li>",
"     <li>",
"      There is typically little change in potassium balance with ileal loops.",
"     </li>",
"     <li>",
"      A rise in the serum potassium concentration can occur with ureterojejunostomy that is presumably due to absorption of urinary potassium by the jejunum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The jejunum also avidly absorbs electrolyte-free water. As a result, it may not be possible to excrete a dilute urine, since osmotic equilibration with the extracellular fluid will occur. This can lead to hyponatremia in patients who drink large amounts of water.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29589/abstract/1\">",
"      Perez GO, Oster JR, Rogers A. Acid-base disturbances in gastrointestinal disease. Dig Dis Sci 1987; 32:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29589/abstract/2\">",
"      Harris RT. Bulimarexia and related serious eating disorders with medical complications. Ann Intern Med 1983; 99:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29589/abstract/3\">",
"      Oster JR, Materson BJ, Rogers AI. Laxative abuse syndrome. Am J Gastroenterol 1980; 74:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29589/abstract/4\">",
"      Donowitz M, Kokke FT, Saidi R. Evaluation of patients with chronic diarrhea. N Engl J Med 1995; 332:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29589/abstract/5\">",
"      Fine KD, Santa Ana CA, Fordtran JS. Diagnosis of magnesium-induced diarrhea. N Engl J Med 1991; 324:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29589/abstract/6\">",
"      Welbourne T, Weber M, Bank N. The effect of glutamine administration on urinary ammonium excretion in normal subjects and patients with renal disease. J Clin Invest 1972; 51:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29589/abstract/7\">",
"      Batlle DC, von Riotte A, Schlueter W. Urinary sodium in the evaluation of hyperchloremic metabolic acidosis. N Engl J Med 1987; 316:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29589/abstract/8\">",
"      Batlle DC, Hizon M, Cohen E, et al. The use of the urinary anion gap in the diagnosis of hyperchloremic metabolic acidosis. N Engl J Med 1988; 318:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29589/abstract/9\">",
"      Cieza J, Sovero Y, Estremadoyro L, Dumler F. Electrolyte disturbances in elderly patients with severe diarrhea due to cholera. J Am Soc Nephrol 1995; 6:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29589/abstract/10\">",
"      Wang F, Butler T, Rabbani GH, Jones PK. The acidosis of cholera. Contributions of hyperproteinemia, lactic acidemia, and hyperphosphatemia to an increased serum anion gap. N Engl J Med 1986; 315:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29589/abstract/11\">",
"      McDougal WS. Metabolic complications of urinary intestinal diversion. J Urol 1992; 147:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29589/abstract/12\">",
"      Cruz DN, Huot SJ. Metabolic complications of urinary diversions: an overview. Am J Med 1997; 102:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29589/abstract/13\">",
"      Mundy AR. Metabolic complications of urinary diversion. Lancet 1999; 353:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29589/abstract/14\">",
"      Kaveggia FF, Thompson JS, Schafer EC, et al. Hyperammonemic encephalopathy in urinary diversion with urea-splitting urinary tract infection. Arch Intern Med 1990; 150:2389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29589/abstract/15\">",
"      Koch MO, McDougal WS. The pathophysiology of hyperchloremic metabolic acidosis after urinary diversion through intestinal segments. Surgery 1985; 98:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29589/abstract/16\">",
"      Cohen TD, Streem SB, Lammert G. Long-term incidence and risks for recurrent stones following contemporary management of upper tract calculi in patients with a urinary diversion. J Urol 1996; 155:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29589/abstract/17\">",
"      Agarwal R, Afzalpurkar R, Fordtran JS. Pathophysiology of potassium absorption and secretion by the human intestine. Gastroenterology 1994; 107:548.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2320 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-9EF4B3CCD6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_57_29589=[""].join("\n");
var outline_f28_57_29589=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      DIARRHEA AND OTHER LOSSES OF INTESTINAL SECRETIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Laxative abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Renal response and urine pH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Urine pH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Serum anion gap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      URETERAL DIVERSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Effects on mineral metabolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Changes in serum potassium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=related_link\">",
"      Approach to the adult with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12762?source=related_link\">",
"      Chapter 11A: Renal hydrogen excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6246?source=related_link\">",
"      Factitious diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40802?source=related_link\">",
"      Pathogenesis and clinical manifestations of struvite stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10692?source=related_link\">",
"      Pathogenesis of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=related_link\">",
"      Pathophysiology of renal tubular acidosis and the effect on potassium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=related_link\">",
"      The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11558?source=related_link\">",
"      Urine anion and osmolal gaps in metabolic acidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_57_29590="Gifted writing sample 2";
var content_f28_57_29590=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Writing sample of gifted child at age 5 years, 1 month",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 514px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAICAYEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiikZlUqGYAscDPc0ALnHWiua8du0dhpjKcY1S0z9PNWuloAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoIoooA5zx2qtpVpuHAvrdvykBro657xsjTWFlboQDNfQLuPRfmzn9K6GgAooooAKKKKACikJOQMfjS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFIWA6kD60ALUF488cObWFZpSwG1m2gDPJ/D0pXurdBl54lHqXAqje61bQIDblLttwBSGVCQD3OT0FAGpRVRtTsF+9fWo+sq/41JBd21ypa3uIZVBwSjhhn04oAx/GD7YtJwM51K3H0y+K365nxy6fZNKJYfLqtn7/wDLZRWnqWvaZpr2a3t7DEbucW0OW+9IQWA9uFNAGnRVcX1oU3C6g2jv5gxUL6vpqH59Rs1+s6j+tAF6iqMOr6bPII4dRs5HPRUnUn8s1Mb60HW5g/7+CgCxRVZNQs3OEuoCcZ4kFQy61pcX+t1KyT/enQf1oAv0Vnya3pUYUyanYqGG5d1wgyPUc0+LVtOliEkV/aPGc4ZZlIP45oAu0VXS9tZF3R3MDL6rIDUDa1pinB1C0Hb/AFy/40AX6KzpNc0qIZk1G0X6zKP602HX9Imdli1SydlG4gTLwPXrQBp0VRbV9NVsNqFoD6GZQf50NrGmKiudRswjDIbzlwR6jmgC9RWW3iHRlIB1SyyTj/XL/jTJvEuiQuyS6pZoy8EGUZFAGvRWdHrulSR+Yuo2mzONxlAGfxoGu6SWCjU7Eseg89f8aANGis2TXtIjI36pYru6ZuE5/WoW8T6GpYNqtoNuckyDAoA2KKwm8X+HlODrFn0zxIDxUqeJtGkTcmoQsuAcjJ45/wADQBsUVzTeOvDSkg6rHnpwjn+lWIvFuhSwpKupQhHztL5UnBweCAaAN2isVPFOiSNtTUYCfr74/rRdeKtDtTifU7dDjdjdnjOP50AbVFYVv4t0K5fbBqEcjY3fKrHjOPT1plx4x0O3YLLeMCRni3lbjOOy0AbsZcqTIoU5IwDnjsafXMnxzoGOLm5b6WU5/wDZKtN4q0pUR3lmRXXcpe3kXI/EdfagDcorDj8VaVK21JpOhOfJbH8qZJ4v0ONmDX2SuCdsMjdfotAG/RWKfFGkh408+YtJ93FtKc/kvFMPirSwkrBr1hGQG22M56+nyc/hQBu0VzbeM9MAJEGqsB6abP8A/EVKniqxZQfJv1ySButHB/UUAb9FZNv4gsZow3+kRkhjtkgcNgdTjFRw+J9LmYiJ7piFLf8AHnN0H/AKANqis7TNastSk8u0afftL4ltpIuAQP41Hr0rRoAKKKKAMa98MaLfXAnvNOgmlBY7nXPU5P60sXhnRYhiPS7Rf+2Y9Mf1NbFFAGKPCugCHyho9h5XB2+SuOM4/LJqSDw5otuWMGlWURYbSUhUZHp0rWooAzBoGkbif7Otcn/pmKU6FpRV1OnWm1xtYeUMEe/51pUUAcV4u8P6JaWNk8WkWSE6haqStuvQyrnPHTHH41meL9F0dPHHge0XSLMRy3F1I4S3UK223YAMMc8vnn0rq/FZITS/T7fFkev3v64rM135/iZ4XVyxRbS9dVzgb/3QyfXgn86AONl0T+yfG+vX/h3TEubTS0jMmkDG2YygySPEDwJPu4B4OCBivR9Hh0TWNMtdSsbO2e3uYxKjGIA4PPI7H1HrWZpUv2L4ka3YuwVb62hvYgx5dlBjfHsAqfnVf4QMp8HsI2DRrfXYUr0x579PagDeuxoNpuivP7MgyPmSUovHuDXLeOLLRLjwB4in8PW+mSXdvZSyI9nHGWVlUtgEDg8Yron8GeG5L64vZ9D06a7uHMks0turu7e5INaK6VYxafNZW9pBb20qNG0cUYRcEYPA+tAHJ6rHaXvhvSW0Szs7N9YeKIXKwIDDG67mI4xu2gge5FZ/gnVNDk0C7n1yLTYRa6hPaxS3EUal4w58voOTsKjPfGe9W/h5ZW2vfC/TtM1KNitqDaMFZkeN4mKghgchhgc5pvgjQNOtvEviq2/s2HyLW7jFtvTcEVoIiQufdRQB1FvJpupadJcaLFYXbJmNPlG0MP4TxkY9K5DTdesr3WRZanpenajHuMX9o2MGbdJecQ5f7zHBHyk4PBxXoS20KRyRxxIiSZ3hF25z1PFeW+BvtN6dD8PJEIofD8sj34EW1UdCywxAkcnB3kg9APWgC74Uvvt3i6DT7yx0kRTaZ/aCxWVspSJXcBRIx5LEBsEYBweOM12y+G9DQ5TRtNU+1rGP6VzFto8GhfEawXTtyRXtvcyzK755BTaq55CqBgKOBXeUAUv7J07/AJ8LTj/piv8AhT/7OsthT7JbhWGCBGOatUUAUn0nT5H3vY2zPgDJiBOB0qB/D2iuqh9I05go2qGtkOB6DitSkByTwRigDNXw/oyEFNI05ccjFsg/pU/9laeWLGwtNx5J8lcn9KuUUAVZNPs5I/Le1gZAc7TGMZpo0uwAIFlbYPH+rFXKKAM86JpRIJ02yJHIJgTj9KsvZWsiFHtoWQ9VMYINT0UAVF02xX7tlbD6RL/hUy28CDCwxqPZQKlooAYsUa/djQfQClZEbG5VOOmRTqKAG+WhGNi4+lMNtATzBEf+ACpaKAI1hiX7saD6KKfsX+6PypaKACiiigApNi/3R+VLRQAYHoKKKKACiiigAooooAKKTI3YyM9cUtABRRRQBj3kWvtcubO90uK3z8iy2kjsB7kSqP0qI2viQ4/4m+lL6401z/7WrdooAxHsteZWA1m0UkYBFgeD68yVENM14spbxCgAxkLYIM/mxroKKAMU6drAhAXXC0ueWa1TBGfQUwabrR668R9LSOt2igDjPFNtqkSaQrapHIH1CFMvar1IYA8Ed8Gsy/8AC3im7+IWj6m+r232Gys5keZLUKzSORhChY5XAzn2rp/GA/caU2Pu6nbfrIB/Wt+gDhdf8B3PiCe1m1TX7gS26siyWsCwuVb7yFgSdpwOPatjTPDk2l2tvZ6dqkttYwReVHbxW8QVff7uc10VFAGIdK1Qtzr9yF9BBF/8TTIdK1eOF1fxBLJIxOHa1j+UdsAY5HrW9RQBzEGg6xAmyHXo4lJLER2CLuJ6k4PU9zU8+j6vJ5W3xDNHt+9ttk+f866CigDnIdB1RGYyeJr+TPQeTEAP/Hani0fUI23jXbx39Hii2k+4Cgn863KKAOTufDOrXOoWN7N4iYXFoX2MlmgyGGCp55FPfQfEDNn/AISuYL6CyjFdTRQBzVtoOrxy7p/E13MuPu+RGoqdtEv2Kn+375cEk7UTnP4dq3qKAMFdF1GKMiHxBfb/AO9LHG/6baT+yNYP3vEdx+FrCP8A2Wt+igDnJ9C1aRSF8TXsZLZyIIunp0psXh7UljmWTxLqMhkAAbZGCnPUYFdLRnnFAHOf8I5eENnxFqnPTBUY/SpodG1CKJYxr16yr0Z44y3vk7ea3aKAMH+xdSP3vEV/+EUI/wDZKWTw/ISWi1nVI5G+8wlU7vwK4H4Vu0hGQRkj3FAGGdBuSqBtd1PKrtyGQZ9zhetVT4UmYnf4i1w/S4x/IV0dvEYoghkeQj+JyCTUlAHOp4WAi2NrWttyDuN6wNObwtA33tU1s/8AcQkH9a6CigDD/wCEcjVcQ6lqsecZP2ksf/HgadFoJi37dV1QlhjLTA4+nFbVFAHOyeF/MbLa3rf0W7K/yFLD4WijkVzqutuR2bUJMH8M10NFAGLP4dtp0RZLzVcJ026hMufrhuah/wCES07IJm1NiOfm1Gc/zet8jOOSMHtS0AYZ8M2fkiMXF+AGLZ+1Pnk565preGLYqQl7qkZ4+aO8dT+YNb1FAGAPC1t/FqGtt/3E5x/JqcPC1hg7rjV3yCPm1W5/+OVu0UAYUvhXS5SDIL5sDHOoXH/xdNTwjoyMCLeckENlruZuR9WrfooAwT4U0xs7hctn1uH/AMaRvCtg0m43GqcYwq6hMqjHsGrfooAytM0Gy025ae2a8MjZB868llBz7OxA/CtWiigAooooAxdQ8R2ljdSwSW2pSSRlQTBYyyqcjIwVUg++OlUW8Z2v8OkeIW+bbxpM4/HlenvXUUUAc4fFSY+XRtdb/txcfzp8fiR5HZV0PWRgZy1vtB9uT1roKKAMJvEaoUWTStVDtzjyAcfXmlfxFEvXT9VJwWO21ZsAfT1rcooA4DxN4nF3Bp8cGi68W+328mW0914WQOevsprZ/wCEs3wxSwaJrMqSoXUpbHGBjHfvnirXigBm0dMoGbUI8BjjOFYkfkDXIWl+3hDwl4y04MLcaL50ti235RFKpkhA9cM236igDdufGyWun3d9daPqkNrbxGQyNGMMRxtXB5YngD14oTxmbe204ato2pWl7dssIhCBh5xUsUDZ5wFbn2rjLPTZNJ0rS/C0AUWh1iyYxbssqCFZ5PzmjZif9s13/jVXNrpRiOHGp2xDYyQA4zj0yMj6E0AOPiKcMg/sDVzuOAQicfX56jfxSVZwNB15ipxxacH6HPNX5fEOlRauNMkvY1vSQuw5wGIyFLY2hiOQpOSOcVmazqmrzane2GgNp8ctnAk0rXqOwbfuxjaegCmgBV8U3Duqp4c1sZ7tAAB9eayvDnjrUdY0Gw1AeFNTDXMSyEIU2gn0JPSrnhrxVJceAdA1jVLe5nu7+2jaRbC1eXDlck7VBKjOetc/8KfFtlb+D/DunXdrqdszxCKOeezdYWbJwN+MZNAHW2/iDUZIy8nhzUYjnAUshP8AOpB4hmW382bQtWUk4CLGjMR64DcVv0UAc/H4klkOF0DWh7tCgH/odVW8WzG2E8Wgao8bMqo37sBixwMHf64H41b8Ra5JaSSWWn2n2y9EDTyBpPKihjHd3wcZwcAAk4PYZrI8LahDovw08NTahbkKYrOAJGfM2tIyIpyQO7Ak0AS6N4t1O+s45rvwvqNoWXJDSRkBt2MZzWnHrd+7gHQL5V7sWTj8M1l/F4Y+HWrBWMf+pAZDgj98nT3rsIzmNT6gUAZJ1e5SGWR9HvztfCJHsZnXj5sFhj6e1QN4gudpKeHdZYgZxthGf/IlbN5bJd2skEpcJIMEo5Vh9CORXG6ndaz4JsLm+urxdY0K3iLN9pIju4sLwA/3ZcsAACA2W6t0oA2Jte1BBGYvDeqSF13Eb4RtPofn60yLWdSZWlbw1exuQBhpoyTyfRj/AJNXvDb3g0ayXWbiKXU5I/MmCDaAx5KgdcLnGTzxzT4Nb0+b+0Slynl6e5iuZDwqMACRn2zzQBSj1rVGYhvD90q46+cnpUn9sXygl9CviM7QEeMnoOeWHHX8q2Im3ruBUo3Kkdxin0AYyaxesf8AkAaiB7vCP/alINV1MhSNAugCcHM8OQPX79bVee/EfxZPB4c8SQaDaTXMlpayxT3iTLCltKyHaAzH5nGQcLnBIHU0AdENX1punhq4X/fu4R/JjSLqniBmA/4RxFBPJa/Tj8lNZl14t0/wxpmm2l213dzR2STTEjfKkQX/AFknucH8a6+0uIru1huIG3QyoHRvUEZFAGXJfa0qqY9HgZjnIN7jHPH8HpzSwXmtsw87SLaNfUXu4/lsFbFFAGPcX2rR48rSBKT/AHblRj88UyLUNaJbzNFVQBx/pScn0rbooA586l4hMqhfD8AQsAWbUAMD1wEP5VMbvXiq7dIsQT1DX54/KOtqigDE+0eIz007Sl+t9If/AGlUscuuBJTNaafuAyix3DnPscoMVrUUAYMl54g3MI9KtSB0Juev6Uye/wDEisBBotm4/vNe7f8A2U10NFAHP2934mebE2l6ZHFtzkXrMd3pjy+lOMviYoMWejq+OQbqQj/0XW9RQBzwfxUW+aHRFHtNKf8A2QU5H8TJGxlh0qVyeBHI4AHvkVvMqkqSASvQ+lLQBgrP4jCyFrPTidp2KJmGW7ZOOlVftPjBopCNN0VZNvyBrqQgnPfCeldRRQBlafLrReAajbWIVt3mtBMx2ccYBUZzx6Vq0UUAFFFFABSEgdSBWPq/hrTNXuRPfRzvIOmy4kQfkrAVRPgPw6ww1jK31upj/wCz0AdIZY/+eifnTTcQjgzR/wDfQrn7bwN4ctlZYdOABJJzNI3P4tU3/CHaBx/xLITjGMlj/WgDdR0f7jK30OadWIfC2i+SYlsI1jPUKSP61UTwL4dRmYacuWCqSZG6Dp3oAf4wH7/w8wGduqRn6fu5B/Wsjxz4eudZ1vSJbKe3jsZJo11XewzJDCxkjVQePvnn1BqLxp4U0VYtFxZDaNRhjI3tyrEgg89Oa6GLwhoEUQjj0yAICWAyTyevegDkNU8g/GfS8zwR2wsmuwwYfPIuYyCc9lYY/Gtv4j6vBp2lWN7vSVYLxJPKEgHmN5b7F/F9taa+DvDoXA0ez+pTJ/Oo7nwR4cubT7NNpNu0PnLPtwfvqcqfwxQBz2r6WdO+GlwZZQdV3JfTzoAH88yKzMPTHI+laWp2d5FqF5f2SvcxarYLbFoyuYZFDbG91O/rzjFa8nhXQpFZZNLtnV1KsGTOQeo/WqieAvCycpoVkvGOExQBi/DnVfs/wst7m4WK3a0t5tseNuFjLYO36DoOKu/Da6s7X4f6DHdX1tvNojNvdV6jPTPHWn23w58OW2gy6XDYoqyQSW5nwPNCvnPzevNWtL8EaDY6da2z6da3LwRLF50sK7n2jAJ9+KANmPVdOlYrFf2jsBkhZlJH61Ot1bu4RZ4mc9FDjJqjbeHtHtnLW+mWkbEbSViAyPSmp4c0ZDlNMtQfXyxmgDlvFU32O+8VQypIk9/pDtaTqDltkbgxqem4E7sf7VW/ElzHP4AtZoJYnKmzlB3AjiWM54+laj+C/DUhzLoWnSEEN88CtgjvyKnTwroCI6JounKj/eUW6YP4YoA4D4wX0GpRSaet7B5NtbR3RQyDa0jXCKjdedoVzj3B7V6bHfWiRIrXdvkKBnzB/jXF+M/hnpmuWxXTobOwlZBFIot12SqHDgHHIII6j6V0mlaKqWrLqkFhNMW6wwbV24wBg0AaH9pWJOBe22T281f8a5Dxo8ev+JNB8No4a23jVb3AyrRRN+7Unp80mDz/AM866ldC0pemnWn/AH6WoJfC+gzXDzzaLp0kzhVZ3tkYkDoMkdBQBwVzDZtHqXih54rbXF1MRQyRzbT5SyrGImHQhlHII6nPYVR0q+/t3T73w5cLDp7y3sk2qzzMIwymUkLGCfmLgD5hwB716JbeDfDkE63A0PS2ulGPPNnGHP4hetXB4f0fejf2VYZT7v8Ao6cfTigCWPU9NSPal/abY/kP75fl9jzQNY00nA1Czz1x56/40f2Rp2JB9gtQJCC4ESjcR68Uq6Tpy/dsbYf9shQBKL21aNZFuYCjfdYSDB+hryLxZebdC8S+H441u7x9UivFiLg+dbyXCSEr7DBU+mPSvVZdJ0yYNFNp1pIp5IeBSp/MUT6Rpz2iwtplnLDF80cJhTaD7AjAoA84ubhLGfxdaAR3F7q8gNrcMMxCJ4wgDSZwAmD/AJNdrpWr6BpGlWlgusacq20SxDN0n8Ix3NakWl2At1T+zrWNSBmPylwPbgYp66ZYKcrY2oPtEv8AhQBUh8SaJOWEOr2EhUZOy4U4H50SeI9FjYrJqtkrDqDMuf51opbwx/cijX6KBTjDEW3GNC3qVFAGXH4l0WRgE1SzJPA/einN4j0ZfvapZj/tqKu3FjaXKhbm2gmUdBJGGA/Ool0nTl+7YWg+kK/4UAVp/EejW6F5tUs0UAElpQMA9Krp4w8OySKkes2LOzBQBKDkntWt9htP+fWD/v2KelvCn3IY1+igUAZ7eItIWPe2oW4TOM7u9VT4w0HtqcB+mTW+AB0FFAGHH4s0KTdt1OAFRkhiQQKX/hK9D/6Cdvj/AHq1pLeGU5khjc+rKDSC0th0t4f++BQBhr418OM+xdXti2cYBJ/pT4vGGgzTCKLUo3kMZlwFb7o79K21ghX7sUY+igVIAB0AFAHOnxpoIJAvdx9o2P8ASpLbxZpNzL5cE0rN/wBcX/wreooAwm8W6GpIN+mRwQEY/wBKhl8a+HopFjfUVDscAeU55/75roPKjzny0z9BQIoxz5aZ+lAGTp3ibR9RnENpeq8p+6rIybvpuAzWzSFFOPlHHI46UtABRRRQAUVlak2t/bQumx6f9k2ZLzs+/dk8YHbpzmqsv/CTMw8h9GAH3tyyZB/OgDfornTH4qzn7Ro/02SU9P8AhJ0yG/siTvuzIPwxQBv0Vz7HxQR8v9jA+4kP9aYy+LSTsm0NR2zDKf8A2cUAT+KSM6SjIjI1/FncM4IOQR75rcrhPEH/AAkSXWix3txpDrNfIieTbyAq4VmBJMnT5elZ+tePrfSrqa3vvFeiWckBMcvm2kgAkGcjO7FAHpdFcPe6nrVpY2N+2rWMtjcSpE0yWp2pvIVCec4LED/gQrT1K/1XR7Ge+1S601bWPA+SGRmLMwVQADySSAAOpIoA6WiubvJfEEN0FbUdBgSZ9kCywSb2OOn+sGT9KWSLxPGjSTarocUajczfYJeAOpyZqAOjorJmt9ZeM+VqVmjE5DfZCwx9N9VX0/xEV+XXbYN7WIx/6EaAOgorAFn4iUAf2rZtgnLG15I7dDWfod9q2tQTz6ZrNjIsE8trKs+nuCkqNhhjep4x+IINAHWSR72Q73XY27CnGfY+1Prj1vNeh8SQaVe6tYK08TzQsuluqShSNyBzOfmXIOMcg5HQ1pPYeIWYka5ZqM8Aad0/OSgDeormjY+I5Nph8Q2jIDyRYj5ueR94471Wjvr641WbTbfxDYG+iXLQ/Z8kHHPfnHcDkd6AOuorCistfCKX1e1aQLg5s/lJx1xuB6+9Q/2f4nI51/Twf9nTD/8AHaAN+eaOBN80ixpkLuY4GScAVJXI/ZNT1OK709vEdtLPAQs4XTwNueV4LnsOtVbe91mPxdN4en1XM5sFvoJ2tFCSjeUcAA8FT5ef9+gDuKK5eYanFf21lL4kto7u4DPFD9nQPIq43FQeuMj86sHTtfEmV12Irtb5Xs1PPGDwRwP60AdBRXNtpfiVif8Aio7ZQScAaaOB/wB90xtG8RMrA+KFDHoVsFGP/HqAOnoritX0/WtL0i91C68T3ksVpC87rBZR72VQWIUZ5OBVnRbC9utNt75fE17LbXcUcsZeGNSFYAjt1ORQB1lFc/Npd/GC8viO5jTOOY4gPzK0s1rd6ZaTXd3r1wbe3VppWkgRvkAJPRc8deKAN+iuEnuJYpLBbjxusTagA9spto1MinGCM/UD6kVqS2d1pFnc3mq+Jbj7LGu55HiRVjHrwKAOnorlf+EX1Fs7vFOrH/dCD+lc7HPcW0Dahdanrq6J54iW/N1G2RuKBzHs4jLY+YE8EHAGcAHplFYT6BM7E/25qwB7LIn/AMTUg0a4SJ0i1nUBuGAz7GIOMZ+7QBs0Vzg8P6hkF/EmpN9FjH8lqN/C90+N3iTWRj+7Ioz+lAHT0hz2NYCeG3WDy31vWHOMb/tOG/PFO/4Rz92q/wBs6z8vf7VyfrxQBvUVjRaGYo0RNU1PKPvDNMGJ4xg5HI9qibQLlic6/qv0DRj+S0Ab1Fc/L4bkkjCnXNYGDnK3GCfyFNj8LhM/8TrW2JXblrxj3zn60AdFRWRb6PNBJAY9X1ExRHJjkdX8znPzFlLe3BFa9ABRRRQAUVnanrVhpkqR3s5jd13KBGzZH4A1TPivSN4UXEzEjIxbS/8AxNAG47KiszEBQMknsKzrTVYtQuf+JdJDPaxFknlVs7XGMIPfnmqTeKtLcFf9KkDcYFrIc/8AjtJbeItCW3AilWJGBkMfkMp68kjHXNAHQUVgnxbo2Mi5mb/dtZT/ACWg+LNJCRuGvmVxuXbp9w3H4JxQAzxbHvuPD7b0Xy9TRvmOM/u5Bge/NVhGmteNr1LoebZaVAsK28iZRppRuZ+eGwm1R6bn9ay/F/iKxuf7EaGPUT5WpwuS2n3CcFXHG5Bk89BzVDSfGGmeH9S15NU/tGKS7ujd2qS2kitOjKoxGCMk5GMetAGt4V0+LUfDOuaBcE/ZLa9ubKEoSTFGGzHtJ5ygKgH1Ws59ZPiQeBbN1eOS5na8u0Dfce1HzRt6kTFPxStLwdfwaVo8jaks0N7dzy3lxEIH/dvId5Xp2B/OuZ0SU2fxMvryWO6OhwQSSWTpaycy3Em+ZcAdQVzn/aoA6DxHZvf/ABCgsZpLcQ3Om7oVuLYSjMch83YSRtYiSL14HtT/AIhWyaP8J9SsklmmiitUtvMuG8x2VmVCWJ6nB607xPewaxaR3GnC/t9U05vtVpM1hMV3YIKEBclWBKkD1z1Aqr4q12PW/A+p2U+k63Hd3FlIPKXTZ2CybSVAbZj7wGD/ACoA0Y/EuoajqWoWPhvTY7mHTT5M91PN5cbThQTEmASSAeW6A8dc11sJdokaRNjkAsuc4PpmvOPhPfvpXgHTY7/StZj1CYPc3SNYSZE0jF37c8k811cviZI43kOk6yVUFiRZt0oA2Ly7t7KHzbyeK3izjfK4UZ+prz3whrOm6FrHjr7fqNvDZDVhcRvIwG4yQRMwUfxc5wBkk+9dO3iO0mso5rjTdSEUmCiy2hJPHXHOPxri/CF9pdv448a39tpt15IkgjAismZgywruAAGR2470Aafjq/kk0Lwz4njtLi0ks9Tt5XjnG2SOGVvJcMBnGRIDj6VqX91P4n1260SxlnttLscDULqL5WlkYZEEbdsAguRyAQowSSMn4g65BrHgrVrSLTtaVmgMqtJpswUFPnGSQMfd61L4D1H+x/CWnW8unazc3Txie4m+yOfNlk+d3z3JYk0AX9KjtfDeva+C32fS0tredUBLLHgMrELycnaCe5PNc94OjvvEmnWAsgbGzsrueWbUGiCzXE/mEnywR9xtzbmIBPTArp4tWUapLeromt+dJGsTZt8KFUkjjPXk1kJq1/o+uX76dpd1c2F5J5sltJGYnglwAxVsEMrdceufWgD0IdKQKAzEZy3Xmuei8TgxAyaTq28LltlsSM+3OTSXHitIXZRouuyEd47FiD+NAHRYGScDNcX4522HivwZrDOERLyXT5D6rPEcD/vuOP8AOrkfi95Cdvh3XxjP37MrnH1Nc98Q9UutU8JXvk6DqUc9lsv4ZJogAGhdX9euARQBkeNJBc6l4m11gftGgX+nW1nIvDRgNG8uPUN57A+u0eldn40ujqFzp3hm2P73VMyXRDEGO0QjzDxyCxIQfVjnivNtY1Ka88HeP3itb11uNQSe3dI9yDb5JxwfUVveD9cN14x8U66+kaxOUaLS4dtuMqkKbmAyw6yO3SgDU8ZeINVm8Qro/h29Wze2lt45WESyvNLIwYx7W6IkQZ2I5+ZcYwc2vFmnX+ueKIrWwumt2tLQSiUTvEYpGc7ZFAUh8bCCrcENVAanc2Xim51ex8Oa3Ml6qLcQS2yK6MqhQ8bFsfdABXP8Ixml1zxDc2ut2Gvjw7rotreJ7e5DRAbUcghwoJJww59ASaAOr1RLxPA9/Hqc0Ul6thKsssI2KzeWcsM9PX2rz/4ZWcvi/TtButSuNuj6DBBFa6eGIeS5jjCmade2CDsXp/Fzxjdu/FEvifRb+ws/D2sm2u4ZbV7lBGAu5SpK5ODjP0rLt9P1XTbXTrjQtD1KDUNNgigd5ZIv+JhCgAKSAfxYHyt1B46UAdJ40lsB4l8Ow6xtNi4uGKyx7oi4VNu7sDgtjPvWTqd7eXHw08UfZZblY086GyuHUhjCcYYFuWABOCeuK0tZnvdb0+FLjQ9Us7mOVbiCSJ43MTjoWG4A9SCp6j86ZeT6rrHhe90zxF4auZRcRPBOtlOgEsZGMruYFSR2PT170AUfh5pFt4g0bVNZ1W1jktNbCw2sDnIj0+MbYEHPBPzSHHRn9hWDrOvLJ+z7drql+FvWt5tMEhy7XEkbNGfclghJPbJJr0FNTl03T7SCx8Pak0SIsaRL5YMagYAOX7V5FFpGvv4ZwfC+pMFh1VPLkCLIjXJJQqucn+6fY5oA98t23W8Teqg/pXI+OGOpS2PhGzRFGoqXu26CO0QjeF4wWYlUA9Cx7CsHQvEnjGTXlR/C1ymmpp8S+TLOqMsvUtnBBJ5BHbaPWtW8m1+bXNP1OHwlF9rhzbtLLqQGyByC+FC4Jyq9aAO6VQqhR0AwKWsA6rrAlIXw/MU9TdRj9KH1XWk2n/hHpXXdghLqLcB68kUAb9Fc6db1jJC+Gbz/AIFcwjP/AI8ac+ra39njdPDrGRmIaNrxBtHY5wc0AdBRXOJqniNnUHw7AikgEtqI4H4JVma/1pJiseiRyR44cXijn6FaANqisIX+ulhnRYVHcm8B/pT5NR1dAAuhvI3crdRgD8zQBtUViDUNaMLsNCUSD7qNeL834gHFLDfa20RaXRrdHzwovt3/ALJQBtUVkLqGpgR+borlmfDeVcxsEGepLbSfoBWvQAUUUUABAJyQKKKKACiiigAooooA57xgpcaMobaBqMJJxn14rbntoJ3iaeGKRom3xl0BKN6jPQ1heLnb7VoEIA2y6gmSe20Fv6V0dABRRRQAUUUUAFFNLoOrL+dLvX+8PzoAWqOl6Va6Ybo2iMHupmnmdmLM7nuSfyA7VeBBGQc0UABGRzQBgcUEgdaYZYx1kQfU0APoqPzoj/y0T/voU9XVs7WBx1waAFopGYIpZiFUDJJ4ApSQBzxQAU10WRGR1DIwwVI4Iprzwp9+WNfqwFMN5bDrcwj6uKAOc03wZYaL4P1LQtLRmhuvPkxM+fnkyevYAkY9MVD8J9B1Lw74Js7LXZFk1Vmea5KNuUOzE4B7jGK6g31oDg3UGcZ/1gqRJ4ncokqMwGSoYEigBtza290qLdQRTKjiRRIgYKw6EZ6EetTfWkLADJIAHc1G1xChw0san3YCgCRVCjCgAegpaqSanYR/6y+tU/3pVH9aZ/bGmbN/9o2ez+9564/nQBeorO/t3SMgf2pYZPT/AEhP8ali1SwmUtDe20ozj5JVPPp1oAuUVUbUrFfvXluPrIKG1OwX717ajvzKv+NAFuis/wDtzScE/wBqWOF6/wCkJx+tRP4j0SNismsaarDqDdIP60AatFZkHiDRrhitvq+nysOoS5Rj+hpV17SH37NTsm2Ha2JlOD6HmgDSoqiNX03YG+32oU9CZVH9ahfxDoyff1fTl5xzcoP60AalFY7+KNAQkPrmlqR2N3H/AI01PFfh9zhNc0xjkD5bpDyenegDZLAMFyNx6ClrLbX9HGCdSs/wlU/1pYte0mY4j1G1bnbxIOvpQBp0Vjv4n0JMb9Y09c+twv8AjUb+LvDqOyNrenB1baR9oXIPp1oA3KKzoNb0q4kEcGpWcjkZCrMpJH51o0AFFFFAGfqem/b5Im+23tuEBG23lKBs45Pr0/U1UTw3bKMfbNUbL72LX0pz04+9wOOgxW3RQBgyeF7Nwyi61JFPQC8k+X6ZNMfwlYO0h+0agC67eLt/l+nNdDRQBzaeELNIhGL/AFgoBgD7fIMD8DQPB2mgktcau+STzqdx/R/aukooA858ZeEtNhbRDAt47tqCrtl1O4+YlH4BL8cjqOawrS4v4PHNh4c1TwzPDZy2RnR7bV5Lh1KyqpY7mBKAMOxPPSu88ccN4dPHGrQ9f916yNek8v4zeFSzAK2l3y4x1+eA5+gx+o9aANyTwfpMjBmS647faZMfzqCPwPpcaBRPqfAxn7bJnH510sNxDNnyZY5NvXYwOKkoA841vwXaXWpRaTYXGp23nIbi4u/7Qm3ogIG2IbsbiSMn+EdskVfXwR4f0TTbmfU7zVbq3iBkea+1OeQooHQHd046etdD4h0OPV0hljmktNStdzWt5F9+FjjPHRlOBlTwQK57WtRub7wGL+/g2T2k8b3sVv8AMB5Uo3lc9hjfntj2oApaHo/hrU9VnsJNC1K0uEhW5UXNxL88bHAJw52nI+42G9qiXTfDkOueJW1GCRILH7JEP38hz8mVVQDnJzjHU13Ok2dnYWrzW77/ADyJZbmR9zSnHDM306dgOmK4K81CPT/HGuXl4A9na3CTrtwP3osvkBJ45HmAf7W3vQBu6d4V8L6nB9v0+FzHKTkpNIuCCQVIzwQcgiqHhfwvomt6EtzcW9w+bq4UA3cpxsmePA+bphBxV74T+cvhWVLqRpbpb+7MzMu07zO7EEeozj8KyvAurT6NpgjvIUfRZNSvIUu48g27m7lAWVT/AAknG8dyMjByADdTwL4ZMbKLIuq/I2bqU4x2PzVDZ+CvDM7SMmlfu45CFYzuyuSBkj5j9PqDWBosLeIdf1rRZfMj06G/nub8BiDc5cpFFkfwbULMD1GwdCas+K4hc6rqdhGbi207RdGN1HFbSmBTM+8IcqRnaIzgH5ctk9KAN3UPCvhiz06aa8soorSGMl3MjgIgHJznsKW18FeHEhV7Wz2xsoIKTP8AMOoPXnrWH4g8TxS/CI319BdeZqGjuzfZ4zJ5bmLB3HoMFup9DW7a6qLD4fR6jalbr7JZBvmJXfsUbhzj0NAHKeM9A0DUfhnf6np1jIPtFnvtzLvR/mxt+UkEHkcGuqXwD4YXONIg5Jb7zdT17+9YfxH1iee2t9LtYUEMy2tzO7jOEa6iQKvbOTk57V6IKAOXk8AeFZBiTRLVhnPIP+NZfjbRdE8PeEdW1Sz0i0NxbQGRMpnkDAPJ7V3leffGP+2X8FeIFtfsMWnrZsWaXczyEg5UAdDnbg89aANqbwh4Yt7IfbdNsvLUqzSSLgFuBn8TjirCeDfDyOWTSLQMerbOTXPeJJfETW9jb6lDpk+nXN/bRu8JdZNhkDdDx2H4V0Hh3xTZa9eXdvaxzx+UqyxPKuBcRMSBInqpKsPXgHvQBE3gTws8vmvoNg0mNu5ogePSnr4I8MLIsi6Dp29V2BvIXIHTH0rGtPF97qbapbaadNe/SJ5rOBWZ2GxtrJKBghjgdMYJxzg0zVPFP25NEv8AThI1stjcatNCTsysceFRj2O9uh/un0oA3z4N8N5BOhacSBgZt16flWBFoukn4lJZQaVbR29lo5kYLGoQmacBePUeQ/8A30ah1jUtZ0qXwmiagbi51jUo1uG2ARiLy3do0Hbjvkk7ayfEd7cW2tfEqeO4a3lhsrKOK4GP3aFWyB+LMfxoA9Efw5okqMG0qxdXILZhUg46dqF8OaIoAXSLAAEni3Xv17Vz9yr+EfD1tbWd2Fa/voreBigEdrvwMInphScd2YnvXR+H7O/sbJ4tU1E6hN5jMkpiCEJ2U46/X3oARvD2jNjdpGnnHIzbIcfpVUaN4a+2m2XTdJN2FDGIQR7wvQEjGcVvV4h42sHuNX1SRneGPRpoW86AmOWSa5u87TKPmwsMm3Z0/eZxwKAPRo7nwpbW8srwabZxLNJbsZIUjG5SA3bpnHPTpW8unWJGRaW2D3Ea81wPwfsv7T8NXd/qmy7W8uJ0QSKGBj8xiWPqXJLH6gdq6D4ZRS2vg6zsLhXWSxaS0w7EkLG5VeT/ALIFAHRLaWy5228Iz1wgrPNppj6pJaNpts0hiE7P5CkHLEcnHXg1qTKzwusbmN2UgOACVPrg1kSael1qUoe9vCyJGWCTlQCM/wAIGOep559KALR0zSmlZDY2RkwGYGFc45wTx9acmkaan3NPs1+kKj+lVDceR4maEwSM1xCgRwvAClt2T+K8e9L4fu57ptUEzbvJvJIoweoUYwP5/hQBoR2lupykEAXttQU97eF1ZXhjZWGCCoII9KdDu8sb1VG7qpyBT6AKo0+yHSztx9Il/wAKDp1icZs7Y4JI/dLwT1PSrVFAFJNK05fuWFoMekKj+lSm3tYVL+TEozkkIKsAAEnHJooArGwsz1tYDznmMdas0UUAFFFFAFPUZb6MRjT7aGdmJ3GWUoqj8ASazBN4o3Pmz0bYAduLuXJ+v7ut+igDBSTxMsYMlrpLPt5CTyYzn3QcYqG4uvFShfI07S5DnDZuGGB69K6SigDmftXiwSY/szS2XGd32lhz6Y21D9p8bN007QV+b+K7lPH4JXWUUAcB4tXxNJNpJlh0EQpexNGWkmJEu1h2XpycGuR8VeD/ABZqfjjQL3Wxb6zbyPNC0Ns0lvb2MRVT8xU73yVHJOCQOBXpHjEF77w7F0U6grE5PZW/zzXS0AcXovh+/wBBlmGiaXodmkoUO0bSZbbwuR7A1oo3iw3EgZdGEAA2MPMLE98jPFdHRQBwt/p3jS6uHntbjS7CdozGzxtIwYdjtORuHY/nmn6Rpni7TNJWxtv+EfWOPhN5nkLZyWLE9SSa7eigDz0eE9cE5cJoKpt2rDi4MIyMECLdsx7YqS08L+IE1C+u7qfRJxepEs1u1uxjzHwpAPpxx6iu+ooA5DRtC17SheLb6hYFLq6ku2DQsdrSNuYDnpkmuMTSvG8Om6t4dTTrOSz1S7uXW7lOVgSWRixKhgRwSVAzndzjFexUUAed+FdC8VabL4guVfSobq/v3mDTo77kUKkZAVuBtXoeag17w54yu9X822uNF8q+gjt72URSKUWNy/Qscg5ZcDsxzXpRGcdeKWgDz1/BeuN4Zn0A6xZfYLgyCTbakMEdtxVfmPHJH0rT1bQvEGpaRc6dLqdisE0LRHFucg4wO/T1rr6KAPMvFnh/xLLc2M6Pp9xDthtZ/LhcNGiSpKsgAYE/MgBAIwDmuv8AK8Tkc3ujL/26Sn/2pW9RQBz8lr4nZIguq6WjhfnIsXIJ9v3nA/OszWtA8TanYG3k1zTyPMik2mwwDskV/wC+f7tdnRQB59458O+KtW0RbSy1a2aR7iMMfs4TZHnEhHPJ2kjHvVO4sdQ0z4kaHb/2msUdxps1vAyW6qAUdG2Y6H5f616bUckEUkkckkaM8ZJRiMlc9celAHN6Zout6d9pjttS05LaSdpkj+xMfL3csv8ArOmcn8azNC8DXmkC9SPV7aWG5HleU9h8qQ5Y+UAH6Zdzzz8xru6KAPLdZ8K+Iba80OQ6r9vjtbyKK2xaZMCbHBlf5sEjOM+hroLnwbdXUl/LPq8fnX8It7qVLCINLGAQFJOemTiutSErcySmWRgwAEZPyrjuPepaAOE1PwlrM3hk2L67JeTWvlvaF4I1bdGwZSzY+8QMZ4HPStTS7DXrq0E2oavdWUrknyFjgcoOwLbME/TiunooAwP7K1lS23xDIQSceZaISB6cY/OuDtfCHiO7vdSfVrn7NYjUJNSZgiyyXkiHEI2g4CKir8p6kD0r1uigDzH4UaBqMHw/0b7Fr91bQSQ+b5X2aIlWYlmGWBPUniuqsPDd1Y2Rt4Nevk3SNKzrDCCSxyeqEda6KNFjQJGqqo6BRgCnUAYn9iXh+94i1X8FgH/tKlXRrxN5TXb9iVUL5ixMFx1PCjJNbVFAHPDQ9S8zzG16cvwCRAgJAOcfSm3GhanJO7weIbq3RuSkdvHyfXJBro6KAOdXQNR2AP4l1MkZyQkIz/45Tv8AhHbk/e8R60fo0I/9p10FFAGAvh+5jjZY9f1YszZLSNGxA9B8gxSf2Hfk/Nr9/j1AQf0roKKAMCbQr97dYk8QX8ZBPzhULH8xUEfhm9AkEnibWH3AAHMY289R8tdNRQBgx6DdxQCOPX9UJGfnkMbHk/7tbqghQCckDqe9LRQAUUUUAU9T1Oz0yJJL+dYEc7VLZ5OCf5A1lXXjPQLWaOKbUUEki70ARzkevAroCAeoBpRQBzZ8a6FkgXbsQccQuf6UHxroqxySPNOsca7mY274A/Kuko60Ac/H4x0OSON1vGxIu4DyJM49/l4pH8ZaEjqr3jgt0zby/wDxNb+xc52r+VLsX+6PyoA828YeM9Ikv/DjWl0XCaihlzbyghNp6fLya3JfiJ4Zikljl1AxyRQi4dXhdSsZbbuII6Z4qbxydknh1gcf8TaAemc5rm20ayv/AI53T34+2LDo0dxFDMd6QuZmUsAeOdowDnBBIxQB0i+ONJkVWhS/lVvuslo5B+hxTovGmmPIUeHUYsAtmSzkAP6VYGn6doOpvqUc7WkN2VhkgBPlPKzAIwX+FskjjAOeelVbXVtd1LVpjp9lZLo8NybcyzuwlfacSMFHAwcgZ64z0IoAt/8ACVabxj7Yc+lpKf8A2Wg+KtLHnZa8zEMsPsU2ce3yc9e1S+HNOnsV1GW8bdPeXklxt3bgi8Kqg/7qg47Emub8d65dfZP7Giju9P1K9vYLW1njJ2urP8zqwx91AxZeoHqOaANWXxvpKZxHqj4BPy6dOf8A2Sl/4TKxMcbpY6u4cZAFjID+ORxXTVheKddk0kWNrY232vVdRmMFrCW2rkKWZ3bsqqpJ/ADkigCqfGEOMro+uMPazP8AU1aXxLB5SPJYapGWGdhtWJH1xmuQs9ZutK1D4g63fQMslmltCsBn3I0iQlgF9NxlX36Vv+E9Y1O8udX0TVJIH1XTY4We6iTbGxlVmA2Z4K7efUEUAaqeIbRojI8N/H1+VrOUngZ6BTVX/hLtPIylrrDfTTLgfzSs/Sdf1TUfEdjpTJFBPZwyTauuw+6Q7M9Fdg7g88RkV2VAHO/8JZbkkJpmttgZ/wCPCQfzFVb3xxaWSRNd6ZrEKSyLCjSWwQM7HCrksOSeBXWVyfxW0s6v8OtftY8+eLR5oSByJUG9CPfcooAtweKElQl9I1mHnpJbc49eCaxvB3xEt/EkurIml6hGLGbajLEX86I5CyADkZKuMf7NJ4l8STXHwefW9O5u9Q06L7N5ZB/fThVQD/gbgVneG7e18LeP9Ws2mCWFl4bsSXc4CpE86lj+AyT+dAHYS+JbaORkFjrDkHGV06bB+h21XuPF1tAql9M1rLEKi/YXBdvQZxz1P4UngC7vtV0Q61qBlT+03NzbW8gx5FuQBEuOzFQGPXliO1XrDVYr/XdV014MS6a0TbjyGEikqR6HhhQBA/iJx9zQ9af6QKO2e7CmJ4knZ41/4R3XAHJG5o4gFx6/vK5rx/4qW38R6Po8elazdTrdrMBbwYScrE8iqshIX7yjcD2B9Kv+I9cm0/xN4XN7cvYW0kNzNeQ7g0ZwgCqT/EQ7DAHJNAG3/b8pAI0TVjkZ/wBUn/xdRv4huBnboGrMVIB+RB1/4Fz+FbVndQXttHc2kyTQSDKSI2QfxqagDnG8UmNHafRtXi2Ehi0Hyj33ZxSp4knecRjw/rWCM7zEgX6ctWN8Zr63sPB6Nehjbte25kCjJKI4kYD3KxsB7kVz0eu6t4R1xb7xLJd3eoa9ZPLDpUTBkS4SRBFaw9t22XDN0O1mPFAHcjxFft93wxrB+rQD+clKNf1IFzL4Y1GKJRkyPcWwGP8Av7UXhnXdQuNVuNG8Q29rb6tFbR3gW1dnjaJ2ZcAkdVZMH1yCO+Oa8WwSXXxAGgwiQQa5ZxSXW3p5UMv70n03Kyx8Y/1me1AHYNrGo7QyaBdsCM/66L/4qq6+JLsLiTw7qqyZIKhVYfmDiukAwOKKAOYfxNfCVUXwzq7BgTuAQAfXLU6TxBqofEfhfUXG4rnzYRwO/Ld66WigDml1zW2Ix4UvACerXcAx/wCP1am1LV1JEegyuPX7TEP61t0UAYA1PXOSdAIABPN3Hk+1Qxa/q7RgyeGLxJO6+fGQPxrpaKAOcn1zWEbEXhq6k+UHP2iNRnPTk0xNb8QMw/4pWVR6tfRcV01FAHPHVNfzx4eH3Qeb2PrnpSDUfER3E6FEAASB9sXJPYV0VFAHPtq2sq4X/hH3b5QSwukxu7j/AOvTJ9Y1xFQxeG3kYjJH2xBjn1xXR0UAc2mr+ImJ/wCKZUDAIJ1BOT3/AIe1dDAztDG0qeXIVBZAc7TjkZ70+igAooooAKQDnNUtY0/+07UQfaru1wwbfaymNz14yO3NYx8HwsPn1rxA3/cRkFAHT0Vy7+C7J1AfUdaYAFedQk5/Wnx+DdPT/l61NuAPmvHPT8aAOlornE8IackpkWbUN2MAfa3wPXHPepn8NxO+46lrA9lvpAP0NAFTx/Zx39npNvNJNGj6lDl4H2OPvHhuo/CuP0Twfpj/ABK8Tw2L31nBa2dlHut7uTdvYyuwLMTngocZ/nW/4n8PwLPpEIu9XkNxeKhJ1CX5AEY5GW4PHUc80ul+ALe21PWJrq81CWC7uEmhAv5wygRIhDHdzypIPoQO1AFn4l3i6X4at7l2PkwXts8mT95EkDMM+4Uj6mrXhnTprTwgxvN51G8je6umOQxlkGSPbHCj2UVj+KfhtYazYWFnFcXMVvFex3M4lnkl86Nc7o/mbo2R+FbUngzRnRh5MuSMAmdzj9aAL3hSZ7jwxpM0okEj2kTMJDls7R1965+GT+3/AIlynbmx8NxbEbPDXkyfN0P8ERA5/wCerVd0zwdYadpMFqrXc0kKAeYbl0ZyB6g8ZrM8FeCBZ6FA2vNOdXmmku7vyL2UI0rk5BwwD4GBkjsKAO761y/jPzLC70fXVV3t9OlkF4EXcVt5EIZwO+1hGx/2Q1WG8I6QxJ23wJ67b+cZ/J6afBmiFgXt7h8EH57yZh+IL80AcQ4l1Dw54/miR5XbWgRtXcSkRgG4eoCofy9q0PhvcJP4/wDHsufmuLqJ14xuSNWhyOemYzz35robPwF4XsVn+y6NbxiY5lALYfqeRn3P50aZ4C8L6cEay0W0jkVQolKZkIBJGWPJwST+NAFD4fwJqOreIfEsqBpLy9e2tpPS3hxGAPQFkZvxz3rtgR6iudsvBeh2dpBbRW0xjhUKm65lJ/8AQqsHwtpBheIW8yxuVLBbmUZIOR0agDbpHCspVgCpGCD3rBl8H6JLK8ktm7u5JO64lPP03VHF4I8NxtuXSYC2NuWLNx+JoA8y8IWWp6nH4Z8HXdtKlr4YvZJ9SnaJkicQyOLSOMnG/PySHHACAHrWt8TdD1TV/HNlZWcEjaVrliun6hdRg4ggjm82QFuQN6sYxkc7/au9bwh4eZcNo1iw94gaang7w9HJLJHpNqjynLlV259OnYUAbUZggiSOMxpGgCqoIAUDoMVgaTaSw+M9ev3WIWl3BapFIJAS7IJNwI7Y3D86sjwpog6adF69W/xqJvBnh9g4Omx4di7AO4yT+NADfEdvLc6z4ZuLfa0VnfPLOd4GxDbTID7/ADOo/GsrxFpL6n8R/C+oyCB9K0y3upHdpFwJ28tY+DyePMI9K0pPAvhmRNsmjWzr6OC38zUy+DfDa4/4kenHHrAp/nQBneCLm3sZtf015ookt9SlkhRplP7uUCXIGeBud/yNdUbu3GMzxDPT5xzWR/wh/hvDf8U/pPPB/wBDj5/SpB4W0JQgGk2YCDC4iHyj2oA5P4uta6hbeFbNrqEJL4gtS3zA8IHkI+h2YPsaj8QyWd98avCQkaJhp2m3t2su4FVZ2jjH0OC9ddN4U0GZoWl0mzYwv5kZMY+VsEZH4E1VfwJ4Ye/a9fRbRrkp5Zcrn5dxbGOnUk0AZcN/bn4u3WbmHyhokCqfNXG4zy5HXk8Cm+DtUsNR1LVPEt3e2iLeP9msN8yg/ZIzgMAeRvcu/uCmelaDfD3wu2oT3b6NZsZrdbZo2iBTaCxyB2PzEZ+laEPhPw7DDFFHoWliOFQkam1Q7QOgHFAFk69pAODqdln/AK7r/jUratp6fevrYfWUf41W/wCEa0IjH9i6Zj0+yx/4VKuhaSpyumWQP/XBf8KAJv7TsNob7ba7SMg+auCPzpjaxpi/e1GzH1nX/Gqb+FdCcqW0mzO0bR+7HA9KcvhjQ16aTY/9+V/woAlbxBoykhtX04EDJBuU6fnUT+KNBT72s6f/AOBC/wCNPXw5oikkaRp+SME/Zk6flUo0PSQONLsR/wBu6f4UAMGvaSUDjUbUoRnPmDFCa/pDMFGp2eW6ZmUZ/wA5qcaXp4BAsbUA4BHkrzjp2psukabMgSWwtWUHIBiXg+vSgCNte0dR82q2A7c3Cf40yXxJocRxLrOmocZw10g749fWnjQdJHA02zx/1xX/AAqT+yNNzk6faE9OYV/woAov4u8Op97XdM/C5Q/1qQeJ9DMayLqtoUb7rCQEGro0ywGMWNrx/wBMl/wp32Cz/wCfS3/79j/CgCpb+INJuJAkOoWzMQT9/wBOtK+v6Mgy+raeoHrcoP61c+xWu0r9mhweCNgqEaVp68CxtgPaJf8ACgCm/inw/GSH13SlIJBzdxjGOvetW3miuYI5reRJYZFDI6MGVgehBHUVENPs1ORaW4PX/Vip0VY0CIoVFGAAMACgB1FFFABRUF7JcRWztaQJPMPuxvJsB/HBx+VYY1DxSWwNA01VwOTqjde4x5NAHQ/N2IPPp2p1c9Lc+KPOYQ6XpPldme+fP5CKmNL4uI+W00RT73Erf+yigDpKK5q3k8XF5PtEGihR93Y8hJ/PpUxbxNgkR6RnsCZOfxoAj8WSCO/8PE5ydQVRj3RhXR1wPjCfWI5PD5urfTfMGpwBGW4dQ7HIIwUOOvXJz6CprzxRrsHi2x8Opp2lvfXVrJd7/tcmyONCq8/u85JYYoA7iiue3eKz/wAsdDX/ALayt/7KKWAeKju89tEH3tuxZT24zkjv1oA6Chc45GDWEo8TEDMmkKe/7qQ/+zUkh8RxIWMmjMowSWWSMAd+5/OgDeormxdeIHjSRG0MRSHCMJ5CGz0wdvNNK+MPNTDaEI8fPnzSc+3HSgDpqK5zy/FhP/HzoiD/AK4St/7MKnt4PEflt9ov9LLk/KUtHwB75koA3KKxPsviEgZ1XTlPfFix/wDalMmh8SqwWC60t128u8TqSc+gJ/nQBvUVzxh8UH/l70pfpE5/rWB4l1XxT4a0C61LUb7R5BGypGkdtJ8zMwVVPzep60AegUVxGmt4y1BbiOW/sdPuYH8tw+ns6McZ3RnzPmU++D61oxW2vmb7PJ4k043Ij3mNbD5sZxux5ucdqAOmorm0tNanjkSHxHas8b7XZLIHacfdI38dc03y9eS181tb00xqpZ5Tb4Uf+PYxjFAHTUVy8tj4qY/uda08DuDZ5/8AZqQ6b4sYHPiGyQ+1hn+bUAdTRXMnSfEzIAfE0Ktjkrpy88/71VdUs9d07Srm8n8SSSi3iaRhHYIC2BnAGaAOworktH03XLvT7a6ufENwsksSu0f2VFCkgHGPak159X0TQ7zU7zXF8m0haaQJaoNwAzxnOKAOuorl7ey1+80+GeLXXgaZFkCy2cZZAQDgj1FKNG8Rn73iph/u2EVAHT0V534Ol1/Wp9fhutfuF/s7UXs0YWkSl1CIwJ6/3iO1bh8OasxO7xTqOCf4Yox/SgDqKK59NH1ZY1X/AISG4Yjqxt0yfSgaRqLlh/wkV2SOoWKPj9KAOgorn7jR9ZkceV4luoUAxhbWFs/iVqNNB1cOGk8U6g4HVfs8Cg/klAHSUjrux8xGDniubk8OX8hXPibVhhQDtEQz7/dqSLQL2JNqeINSYk5LSbGP0HHFAHQ0Vz50PUQ6NH4iv1KnJBSNgfqCtH9i6uWJPii/AJ6C2tuP/IdAHQUVzzaBqLEFvFGrcdQsduM/+QqafDd0fv8AiTWj9HiH8o6AOjorAGgXCjC67qhGMfM6k/XOKmi0e6igmSPWr/fIPvtscr9NykUAbNFYa6LqGAG8SaoQPSK3Gf8AyFWtZQvb2scUtxLcuowZptu9/c7QB+QFAE1FFFABRUN7dQWNrJc3cqwwRjLOxwBWG3jbwyAT/blgQAWJEoIAHBJ9KAOiornW8beG0Xc2s2ePXfnPOOKY/jrw2hX/AImkbbs42xu2fyFAHS0Vzo8aaE0aOt1OyOCQVtJjwPontSJ400RxGVmu9khwrmwnCn8SmKAI/HKwbdDkuSgSPVIGDMcAHdx+tclF4p0L/hbl7ez6tpy2lpo8cCXBnU+Y0szMVBHHAiH5itbxn4k0iaPSVeV2gTUIpJS9rIVKqGbIJXsQOmao+GdR0+y8Y+J9UleKHS75LRLIJE43LGjBmI28fO5AHtnvQB2EfizQ5dGvdVt9RhnsbNS00sR3BcDOPc+1JoHiSHVLC9uLq1n0ySybFzFd4UxDYJASQcY2MD7c+lcl498XaDNYWFub0iA6jbNceXG4IRZAQQcY4cJnPbNLf6p4U1Pw7qWhxS6iE1BZfNlWynZi75yxO3n6HjgDpQB2Oj+JNL1e8e0sp2NykCXXlOjIxhckJIAR0JU+/FZHi0Je+LfC+k3SeZZTNPdSRsCVkMSDardiMuGwe6isDwZ4j07Rke3vtI1GDUJSEa8isp5VvdoOCGK7hxkhD0HAJq54r1uK8fTL/TdO1h9S026WaFX0ucLIrq0ciFtnAKM3PQMFJ4oAi+Mt4NG0LR54I1EceqRStChCCQruZV/FwoP1qW9/tXwZYaXq+paxc6gGnhg1SOUr5eZWCF4hgFQrsMDn5eOvNVPF8Fl4yh0CTVrbUrJtK1KPUWgSzeXzNm7am4DAySpJGemPeo/iR4j029u/DOk3C3kRm1WG5kR7Z8tFEGkOOOfmVAfYmgDL1Dxh4hiv4JF1GOL+1dP1C/gszbqVtYIYj5Ll+5ZirEng9K6fw5rWv+Jr2BrKaGy0+yt4PtcrwiQ3Ny6B5I15G1UBAJx95sfwmvMdQ/tBNTvHGk3d9p0Oj3WnWcsVqwkkiKRlE6fIzN5iewGa9G8BaxB4f8Fadb3djq73mc3Pl2EhYzv+8c4A6ZYjPTigD0aiuaTxdC7qqaRrx3HGTp0gA+pxUy+JUaMONJ1nnsbJwfyxQBv1518fPtI+HF61tCXWB47qWXdgRJE4kJx/FnbgD1NdI3icKpc6PrOxep+yn+VYviXxHa6x4T1myfStXAubaa3CS2LHeWQjOO45oA2tEt/EEN+JL7VLLUNMlUsMW3lSIeNuCDgjGc5GelcR4k1C7h+KOq21g+y9u9OsrC1eNdzxNLLMzyEH+FUjZv8AgOO4rovCPiJ7fwxpFre6RrCXkFlEkym1zh1QBhnODyK47T9VM3xq1nWG0PXpIbbToIYkFkciRi+48nptVf1oA7XXdDittE0/w3o0j2MN9P5c00bESsgUvI2/kmRgpG49zXl+qanJa+GviotvC6INShtLOAt8kh2pEEVeykrt46816LrXiC7upbO4sfDGuPd2UxljWWAIsgKFWXcWwCVY4J4zj615zoWgai+qG3u9Mv1mjvtP1y+gMed8iibIUk/89Ap64+WgDo5xefDi801YJZtT1TVrKb7UJZSReah5kKxsM/dG6UrxjC4/u113hmbU9M8THQtY1FtSlm08XwnaMJ+8Em2UKBwE+ePC9sd81i+JLe+1rxr4Q1ltF1CK10WW5llVgpL74dq4GeSGANak99HceKbLWxpOtF7S1ntRH9lX5vMaNt2S3by8fjQB3Fcv8TppLfwLq0seDti+YFS2VyMgAEZOPcVI3imQPtXw7rz/ACb8iBMfT7/WuQ+KXiS7uPAmqRDQNZt45Y/LeWREXbuIAxh853Ff1oAs+Idb1jS9StPDt/qEKTajNC1te20XlssZmRJIgvzfMAww3pnOMc4Wv63qWr+BfGunXhS5Qamuiae4GGk3FIyW9WDFyfpSeIbjxBqusx+Ij4e1aGCx8j7HFsTzBEsiyTuyk5DOF2BeuF/2qydNTWl8L6c9x4a1OCa88VNqz25KllPnPJs9h8g5PHT1oA9cttRntfFuo2F5dRNZLZR3dupTaYVBZX3NnnJCnnpzVf4canqmu6AdZ1OSM2+oSvcWMKw7GhticRhjk7iVAfOB97Fed/Gm7vXWzktdNvbS81mE+HWYlcYnkjfgg9kWcZ7MR2zXplrq0trBFa23h3VhDDGETAhACgYAH7ygDzv4cjU9Z1/xkNMu5NM0mDW7lri7jCNLczhUUIu4EBEC8nqSQBjBqbUfFOtXWl/D6/tpFOrarJNAsceRAztE4Ejr1KKBux64qr8IdTv5/hgTBoWqvLqs95cPcxmEKryyyHcAzg4GR2rSsNJ1TTtT8JPa+G7+Wx8PafNaR+ZcQq0kjiJA+N5/hR88/wAVAHc6X4cSwtJ1uNRv7q4uArXNxLNguRjkAcKMDGB2rcjCEb49pD4bcv8AF71wHjebxbrehSafpGhvamfKzyPeIrGPuikZwW6Z7DNTfD+11fw14btdKuNLvJ/KBdppLtHO5mLMo6YUE4HtigDvKKwxrGpNyvh+8x7zRA/+hUsmrakiEjw/eueypND6+7igDbornv7Z1k/d8MXY/wB67gH8nNO/tTXTjHh0jj+K9jH8gaAN+isJNT1oAmbQdvoI7xWP48DFH9q6tgn+wJQBzlrqMf1oA3aK586xrGMr4cuJMgENHdwFT+JYfypr6xruDs8Lzn03XsIz+RNAHRUVz7anr+7CeHo8erX6j+SmpI9Q13y5Hn0SBSMbVjvgxb80AFAG5RWJHqWrkkvoRAAJ+W7Qkn05x/OtLTZ57m0SW7tHs5iTmF3VyvPHKkjkc9aALNFFFAAQCMEZFAAHQYoooAKKKKACjAxjAxRRQBheJXKXmg7Q3N+B8o9YpOvtW7XOeMMi68Ov/d1OPP4o4/rXRbh6igCG+tIL+zntLyJZbeZDHIjdGU9RVXRdMOlWxt1vLq5iB+T7S+9kHpu6kfWtHr0qlqeqWWlxwvqFwkKzSrDHnJLO3QACgC4QDjIBwciloByMjkUUAFZt9o1te6zpupzmX7Rp4lEIVsL+8ADEjvwOPqa0DIg6uo+poEiHo6n6GgB1FJvXH3h+dJGxZeQAc8jOaAHUUUxpY1HzOg+poAeRTYo1ijWNAQijABOeKia9tV+9cwD6yChLu2fOy4hbacHDg4NAE9FQm7tx1niH/AxUwIIyDx60AFHemNLGv3pEH1YVC1/Zpndd2649ZAP60AWaKoPrOlp9/UrJfrOo/rSx6vpsqb49Qs3X1WZSP50AXqrahY22o232e+hSeDcrlHGQSrBlyPYgGmpqdg7hEvbVnJwFEqkn9asNLGv3pEH1YCgB9FV2vrVfvXMAx6yAVXfW9KTO/U7Fcetwg/rQBedFfG9VbByMjOD60481mpr2kSfc1Wwbr925Q9Ovel/tzSf+gpY/+BCf40AS6Rpdjo2nQ2GlWsVrZwgiOGJcKuTk/qauVm6hruk6dbJcX+pWdtBIcJJLMqq30JPNcZ4g+Mfg/SFnEWoHUpodu+OwXzTknoCOCe+PSgD0WkdQ6lWGVIwR6ivGrv4zX0o36P4VnmhHO+a6jQkH7uFz9c+lEviXx3ql5cfZtS8K6TZlwIFa7jkm2HqzjJGR6CgD2RFVECIAFAwAO1DOq/eZRxnk14hdeH9cvpNPXVPibYp5SyPMYJtuXY8EIXIIUcDpT7D4Y6FOwfUvHWoar+7ZN5vAr4JyQGVuFz2/PNAHq914m0O1heW41ayREUMxMy8A9DjNczffF3wPZlw2v2srKu/ERLZHseh/Ose3+G/w4gkWS5FvdyjG57i4BMmOm7GOntiuntI/A+nwmK3XQIIy3mbP3QGfXB+lAHKy/F651FXXwl4M17VpNgZWkQW8Zz33N2H554rkfipc+Pf7CM/ie9sdN0m8ljjjs9PRnaEqwYNI4G8ggENt4Fe1x+J/Dy4jj1nSxxnatwn+Nee/HLXtKu/CNsthqkT3K30LK1oRNIgyckBTleP4u3XmgDv/AAIyv4R0xkkEimEYYKQD9AecVvVxnw/8Q6VJ4TsB9r06AIm0JDdiVePRyqlvc465rePiLRx11O0/7+CgDVorHl8T6HCxEurWSMOoaYAiiPxRocsTyxarZvGhwzLKCAfegDYorBbxh4eUEtrFngAEnzK2LO7t72ATWkyTRHjchyKAJqKKKAIby3W6tpYJGkVJBtJjcowHsw5H4VlN4asdp2TakjHHzC/mJGPqxFbdFAHP/wDCLW29mF/quWxu/wBMY5x/L8KX/hFbM/eutRb63TVv0UAcx/whdhuY/bdXAP8ACL+QD9DTx4N0zYFaXU3Gc/NqE3/xVdJRQB574v8ADGlWh0V0W6y+pwRkvdzvwzYwPn469e1dLbeFNHtnVoreYMp3AtdStz+LVH4yfaujgBiW1O3Ax2+bJ/QGuhoAxLjwxps8m9luF9luHA/LNcR8VfDdrZ+HBc6at2l3GzESRyMzIhQ7yCTxgd69Srg/jjKYvhfr23zDI0BVRHjc2ewz7Z9eKAKPw+8I6TqngDw/c3i3rSTafCz/AOmSjJKDnhuM9fxrH1XW/hxo2oXWlTxajLdxkrLEj3DnaOS4O7lR3Yd+K7f4UMW+GXhVmABOmW5wOn+rFM0TwfZ21xrCajBFeRXN815CJIwRGGUAqD9Qc9O1AHBR+J/hhcQCa3t7qdGJPSfcUU4aQAtkqCRkjPtWxH4v+GYQqt/bIFwpAaTIAJAJx2ruV8K6EudulWi5Jb5YwME5yRjp1J49azZ/h74akeN49OSB0YtuhJUtndkH1B3tn60AY9tf/D2eASi7s1UoZNkszK23BOcE5q22leB7i1t382z8sx+ZFi6KsU27icZz05NMm+E/hGe0+zTacZI9jRjfISVQkEqD1A4rGvfgxpUkymy1G8tY/MLOFxu2k5Kq3UccfzyOKAOqt/BPhaeMSQ2MUyEAhhO7AgjI53ehBqwngjw2kTRLpUPls28gsxycYz1rhIvguttJAbTxDex7QEklC7ZgADgxspAVgSDyCMgEAHmktfht4rtZ7nZ4wu3jkdXXMrADGQQFwQobgkDgHkUAd6vgnw0P+YPafipNT/8ACKaFuZhpluCxycLjJ9685fwB45tjItl4zlaIMDDlcSRplVKZOc5XccnowHvUdl4I+IQeNZ/FAt7fBEi2zndndjKlumU5Oe/SgD0weF9DH/MLtT9UzUMng7w/I5Z9KtmJGDkHpXnk3hv4oeQWh16181okDRmRgGIxn5sfKxC9QMZYnFOsvCnxGmKT3XiCKzeEhVto7h5UnXjG9iMgLzkDlsdQDQB6APBnhwf8waz/ABjpU8G+G0JK6JYAk5P7kV5zB4B8dqHjbxO0TIU2yxzu6y4ySWRwSvReATk57cUsXw68aXTJ/a3ihZDEhVJIpZFLEkncRgAHOD6cYwBQB6Svhbw+AGXSLDA5B8laINA8PxgrDp2nAcsQsa+vJ/OvNpvhNrc1nKD4nKXbTpcKyIwjDBcFdufukjP4mpF+DUktssV7r8sn7xmOIRnY38GSecEdfQc9TkA7++s/CsVpJJfQ6MltE2XeURhUPuT0NU5rHwTaytHNb6HHIqqxV1jBAY4B/GuaHwghlixfeI9WvJVwY5J1iYxtjBcDbjeRj5jnkA0WfwQ8MW1ssBuNUkjUbQrTjaBz0GODyCT3IBoA0LzxF8OtPkELvo5kZVbZHCrHaTweB0zWJffEHwHaXFxDaaTFdSW0fmziK0UbF3bRg4+Yluw9D6V0+l/C7wppzIyacZ5FIO+5laViQpXJJPox/Hmuh0jw7o+j2ywaZplpbRKAAqRjoCSOfqT+ZoA8th8Y6lq8ccXhfwKUeTJR761MSBGOBJ0Axj+HOfzpx8H+O/EFvjUL7S9HhdCpght1YtkY5A+7jrw3U+gr2UUUAeU6D8EPD1mrHWbi51mRpGkP2gKq8444G7t/e5rvNN8KaBpkUcdhounwLGSU2W6/KT6HFbVFAFJdJ05TldPtAfUQr/hUqWFpH9y1gX6RgVYooAgFpbDGLeLjp8gqOfTrG44uLO2l/wB+JW/mKt01kVipYZKnI9jQBTXR9MX7unWY+kC/4Uo0nTg24WFpn18lf8Ku0UAQJZWqfctoV+kYFedfH1hF4E8uOHzTNcxxrAkjRmV8/KAykHrz1FemV5b+0Ht/4RjTleYRo16NwaQIu0RuxY564AJHvigDrPBMUWpeENIub+C2nlkgD5aMEjd2Of4vU9zmttdNsV+7ZWw+kS/4VlfD4xN4I0R7ZSsD2sckalNhCsMgbcDHBHFdBQBUOmWBYsbK1LHqfKXJ/SpY7W3jGI4IlB7KgFTUUAIqKv3VA+goVFTO1Qu45OBjJ9aWigAooooAjuTMLaU2yo04Q+WJCQpbHAJHQZrnhJ4wJGbXQVH/AF8TE/8AoFdLRQBjH/hIDCuBpYlwM/NIRnvjiq4TxSVXMujqcfNhZDz7V0NFAGLEniEAGWfTWIHRY3GTj61E7eJw7CNdIKA4DN5mSPXHat+igDivEX/CQedo5k/sgMLxNn+t+/sf07YzV6SPxizfJNoSjH9yU80/xk0gn8OiJEbdqsYbd2HlyHI9+K6SgDmFt/F5Vt9/o6t22wOf5muJ+OA1yz+G2u3d/qFn9nijLIIrb5lYnCck8ZJAz6kV67Xmf7R0qx/CHW1c7Q4QBuchgwZcY/2lA/GgC78PrfW7fwJ4bi0yXTFtE0+AKssTllGwfLkMM49e9b7x+KSDsutGU44zbynn/vun+BCT4M0MsMMbOIkYxztGa3aAOZEHi/LeZf6JtBbBW1kHHbq/50xbPxcxBbV9KA/2bRv6tXU0UAc3Fp/ib7Jsm1u0+0bid6WYA29hgmmSaX4nKHy/EcCvjjdYqRn8xXT0HpQBg/Y/EKthdWs2U5+/Z8j8mFL9h189dYtR9LP/AOzrbjLFAXG1u4znFOoA5+ew8RFEWHWrRSM7mayyT/49UQ0vxIUUP4hhDAnJWxUZGeOpNdLUN1dW9oge6nigQnAaRwoz9TQBg/2P4gJOfE8gH+zZxf1FPXR9cVR/xU0zNuyd1nCQR6cAVdi8Q6NLdC2i1Wwe5LbViW4Tcx9AM81Y07VLPUfMFncLI8Zw8ZBV0+qnBHTuOaAM9tN1on/kOKB7Wa//ABVOTT9XRSP7aDH1a1X/ABraooA5t9J8RMP+RmCcH7lhH/Ummf2Hr5OW8W3YGc4Wytxx6coa6emJEiO7qoDOcsfXtQBhDRNW/i8U6j+FtbD/ANpVg6Rqd7d69c6BfapqFhrFvGJ1SdYGFzEcjfGVUbgCOeOMgGu9JA6kD615n8XtS0STRVubTVbaLxLpr/aNNeEiSUyjrFheSsmChHTnPagDr/7G1I/e1+6/CJB/SmDRtZVm2eJbgITkA2sTEe2SKb8P/FEXjHwrZ61BbTWyXAPySjByODj2zmujoAw4tJ1QZ8zxFePnHS3gGOf9zv0qSfSLyYtjXtTiBbI8tIBgenMZ4rYooAwB4futwLeI9abB6EwAH8ohSjQbsAKNf1MqBgFtm4/UhRW6zquNzAZOBk9TXHN8SPDUOrSafe6jDbS7fMhdmDJOvOSjDOSMHI6jFAGs+jahsRIdevECnJLRo5PPckVH/YepH73iXUf+AxQj/wBkrR0fWdN1m2FxpN9b3kJ/jhkDCrzMFUsxAAGST2oA50+HL1pNzeKNbAxjavkAdev+qpG8Lzt97xJrx/7axD+Udc7q3iPX/EfiebQvBJjsoLIA3+r3UPmIjEfLHGhxvbHOcgY9asf2N8QrAySWnirSdVLdIb/TTAB9HjY/+gmgC7Eto+vy+HzresR6jDCt0BJIoM0bcblO3kAjBx0Jq9c+Gp5Ahg1/WIWUnJEwbcMdMEV5X8TPEmraTd+GdY8QaFPpepafebTfW0gmtXhY4kBYfMMqPlVgOT7V7pBKs8McsZyjqGU+xoAwIfD95EQW8QarIFGMEpzxj+7Xnnxs0WW00Gznk13U5Ge7KIJWRkXdG5xt2jPTGcggEkHNey15P+0ZcPY+ErK9imigeG6Ul5gWjK91IHc4Az259aANzwdoD3Og2U8mr6vE4Uhoo7hfLDdDj5AevPP61uN4YVuur6wec/8AHwB/7LU3gxYl8L6d5CTJGYVYCZgzHIzknv8AWtqgDFi0BYoXjTUdSOTuDNOWIOOP/wBVV08NzhlL69q7YIP+tAz+ldFRQBzlx4YeeXede1yMYxtjuQo/9BrU0bTf7Ltnh+2Xt3uffvu5fMYcAYBwOOOnuav0UAFFFFADZHEaM7HCqCSfaufPjTQd20XzFs4wIJP/AImuioAA6UAYNz4s0m3j8ySWYrkj5beQ9PwqmfHejn7iag/+7ZSf4V1VFAHOL4v08kD7PqQzjGbR+/4VJ/wlFpvKiz1MkHHFm/8AhW/RQBxXi/XbBU0GeR5owNRifD28meVcYxt689K1T4v0v+Fb9vpYzf8AxNL4vUeTpTEA7dStj+b4/rW/QBzcvjGwj6WuqPxn5bKT/CvM/j74isNW+HtxavBqVmXkUCSa0ZVYc5UZPUjpmvcK8v8A2hIJLrwXHHG0Q/f7mEndQpJx7/TmgDS8CeJYU8GaIiabrDhbSMA/ZicjaO+a6KLxCJD/AMgrV1GM5a2/+vVD4VXBu/hx4dmaRZC1nHlwc5wMfnxWr4t1R9E8MapqcUQlktLd5lQsF3EDIGTwKAMS6+IWlR6gdOtbXVb3VFVXks7eykMkSE43PkAKPqee1ZsXxZ0RdWTTdQsda029kH7uO8sXj8w88DP51B8LrvSNB8I6VPqepwtq+vD7bLczr5ct07kdQefl3Ko9sY61ufE/SLXVvDJW6jRpIJo5IGIGVfcBwT0JBxmgC0fFac7dG1xsHHFpjPvyelLF4oeRwq6BrgycZaBAB+b1wXhrVrzwL41l8OaperceGJITJY3E1wGe2IblHY8nG7H4CvYKAMSbXZY5GRdE1aTH8SRx4P8A4/UsGryyRl30nUYcAkq6KT9MBjWtRQByGu+MDaRSQ2mnXxvyBsSS3bAB/ix3A9qyI7FLud7nxLp2qapKNoS3eFfLUA/fClgM+prS8W3a6b4p0e5mRfJJZXkc/cTqxHp247jNReO9BuNR1XTb+O6t47WEruSeTYGcMCp9D9KAJ76SxvrSSzuPBmozWzDaUNvAAQOnWQV4/wCIb/VPD3itZLW31FZ7J0+yXFw0Zkjjdcm3uCr/ALxDjCAnjrnjFe2eLNX1zStQ0s6Xpcd/p8snl3ZywkiyQFYYzx1zx+IrivGfgy5t117Xb26+3xmzkdUji2ymT+E4zg7V+7jBz65oA7fTvEd5f6fb3VvoN9LHNGHDpNBtOR2PmdKtNrF2u0Not8HK7iAUYD2yDjNZ3wtdn8CaSWjWPEe3arhxwSMhh1zjJ9yRXV0AYA168YZXQdR/HaP60zWPEz6VYTXlxoupNBDH5kjL5QCjv1cV0VcL8bzMPhhrZhjjceWvmiR9oEe8bzn1xnigDk0/4STxiq6lrOnazDojAtDaWk8EPnRk5DuzSBk49PmwSMkHFdLYRaf4e0dbux8ER2VrbRlvMR7UlI15yGDnPc9a6LXtJl1bwylno+pSaZlEMVxEMlVAGMcjt/k1V1rw/OPCT6Zo0zRzuqRlgdqt/eOOi55JwPzoA4L4K6veQWuv6fpmkyT20WotcRRG4RTDDOPMQEE9TycD1r0htZ1JSB/YFyTjnEqYB+tcN8GrQ2ni7x+iybkjvYImXjhxEC2PYZwDxn0Fer0AYK6zqXz7/D95kY27JYzn8yK57xZ4/vPD2kzXFz4duoZijfZ0muYP3rgfdAD5J9hzXf14t8fLj+z9e8KX0kDXSx3BaONojJGrrggkAjvgn2B5FAFLV7vVrzUdMbx+t/aG9cJaafY3kUS7ivAcZLhs5G4YAqj8RNBHh/R7DVNN8JDTp7K6jb5b1JGmjzh1IJOeOSfxr0G0sdD1nUdH8X6lqRj1Jbf7OkYuNsKu2N21W5Unp2ODzWF8c2bVtFs9Dmt/M1O9vIxpy28u4yD+Jyv90A854xz2oA2tG8M2Oja6mvaH4ZZLmS1EAMF4FhKHDZCdM579aPiV4w1fQPCF7cjS2tbmQCK3dZ1dhIxwDjGK9BtohDbxRKMLGgUD0wMV5P8AtHLeL4d0q5t9v2e2v4XkG4gkl1VfbHOeaAL3g03/AIF8FQWx8PTyRQRtc3V293Gplkb5ncgnOST0/CoNE8S+M9X8TRXdnpHm6L5GZYTcwqFL8pznduUA7gcda9TPlzw87ZIpF+oYH+lYZmWXQtUt/CqQQ3Nqz20QVAsayhQenAwMigDy34m6p4q1m51Dw+dO/s/zdPdrZDOHjuSc7mYgHOwD7o5yc11Pws1rW774faJcRabb3EP2SNEf7TtZyvynII4OR0rurCCe30mKK/uftFzHGd85UKScdfauR+CAkHw5sfNVl/f3JTcc7l8+TawPcEYOe+aAOhhv9aP+u0eJR/s3QJx+VeTfHm81nUNA0u2uNDktVnvVtx/pKOrlwRg9NvqCeMivdK8b/ac+bwvosTJLJHJqKBo4xnf8rEA4IOMjsc0AdX4Pv9fj8KWMUWhKfIgWOMy3w3Pt4+b5cg8VfOo+LSPl0GwX/evs/wDstaXhB3k8L6W0hRn+zoCyMWDYGMgkknp1ya2KAMKG58QmEmXTrJZMn5RcEjH1xSR3XiIkl9MsQuDwLk5z2/hreooA57+0/EJOB4eg+p1AD/2StLSZ9QnSQ6nYxWbA4RY7jzdw9SdoxV+igAooooAKKKw/+EW0lYwiQzRqOyXEi9sdm9hQBuZornpfCGlSIyj7bHuxkx3synj/AIFTJfBmkyvukN+xxjm9lx/6FQB0lFcufAmgFiz20zkgD5rmQ9P+BU9/A3h13Z5NNR2Y5JZ2P9aAHeNA7JoyxhyTqduTt6YD5OfbAroi6jqyj8a4PxF4Y8P6Z/ZCwaekH2jUoYz5e4buGOCQfY10P/CKaL/z5Z+srn+tAG0siMcK6k+gNcB8drZ7n4dXphinklililXyIvMddrg5Cnr6fjXSjwpoqxui2W0OMErK4P55zXG/FjwfpifD7WJLG3mS6jiDRlZJHJYMMAjdyM9aANf4KFG+Fnhzy2DILYAYGFHJ4X/ZHQH0xXTeI9Li1rQdQ0ydisV3A8LEdgRivM/gt4Y0DU/AVlPd6OpuYZJrWT7So3ApKwIwOAMjoOld4PBXhof8wPTz9YFNAHk3hqHSrvwxF/wlttPba94NJVoIpwC0W/KOc5wrbQcdRgdsZ7bW9Yvta1qKw02aOHTri0IkMyDbubr8w5BCjIPTmofHPw4tri6TXvC9naxa3bq2+2YbYr9NqqInORt4UYP5+o43wpPa6j4dtbbRrzTLK0VAFOswGO7WIk8ZJ2SAc4YHnB6EUAVvHfhG88N+HFlupY71F1aI2bpyQrQ7Dwed25QTjOete7aHeNfaPZXMuFllhSR1B+6xUEj9a+dtb0ewulj0KB5NU12S6MzSW8hkj8pYx88QJwPnkAHdSuegr3XT/COjpZW4vNJsHuRGvmt5Qwz45P50AdEzqv3mA+pqJrq3X708Q+rgVmy+F9AmffNommyP6vaox657ikXwp4eXG3QdJH0s4/8ACgDM8e2tjqugy/vFmniG6OOOZVL56rzxyDj8axtA1Sy8a+D5NL1K5trfV7QiOaMShjHIpBjf/aBG0nsSSK7FPDujRoqR6VYqi9AsCgDgD09APyrm/iB4M0G/8PX1w2i20l/DbSLbPF+4cORwN64IGcc9utAFJv8AhOYYhp2n3eiXMCo0Z1AsVeJlTG0pyPvbT3wOork9c1W41u+0/wAN2Gqpq14ztcXEmSYY5NmAAwH+pUqx3c/Nx14qfwL4D0fxRpc8+rx3YSK8fZZmYr5GMDymx98Lg4JJ3bs10mi2vhzQ/FzeGbTw3ptrAYlEMyQIWkO3cQ3U9M9cEnPGOaAOx0x9M0nSrSzhubaOCCMRoN4AwBjjmpxrGmkEi/tcAgH96vBPTvVf/hGtC2In9i6ZsTO1fsseFz1wMcVLFoWkwqVi0uwRSQSFt0AJHTtQAn9vaRtB/tSxweQfPX/GobjV9Bvrea2n1DT5oZEIkjaZCCvfPPSraaTp0YAjsLRQOgEKjH6VJ9gtCpU20G0/w+WMUAeQ32sXXg/Rm0fVZWvtAt5QbHU7KQSmKANkQXCAM/yqNocKwIABweTXtvj3p0enxie1F5e8FvsTAxEEHoSTyMAkdgR9K6f4s3GmaB4dIi0ZGnvZBDHNFEihGY5YluMfKGJ5GQp5BxXEarY/YPh54T01BBdTarqKTyhxHbmfdJvTeCASoO3kcghOooA7T4XG08PaVqFxrmq2EWq6tePqF1ALhWEEjADyww6gAAfn1rsf+Eq0Hj/ib2PJIH74ckDNTx6DpKqCdLsN/ci2QZP5VOml2CY2WNquOmIVH9KAKcXibRJZVii1WzaRjhVEoJJrkPjfd6Pd/C/xAtzLbXDJbM6IJQJAw6FDnhvT+or0JbWBPuQRL9EAryj476jYf8I/YW0AgklOrW/n7Qu+JVYsXx1IyuDgHPIyOSADi/hzo+oWWkR3VlrHh+aS4LNt8QHzJ4VGNoUocMCSck4xwOnA9C8L2OiaRrkut+JPEmn6n4g2eTHKNsUdpCefKiQE7R79TXnXjnS20nRfCtmUjikisUt/PkhV2TzWyx9AAEVMnB+YAE817vpNvoF5AosINNnCIoJijQ4GMDoPagCRPE2ivGsialbMjZ2sHyDg4NYXivUvCPifw/e6PqmoQS2l0hV1V2U8c9RyOldallaooCW0CgdAIwMU6OCDAKwxr/wACgDxTwX8Qj4N0z/hHfGl5DNDbQsNM1lCTDcxKvEcnAKOvC8/eyMc9c/4U3+oJ4KguPD3iLQLCS7uZ57qzv2DiEF3IdArAqx4BDEj5eMc59S+Kki2Xw+16aMRxu1sUMhUfKDxnoSSASRgZz0rhvDXg7w+vwgstZv/AA7o1zqa6ebkNNZoVOcsqsEGGABAB59c9aAIrzxBbra3egr47j1fWtWBWa/VVSDTrboxVVyA3JC5JJZh2Br0LSfEvhXTNKt7Cw1O2FpYwJEiqS2yNQFGePpV/wAL2OkHw/Zvpumafa2s8aSiK2hVY8kdRgYP1rVSztkztt4Vz1wgGaAMNfG3h5hldSRhjPEbn/2WvLv2i9atbrRNFXS9QVZzeESSIpdoYipDNs+pTrjgnnmvcVhiXpGg+iivFf2mIhDpugXELi2YXu5p/L3KuANuR6k7VHB6+1AHdeE/FOj2/hTSFu7qztJUtYlkhRwVjbaAVGOOvFabeM/Di9dasj9JAf5Ve0C2t4NDsIbcRPFHAihkXCnAHNXfs8Oc+THn/dFAGXaeKNFvFdrW/ilVDhioJx+lVX8a6AhAN65yAw228rcEZHRa6FYo1+6ij6CgInZV/KgDFh8VaPLCZRdOsYbaWkgkQZxn+JR2q9pmrWWqeb9guFm8vG7AIxnOOv0NXdo9BS0AFFFFABRRWEY/ExU4u9HU7jjNtKflzx/y06+tAG7QTgZNYMcPiYFzLe6U442hbZ1+pJ3mgx+JcEebpR9yr8/hQBvUVhpF4iDKXudM28ZAif8AxpjR+KCTtutEUbjjNtK3Hb/loOaAIfGihp/DhPQarGf/ACHJXS1574vXxFCujve3ukyZ1S3WLyrORNjHcMtmU5HPQY+tdK1p4jYn/icaao7Y05/6zUAbtcv8TUZvA2rFGVSkW4gnG8AjK59WHH41O1j4lDHbrdiw4/5cSuP/AB81jeObLXpfCGrJPf6cYngZXVoGA2ng85znGce+KAMH9muZW8B3VvHCYY7fUJ1SNm3Mqltw3HueeT616xXhP7P6eIZtF1ZLSWws4o7hETzbZpQ6hcZBDqSeOSR19a9WNn4nZT/xOdKU44I0xz/7WoAueKdQTSfDOrahMxWO1tJZmIzkBUJ7c9q5n4U6HbJ8K/C9nqNvbXZSzSQ+YgcbmGSRuHfJryL4veIfFiatqOkPqSXOi3gisJYRaCH94WGdmXyd3IOT04Fe26foeuWthbW9tr0NvBFGqJEunKNigcD7xoA5X4Ti2n8c+PJLe0giitr/AOzRuiBScDnAHboMjrivVK+YYPEl9ovhjxPqen3H9o/btWntnCwiHaiAglO+c84HfmvYvAGneIP+EO0hrnXCZGt1fDRrKQCMgFz97HrQB3TMFKgnljgU6ue/s/xJ5SqNes94YksdOzkdh/rBTV0vxHvUv4ityoOSF04DI9P9YaAOjrjvi1LJF4FvxDHLJI+0KsWd2Qd35fLyO4yKtnRvEDEn/hJ8AkkbbFOB6feNeafEbxJa2tje6UfGj3urhvKS0S1UbJRjO4gcYHUZ5HHegDrvgc7T+Ebi6aSZxcXssiiUEFVzgAZ7YFYc/nj473LWUsEBCwi4Bj3NKpiHJ9hgAe+TVD4GS61qOjS2bapcQJbF/wB6kKskxZsiQFhxuzkDtis4X9zp/wAUvEc8mp3R/szfPNNLHGMRCINtA7gkjGcCgD3+ivEfhTrPi7xFqGqW2p+IFG0/aIHFon+rbGAASDgZ5OCM9DXok+ga/KPl8Vzx8g/JZx0AdVRXLDw5q5XD+KtQJznKwxj+lLH4Z1BZNz+KdXbj7v7oD/0GgDiPj9eTyppWk2kQcyky3DFhlIyyoNqHhyScEdhn1BHM+P8AVIn8L+AILxLZ5Gbdhg0ckfkj95hsfKCPlI6nPB4zVjx7ps03xJ0PTDqV5PPLsjW4leIPtD7mG0gcZAIIwc+tVPitpVy/j3SdKstQ1G5kgsJZyIo0ZwckqhIUBNx5Jz8wGMUAepfDXxyPF8V7HNp8mn3NrKyrGzbxJEDhXDehwa7avGvgj4S1i18DRNdald6bezSOZ40hQksDjO85LD0PpxXef8IxqJUhvFGqnryAg/pQB000iwxPI+dqKWOBk4FfPnxasFl8Z6NawrCDK/muJzyqzybR5YHIYbW6YI38GvXF8J3e8F/E+uEAYwJVAP8A47Xh2qQfa/ijeS/2jqNz9jkW0gkll+d/LGXKdA5BOOnHqaALfxfNx/wsNoI0eW1ght438o7mjUKWB65BBBIX/gXqa7v4E6nbajbaw1qCkbSpJGnl7FCFByMcY3Z7k+tedX2nPrHxjvdM825mlikIE0wYvFHsBy+MBl9Dg88E13nwk8L65Hp1/Nql9qdhI8wSP5Y1MqKMB8beAewIyO5NAHr1FczL4YupWU/8JHrCgLjCyKM+/wB2mf8ACJSH7/iHXj9Lsr/IUAeWftF+JJhp99pSXNvJpskIS4tySWyXG1jj/aXAA64b0rsPGE8mifCDTrZmn8x4ra2MiHDLwDkkA4Hy9cd/xrhfjZ4PsvDnhgx2WoajNc61qkYMdxcEqxI5JPGMAE565Oeta/xW0xdJ0Dw3ELzVrr7Tdxoy/a2ZvufwbsjP1zxmgD0rQtb0q1urDw215CNWWxS48hdwynTIzz1HQnNdLXg3wz0NvEniq91W9ub2C7tFWJtrruQqSEAbnIAznGeTz6V62fDrnrrWsZwR/wAfAH8hQBvV5H+0ciz+GNPgFzBFO10THFMgbz8KSQoxknHbjr7Cu3XwmON2ua82P+n5h/KvMP2g9IW10zQmjup5na8ZR9qvGJyy4wuf6c+lAHsHhZmfw3pjyKUdraMspUrg7R2PI/GtSuU07wzb3WkWrSX2sRyPCmcahLlTgZxk/wBKvf8ACORrFHHHqWqoiDHFzkn6kgk0AbtFZEOhrExI1HU2z2a4z2x6VWfwvC7EtqutnPYahIo/QigDoKKx30C3eHymu9UxtC5GoTK3HuGzn3q1p2lwWEjyQyXbs4Cnz7qSYYHoHYgfUUAXqKKKACiisi41+2hnkhNrqTujFSY7GVlP0IXB/CgDXorAPim1HSw1tvppdwP5pUw8QRFY2Gn6r84JANm4Ix6gjigDZorCHiMH7ukawf8At2x/M0+XxFBE7q9lqWVOPltWbPuMZoAreOFzZ6W2M7dTtT0/6aAf1ro64rxJr0NwNNxZaqqrexOc2UmGAPTpyfatSTxTCjbRpetscA/Lp0uP5UAbsqs20KV2HhwepHtWX4qZ7bwtqT2/lh4rZyok5Xgd81Xg8TCaUIuj60uf4ns2UfrVTWNenm0i7SLRNZDPA+D5Srjgju1AHnX7M80pg19JDKVnkjug0uCdzA7gD3UcdffpXuB6HHWvAfgBPHZ6rrAs7S8nHlxKwSMYXLMSzMSBkZPA5xjr29hPiMZIXSNYbHHFt/8AXoA8M+LejX1t40QziKdXm/tqKZHxLGkO0bG3cEAtng8jtX0MtyzaWLnG1jD5mPQ7c14zqs0PiL4q6952lXtx9k0m3tEh8kuYnkZnLOmcDG1fXg118XiFrXwkbU+H9fjWK0ZGY2+0jCnJyT+PNAHgd7dyxfDG41C2ZFdtUMVtHExIuJLhiHLDqrgAjHTvX1fodqbLRbG1IIMMCRkE5IwAMfhXiPwet4Zvg/b22oeHLvXLS6m+0JsiQBsnAZcsMEFM57Zr1hNc1BFWOLwzqRVRtGZIhwPq9AHSUVz8ev34z9o8OanH027Wikz+T8U4a9dk8aDqePUhB/7NQBvAADAGBXgvxX+Gtxb29xr8GrMyxTmRrdowqFZD8xYjuMjn0GK9Zu/ENzAqmPQNUmznhEXjn61xXxW1q9v/AANqltNoWpWtsVXzZnVGG0MMjGe/T8aANX4FxND8PrWNoIIAksiKkDhlChuuQTz1zmvPI9IXxN8avE2nw3cECSQt9oMSkPj5QQy9H4GMuCBu4ANdl8Lr6+03wLYRaZoEl1bO0jxtBNGq4MhHJOMn1Pc1yvhe5utM+OOsyPpjx32pIPJtzdxglURS6emRuD8dqAPUPB3gu08MXt/NakeXPJmGPGTDHgDbuPJ5FdZWNcalqcJGNEmlB/55zxnB98kVXGs6sZlT/hH7kcZOZkx+eevtQB0NFYDazqY83GgXR2kbf3yfPzj8PWqjeINeCs3/AAisqqMkl72NQB60AeW37Q3v7SdoTOzx27qpXazBZPJYrhgcDoQVIHODWpNvv/2loo1PlmzsfMYgsu5NuMbTw3LdR06Gub8HwavrnxQu/EWk6bHL9mfF1Bc3QVXG51Vk2jazAhvm9vXFaOkXerj476xcJYRnUXtVAsWugAm1Fyd5XBBDfw9xhgOCQD3uisA6jr3QaEmfX7WmKmgv9X2sbjSFVs/KEuFNAGvK2yJ244BPNeL/AARsbfWNV1bWZYopzHdO4ueMvcFm3OuOMbdo79M55rsPFviXWNO0K/nuPD8sVssMm+dbtD5QCk7iMdOPfnArnPgwNTsvD062mn213HGyJE4uljGxh5m3CoQMGQ9KAOX+Hd19s/aC1yOWR454Gm/dNcHc4BwDjHIAPA6juSOn0I+7jZjrzn0r5y8CXGsRfF/Whb2to1yLm5f7M0rIoyF3YkCYKqxI6ck57V7iLvxAIVLaXZ+bjlVuiQD9SooA3aKwobzX/MBm0u18vuEufm/liiTUddEjCLQoWUMQGa+AyOx+4aAPNv2oIDceFtCjRFLtqsQDNnAwCSDgE84x071Z+MVyWuPAiW0LFJb8fck2gKY+MHoeSPXPpVD9oSfXLjwPbCbSFiA1G3INrdNLKfm6KAgIPuM/Q1T+L93qn/FCT3VjYxwrqUQhEd84D5jJBkAiXagwScfSgD0D4SeG9Q8M+H7m21lIjfSXksrSpJ5nmKxGGzgYzjO3tXcVgxT+JSJDLYaUMAbAl07EnPfKCnwz+IDOvnWdgIc/NtmYtj24oA268S/aLeZdT8IJAuC10+JAoJD4GzjvhiCBkDIzXqT3mvbyI9ItCueGa9Iz+Gw1498eH1iXU/DBuYIbdlmcrDFcyTJKMop3II+CN+AfU/hQB7pYKyWUCtksEAJYAEnHU4z1qxXOW9z4ne3iZdP0UAoDzqEh7e0OPyq35mv+Sp+z6WJccgTyEZ9jsFAGxRWGr+JCw3R6Sq55w8hP8qHuPEQHyWOnMc97hl4wP9k980AblFY1tL4gZz9otNMVe224cn/0CrVi2qNdOL6GyS22/KYZmdy2e4KgYx70AX6KKKACiiml1GfmHHXmgBTnI6Y70tJuGM7hj60m9f7w/OgB1FMMsY6yJ+dAljPSRP8AvoUAc742kdToCRsF8zVYVbIzlQGYj2+71rpQQehzXJePbmOP/hHW8xP+QvCOueqSV1QkjxkOmPXNAD6gvgzWVwE5cxsF4zzjjinmeEdZYx/wIVFPdwCN8XMKPg4YuOD+dAHjXwA2ReI/E0Ilkd/kLKeApVihwDz95Wxn+HaR1zXt1eG/BdLez8e+JlVYUSKOOF5z8ryylixZw2NpbOQFyMc5r2o31ov3rqAfWQUAeceAUJ+Lfj6Q7tvmQj7wIJ8tR06jgf8A1q674hyGLwJ4gYBD/oMy/O2ByhHX8a5vSZ7bTfif4mk+2rLBd2EN6ir8/l7co+OvXaDtB/DvWN9rubvwP41vNWvpp/Nt54FiYI6oShB2KDjAyBg8jBzQB0/wUiaD4YaDGyMoWJtu5QpZS7EMQOASD0rt68x+H3ii0sNF8I6MDAIp9LikWdpwfMcAhlHqRgEn/aFegPq+moMvqFmo95lH9aAL1FUf7Y0wruGo2e3189f8ajbXtIXrqdl/3/X/ABoA0q4z4yOI/hj4hZofOH2bBQHB5IGVPZhnI98V0C69pLo7pqNqyJjcRIDjNcl8YdR0+TwHfWhu7R5rl0hiieTiR9wbadpzjCk/hQA34Lazb3vgmx062iZJ9Ohijlj24VQ3K4bJ3YXgnuQa5a5mt9B/aJa5MpAv7PyZfORW527gIz97dwvygdCxzgcaXwKvLOw8Ei81K5tbE6jMbiKKedFYRhQi9+ny8DsKZ8XYfDd7p83iCzv9Ol12xh2wstwj4j3AudnO47d2MDd6EZoA9cBBAI6Giuc0HxXol3ollcpqVkiSW6SbfOUbVIx0zkVYfxZoC9dXs/wkBoA26yfFczweHb9oyyyNEURgobazcAnIIwCecjpToPEOkTwiWLUbYxkkBi4AJHpmuQ+KfiPTo/B11Bb31nM06mNlMwOVxyMdyeB+NAFT4E2Sx6Lq19E/mW91eFIHKsuY4wF4B+6m7eVUcAEYrjvid52ifF7T7m0lZvOQXbEA7ol4Dohz951jY8c4B4wK7r4Uanpuk/D/AEiDUdUsobhofOcS3K7huJPzEn72DzXO/Ha80PWvDltNYano1zc2twr+WbtAJFPG0nPQ9PXOOlAHssbCSNXXowBFOrjfDfjfQpdBsWudVt0uBEqSI5wwYDBBHP8AWtJPGXh95FRdThLMcDAbGfrjFAGH8Z7hY/BV3BKHNvPG6zbVydgUk49TxkDrnkdKu/CfSYtJ8CaUsTs5uYVuWz0UuA21ePujOB7CuU+M2v2F54ee0sbrz5G3LKInICgDqfxIHHPOK7nQtV0Wy0S0to9QsYYraFIsGQIq4UcDJoA8A1YpZfFPxBdGW/gUXZV7hptsaOZQVC8gEAclXB9RkAZ+kdAuftmh2FwH3+ZAjbs5zx614v4/0bwqdc1fxda+JNLmnktwDYFoZELAqNwJPBOOTjpXcfD7xNptt4Qs1v8AVLHEYKoYpQ4CdhkDnHToKAO/orBh8XaFNIqQ6gjs2QNqOe2fSpX8T6Mhw18gPXBVs/yoA5H4/XKw/DyaMqxee4iRCA3ysDuBLLyo+XqMHt3rnPjFZ3cHgPQ9Tm86W7gWCOZtgb5tyNucDsMN0IJLYHWpPi9rFvrl1oWm2ssU1o15Ez/vNjE7iGPzEABUBOT/AHuM10PxG1bw3r3gvU9KTV7CWR4/kRZgWLKcgKQchuODQB22g38eq6LY38G7yrmFZV3DBwRnkdqv1478FfHFovhaW01u9ihktJVjiQr8wRlBHQnvuxXoUfjHQpJVjjvWd2YKAsEh5/75oA6CvFv2iPNF/wCFmDzC382ZJFiPzZZQqEDPzHdj5T+HNeoyeJdKiC+Zcuu7kfuZOf8Ax2vG/jvfaXfa14XmF2wDTBAwYIUKsHBKupI5AGQAeT7UAe72oYW0IdQrbBkDtxUtc3H408PCNAdXtS2BkBs81Mvi7Q2tzOl8rxAA7lVj16dqAN6iuZ/4TnQsZW4nf/dtZD/JasR+LdJkjV1kuSG6D7LLn8ttAG9RWJH4n06Rgq/a/XJtJQPz21bsdXs764aC3eQyqMlWiZcfmKANCiiigArKm8O6NNNNNJpdmZZm3yv5ShpG9WPf8a1aQEEkAjI6igDBbwjorYH2WQKOircyhR9AGwKVfCOiKyn7ESVBAzNIeD/wKt6igDnR4J8ODrpNu3+9ub+ZqeDwpoMH+q0iyX5dnEQ+76Vt0UAef+PfDOjJY6YI9NtY1fUbdJNsYG5SSMZHbmug/wCEO0ABQunIiqAqqjuqgD0AOKr/ABAikmsdKWEgN/alsTk44D811FAGAPB+ggj/AIlsZwQRlmPI/GmP4M8O/O/9kWrOcnLDOT+NdFSOcIxIJ47daAPn/wCEuhafcfEG+hvtPtZJLaB5VBiyq5lIQ55G4DjI7V7Z/wAI5omSTpGnEnnJtkP9K8d+EdxJJ8VfEEMUIFkjSPGUfIJzgsRjgk5HPQjHevd6APL/AIuHTdN0JNN0/TUW+ugzRLaoI2+XryuDg55xzWlpfw70dfBA002kK3NxalZZihJLuvzHGfesC7KeJvjKLeNYrm2sY9lzE75MGw7g+3PG5iBnrx2r12gD551HRIfDcfhDz7CKO6spZbU20kf+vwVG4P0KhD7E17cfDOhvknSbFg3PMKnNcP8AtCLcDwbaTWjMskV/DyH28FsEZ7CvRdIuDdaVZztkGWFHOfUgZoAhTQ9JSPYumWQT+75C4/lSromlL00yxH0t0/wrQooAppplgmQljaqDjOIlGcdO1eM/Ha2tDe6XpVhBaW80jebuUKCzuwTBH0J9/Svcq8JVLfxB8ejHK8zQwSiRYzjBaJDxn+6Dzj1oA9csfDOk22nWdqdOtGW2iWNN0YbAA7Zqv4i8MaZfeHtTs4tPtEe4tpI1ZbdSQSpwQO/OK6KigDzb4JXFpf8Ag2Ozm+zT3WnubST90of5OPmGOue36mvQRY2g6W0A/wC2Yryn4T27aN8QvGGlO1uFaYz7UTaSzHcME/7J5GcZ/GvXqAKz2No4UPawMF+7mMHH0rxD44xufEFpY6fHbW8slsEj8+3Xy33OAQrD5lPcnB9OK94rwjUmPiH4vQwOlwBBqUYRDxGyxqS5GO+Ac+vANAHs+m6ZbWumWtt5EJEUSpwnHA96wfiZoMOr+ANdsYYIVkktWK4jB5X5h/KuupHUOpVhlSMEGgDz34LXv9peEIkn+ySm2YIhjfzCBtBG7I4PJ47V6AYYyCDGhB6gqOa8k+DBfTPEfiTRZhAkkdw8myOBVIG87SWXgjaRjIz1r16gDx740Wi3er6NZJaswmlSFNseAhdxlwR3GOckCvW4beOOJE2Kdqhc7RzgV5R44gFx8TtEac7U+1RL98kFBnCuucAFyMEfxCvXaAKOr2kVzpN5btEjJJC6lSoweK4X4EXguPBrwRuHhtbiSFfk2sjA/MrY4yCfyNekV4/8JbmXSfHvi3w1JLEIYbt5YITgOEYBwcDqPnPzED05IoA9gPIpnlR5z5a59cU+kY4Un0GaAPIdcZtW+OuhW8aq0dgryhjnbhUO4AgfeBYcMe9evEZBBzz6HFeMfCy0kn+KXiO8k3kQh8bSHjAkKkANkkng9OOPpXtFAHgXgSF/CvxovNMaRmt51kjV5JyZGTcCgKk8gZwG59699rwX4w240T4k2XiEr5b+RHJHcFSyr5T/ADK2OQCG7A5P0r3iJ1kjV05VgGH0NAClVPVQfwrxH48yKnjTwabeNft8XnyW7HCl2+UBVJwCepwTj2r2+vGfj2sP9veE2mQSOJpNiLCZnBxywXpgevXpjmgD2O3z5Eed2dozu69O/vT6gs122yEsWZgGYli3JHOM9qnoAKMUUUAFFFFABRRRQAVjXNlrb6lJLBq9rDZn7sJstzDju+8Z556e1bNFAHPpY+Io4UU61ZzSZO92stvHbADmnG38RqBtv9Pdj13QMAPpg1vUUAcsbPxg3/MV0pOe1qx/9mqxNY+JHghWLWbOKUD9432PcGPsN3HauhooA898UWmt2y6V/aPiCGWOXUbeNUXTlGWLjHO/iuhXTPEAdydfhZWIwDYgbeP9+ovG65Ph/IBxq0B5GezV01AGHHp2tKxL62jgjGPsgGP1qCey8StITFrFlFH6fZc4/WujpCAQQe/FAHz98LkvD8UNehhvliupxPM0i2y4dVkVCTzjOcY28Y969N1u28Q6Vo99qE3idmS1heYqtjECQoJxk/SvPfhbeI3xq1yCORSjQT/ciCIzJJGhwCAQcKDwSCCK7z4z6umk+C52Zm3yN8qJJ5bPtBYgN24HX25oA5b4R6VqWpz6pro1meKSSYW8g+yR7JMKGJVsZPLDJ6cYHTNeif2PrB+94hl/4DbIKq/CuwuNN+Huh216Ntz9nEjruLbC5Lbc+27H4V1VAHmvxT0K8k+HeuJdanJfDy1dY5YVxuVgQAB1z0x3qx8Pl1bVvBemXNrrsccJhCL5NqpAKMytgPkgcAYPTFdd4oszqHh3UrVEV5JLdxGGOBvxlf1xXH/Au4u7nwSz6gqic3cpDIQUZScrtx0AHy4/2eaAOmk0rWHgRF8RTxyDOZFtYST6cFcVA2g6wx+bxXqA/wB22gH/ALJXS0UAc3LpN9Z6ZdPLr+ozuqlwxEakYHQYUV5d8JNCur/xJrd6bm6sAsMYXn9+TIxYlsjj7jY9QVNes+OG2+EdWOXA+zvuMbAMFxyVzxkDJFcf8BEkk8MaheyvJILq+do3nBE5RQq4lz/HkN+dAHZ/2VfqCItbu1z3aONiOPcfjTP7I1Q/e8R3v/AYIB/7JW5RQB4r4h0+68P/ABl066gv72GDWbcQ3k8EMTSSODtVmwvyqCUBOMHcOeK9H/4Ru7P3/EutH6NEP5R1yfxxkn0600TWrYFTZ3fzyIAGAKnALnohYAEd+PSvSLC4+12NvcbGTzY1fa3VcjODQBjT6M9vYOz6xq8nlIzFvOG5u/YfhXkvws05tf8AF1/cT3eof6BGyxzify3y7EEFQ3UbSCcZyOeteveNbpbPwxfyNK0YZBGWRdzYYhTtHc4JxXEfAe1k/s/V7+aQSme48tGcYlQKSSj+rAsfm/iGDQB3dvoaw4xqOpsR/fuWbvnvUZ0CU/e1zVz/ANtIx/7JW5RQB4hPp76F8Z57e41q/trbV4oTHKrorSPhlIJCc5KgZxxgc5Nep23h7yZvMbWNYm4I2yXPHPsAK4H44abcJLpPiHT44Xltn+yvIVJMYZgRkj+EuFVs9M5GOa9N0W8j1DSLK7hffHNCjhvXIoA8g8TWW34naVBFcXYc3EcPnCeRptrAk57bSFkHbG0EZr1lNGjTJW81DOCMm6dsZx2Jx2/zmvNPE2Ivi3oREqwT/azIxdQ25DEUXPHfLKDxjJr16gDCPh3P3tY1c/8AbwP/AImvLPEmlPoXxo0uWK/vRFqtkIXnknVG3I+3YrYy3EhOD0KivcK8j/aPtBH4b0jXUEnnaVqETB0I+RXYDdjHIDrHkemaAPQbPw8lszk6nqs27tLckgfTis/xPpVrY6FfX0l9qSfZoZJQftchGcZGVDDdz2/Cug0i+TUtNt7uL7kqBuDkfge49+9UfGcyQeFNVkeZoALdwJFbaQxGFwexyRzQB5Z8D/D1jNN4olEVxHCbuNY2juZVJ25PUPnB+VsH19MCvTj4aibO7U9Wb63Zrif2dmJ8I6mrqRIupSglkVGYbE25A74xnOTnOa9UoA8e+Nvh8WfhqzvrS6vjcw3aRiR5TJtR+CPYHgE9q3vAOhR6p4Z0zUbi71eJ3XKxfbyy7QcL93joBXS+O9OGqeENWthu83yGlhZRlllT50IHchlBxXEfs/6lFN4duLCNUi8llmECNuEW8ZYZ/wB4Mcfw5x2oA7SfwnYTzmWW41IsTnAvZFH5A15T8c9Hi0ubwwLLzXR7iRSJ7p8q7BQr7zkgA9sgE4r3evHP2j7eKXT/AA5LLam4ZL1hHvk8uJW8tiNzEEAnGAO/TBoA9Ch8N2k8EUj3OofOgJC3km3kduasN4fgZAn2zUABjpcHPHQVc0SRZtGsJEQorQIQpzkDaOOefz5q7QBy8vgqwlkd5LzVmLHJH21wP0qWXwdpcqgSNesApT/j7kHGMdj7V0dFAHPWfg7RrR3aKG4LOpQl7qVuPxarmk+H9M0ly9hbtExO4kyu/OMfxE9q1aKACiiigArLvdXa1vHg/s3UZlVd3mwxBkPGcDnOe3StSigDnv8AhJZD5G3QtZPmgHm3A2c4+bnint4lhDso07VSVODi0brW9TXdUKhmA3HAz3NAGHb+JYp9pXTdVVGBO5rYgfzzUE3i2OPy9uj63JvXd8lr09jk9a3bMzCPZOpDLxuJzu96sUAeb+N9de9tNHkTSdYg8jVbeXEkAUv975R83WuhPim6P3PDOun6xxj/ANnqv8S3KabpDKGP/E1thx/vGuvoA5628Q3cocy+H9UhVf7wQk/QBjT/APhIJz93Q9UP1jA/ma3qKAPm3wHqklj8Zr2eS1v598FxsghtsvuZ0Z0yWAwh4yeTkdgK0PjV4gOv6toujJpV3BIbiONkuVCPmRgcja2CMIflJ+bPbGao6PdRaX+0laRx7EgmE9tCI8kMCoOD0wRtzk8nPWtvVJDrX7SemWTgtHaW5ulIOUCquB0zliT14xjFAHqC+IL2JVjj8MaywUBQf3AB/wDIlS22ualNLtfw5qEK/wB6SSL+jGugooAwX1i8cFToV6ysSpyV6fn0rzX4O6hfaXLr+mf2fNPPFdviASqCirwpbtuIxnGPxr2dhkdSK8j8DxNpPxt8X2ewpbXapcRgHIDty2f7pPJ96APQH1y9jba3h7VHPrE0JX8zIP5VLBq15KkhOg6jEV+6sjwAv9MSH9a2KKAPLvjBrWo/8IVcw/2JdwvLLEsTtNEcsHBIwrE9AR9af8L7jW9O8CaYkXh24laRGnkluLpIpJXdixZlOSCc9K9MeNJMeYitg5G4ZwadQBhNqmrhyF0FyMDn7Uo/pUsOoaqw/eaKUOP+flD2+lbFFAHn/wASf7T1bwnf20fh+6MkQE8UjTwbQ6nOcbicDk9O3aqfwl1++vfBlsttps12bUPF5huI1DEHIXBYnoQMmvSpEWSNkcZVgVI9RXjnwknj0H4heKfC8ku0K6zW0TEDC9+Pfse4FAGv8T9d1iHw4sM2kiwNzKsaXX2yNjC20tu245HykH2PHOKX4RnVrPwLpaWeh26wyR+Yzy3+Czk8nAQ4HXHPTFX/AIvTbtItbExg/aZG+dlJC4XgcdMmtD4TQJbfDrQ4YlKhINpDYzkMc9Ce9AGo15rvmOq6RaFAcKxvTyPXHl8UW15rbKpudJt4yTgiO734GevKitqigDhfGVvrWv8AhzUdL/sFUEyEI5uo/vA5Bx9RWH8I9f1a58CwW1npsF1dWEjW0rfagIzg9VODkdsda9Wry3wl5nh34t63orEpp+pRC8s4QgAVwf3h46A9h7GgDA+Id3qdr4y8PXV7p1pZzvdIS0Vw0hK8Ak/Jjsoz2H4mvVftPiFvuadpm3sTePyPwjrgv2howvhdbkIhkjeMkszL8ocEkEdx78V6hpriTTrV1bcrRIQfUYFAFG3m1wbzc2dhjHyiG5YnPvlBXO+P7DWPEXhjWNGk0eGS3uIHVJFugDuAypAxn7wFdzSEZxyRg54oA8g+CviDxBf/AA7sUs9Lt7j7GPsvmS3eCzKSGB44xwK6vWZPFN5pV3DcaTpaQtGS3+mtnjnsvtXFeARF4S+Mmt+FxGYrK6V72x3SYyXO9wF7gHNezTxJPBJFIMpIpRh7EYoA8e+CNxqv9g6pFpUOnvEt4WX7RI6NyozyFO4ZGA3evRQ3iknmLRVHtLKf/ZawPAOkDw54h1a1n2rNeqk6sY1BkK5U/MMZwMcADFd/QBzwu/E2MHS9PJHBYXZwfcfLXjfhyTUPB3xO1GztrCGKLiJYVOIv3zF0AIGSAerH1Oa+ha8j+PemzafYQeLNKeWC9s9sNy8XWSEnKg9htY5yelAHZC58ZMR/xL9FUe9w5/pXnHx3l12PQdJuNS+wQLHfKAttJPlwwKkMV6Lg5z7CvXPC+pJq2gWV4j7meJd/IOHwMgke9ebftHK0vh/TUVZCBMzloW2yJhcAjPBGTyPSgDsdB/4SQaZZFDo0lt5SlSrSZIx+PXjvV/z/ABKQMWOmKT2Nw5x/47WjoiGPRbBDjK28YOPXaKu0AYKyeJc5a30rHoJHz/Kq0knjAyN5UGiKmflLPITj8K6eigDnY/8AhKzC/mHRFlx8uElIznv83pirWmp4gF4Tqc2lta4GFt4pA+cc8sxHWtiigAooooAKq3Go2VvM0VxeW0UqqGKPKqsAehwT0q1VS502xupWkubK2mkZQrNJErEgcgEkUATJcQugdJY2QjIYMCCKY13akjdcQcHjLjrVGXw3osru76ZaFnUqx8sDIPaqv/CH6FGo+yaXYwyA5DeSDj8PpmgDUbUrFWy19bAY6GVf8amjuYJVLRTxOB1KuDWYvhfQ1AA0qz/79ippNA0qTG7T7c46DYPTH8qAMrx35Uthp0ZeMudRt9ik9W39BjvXStLGoyzqB6k4rhvGPhvSYRof2XTraMnVLcMVQDK7uR+VdJJ4X0KSFYpNIsGiVi4QwKQG9cYoAvvf2affu7dfrIo/rUcmq6dHjff2ig8jdMo/rVFfCfh5emiaaP8At2T/AAqz/YWk4Uf2bZ/KMD9yvA/KgD54t9WiP7TkMVtLGUe4f/VSblKeXksRnA57jn1Fa/wiurXVfjH4k1iSSGNoIJIAIuIxmbAyx/iO0nbgY685zWDp8FpJ+046B0mhTz5fLbCJFthbGMcMoKkEnu3sa6z4A6Vp2p6n4w1C6tFuJ2u443aYb03EF22BhnHzLyeuKAPbkurd496zxFM43BxjP1qN9Rso/v3lsv1lUf1qtLoGjyxeVLpOnvFndsa2QjPrjFMXwzoKjA0TSx9LSP8AwoAtDVLBhlb61I6ZEy/415L4z1PTdO+LnhrVra/094rlvstxKJQTGfugZVunXO4cdc161DpWnwqFhsLSMDnCQqP5CuH+MehxS+D3vLO1gRtOlF6zKAhUJklhjrjrjvg0AdjFr+jygmLVtPcDglblD/WpG1jTFOG1C0B6Y85f8aq+GLu01bQLK7gRHSSIZyo645z/AD5555q8+mWDyM72VqzscljEpJ/HFADlv7RhlbqAj13iq0+vaRbvtn1SxiYc4edQf51YGnWI6WdsPpEv+FNOlaez7msLQt6mFc/yoAhfXtISISvqlksZG4OZ1wR65zVN/GPhtCQ2u6YCP+nlP8a2FtYFUKsEQA4ACDipFjRfuoo+goAzI/EWjyRCSPUrV4yNwZZAQR61zc1l4QHi2TxBLdQDU5EQFvMxwv3Tgf8A167mont4XcO8MbMBjJUE4oA4j4gyWeuaNElrd6dPgl1guZfLSRiCFy45UA88elJ4G1nRvDvhLTtM1DXdPa5t0KufPU9WJ69+tds1nat962hP1QULZ2q/dt4R9EFAGYvirQmIC6raNlBIMPn5ScA/TNVG8deGlJH9r2xIJBwSeR+FdGqKv3VA+gp1AGGPFmhlEb+0IsMoYcHJB79K84+Lt7p1z/ZOv6XeM1xpdwrzKrGNXiJ5yTjnOMc17EUUnJUE+pFZ3iDRrTXdEvdLvo1a2uomicbQeCMUAecfF7WtJ1jwt5Ntqlsyg75Y1YMHXHQg8Ffaui8D+JtLh8GaX9qvrdPKgWMhSzbdoAw2cnPqK5uw0++tPh/rGj3trCZtKwIGwQZUHIyfwOAD7elbvwRbd4Atd7xu4kfOM71zghZNwB3AEDnnGKANiXx14didkbUQWXghYnP9Ksv4r0dAhe6I3KGA8tskHp2rdooA8O+Lt3ZDxB4Y8Y6bL5j6VcCGdCGQlZflU8jkBuo9DXp48X6AuJDqEe6RQflDMOOOMD61P4x0aPxF4ZvrAkB5YyYpAASjjlWGfQgVyPwJ1L+0fBS211FHFeWEzwPbnlogGOAe+M7sHuAKAOoTxNoFwzTLcq7RIWL+Q+VX/vmoD488P/w3c7f7tpMf/Za6cKo6KB9BS0Ac4vjPR3R2V7ohTtP+iyD+lRX/AIh0fU7O4sZkupIbhGicG1cjBGO4rqKKAPAvhLr8HgrxLqXg3U5EitLYkW0u190wHIkK46MCRxwStSfHTVdJ1688IQ2s07TJeGVWVHTYMAE42bieeMV1/wAZ/Cl1qWlrrvh+InXdNUkJH1uYepj9yDhlHqMd64F/ENn8QPG3gaaC4lhKLNDceUrDcSOFO5Qd2V3DOV4Yc7c0AexDxno0QEfm30jJ8pIsJzkjjrsqeHxXp8xAji1A5XcM2Uo4zjutb4ooAwrjxPaQSbGttQZv9m1Y09fElj9mWaZLyBWJAEls+ePYA1tU0qC4bJyBjGeKAMX/AISnTP4ftrf7tjMf/ZKmttfs7i5jgijvtz4AZrOVVH1JXArWooAKKKKACiisvV7DULyQGx1ifT12gFY4Y3ycnn51Pt+VAGpTHjRpEdh8yZ2nPTNZB0/WI1fydaV2OAPtFqrAev3SvJpZrPW3t1WPV7aObu4ssg/gXoA2MfMTzzS1hrp+uCJVbXEMgzlhZqM+nGTTDpuun/mOgewtUoAr+PJGii0NlTdnV7VT7At1rp64Lx3DqNrpWledqcUrDU7UK8lsM7t/+yQMe3610f2HXNzE6zbbSDgCx6f+RKANqkI+bPtisqSz1c27qurRLKeji0HH4FqrwaZrayEz+IDInHyrZxr9eeetAHz34VUH4461IVZJdOstRljjhjxKHZjwjE/MAGJwfusWHeu8/ZgV4/DXiGKWWeRk1eQfvozG2Niclff7x9ST1rg/BFlcan8UdTWGciR9OuImkCZJDYYxYxhDzz3OBznNdh+z1EYbfW9Ii1S4iu7S9a4kiYI7TJIPleTcu4NwQQMAbcUAe5UVjXOnatI+YNa8pPQ2qsfzyKqrpGvAvnxHkH7v+hL8v/j3NAHR1HcQpcQSQzKGjkUqykZBB6iueGia6fveKJ/+A2cQ/nmpbfRNUSZHl8S38qqclPJhUN/45mgCj8PPDt/4YtdQsbqS1ks3upJ7YwqVIDnJ3D17n3zXXVjS6NdSSM39u6misOFQQgD6ZjNLDo9zCG261qMjHAzL5bY57YQfSgDYorEutHv5Zi0OuXcMZ6IEQ4/HFLbaPfQuWfW7yXPZkTH8qANqmlsOq4Y5zyOgrnp/D2oSsp/4SXVIwFwRGsQz78qaIfDVyk6yP4k1uQAg7C8QU+x+SgDo6KwLjw40zljresrnsk6gD/x2nxeHREvGq6qzDoXnB5/KgDcorBOgTsqg63qmQOSJAM/pSx+H5E/5jGqNnrmf/wCtQBu0Vzk3hiSYKG1/W02/887gLn6/LQ/hVXhWNta1w7f4vteCeMcnFAHR0Vg2fhmC1Vh/aGqS5zzLdFqWTw5GxOzUdUjBJJC3BoAn8VRPN4c1JIm8t3hYbwAcDHJxg54zxiuM+A7xt4RuxEFULfSLjeXbACgFmPUkDPp2HArq5fDhe1aBNW1WPIIDifLDP1rI0f4d6fo9p9m03U9atoSxd1hvGQM5+8xA7mgDtaK54eFofKlRtU1pxIoUlr58jB6g9j61CvgqwDhmvdXcj+9fyHtj1oA6cDHAHFeUNE3gv4sG4YpFo+sxySSzOMKshYce2G2DJ4+fH07x/DdoYVjW4vkC91uWyfqa5/xh8PYdb0qOG0v7qG8imSWKeaVpAhB5+XPPHbpnFAHdjkUVz8nhhJdhl1bWdwUA7L6RAffANJ/wiloVAbUNabB3fNqU3/xVAHQ0Vzkng7TJDmSbU2+t/N/8VTrfwfpFu7MiXRZl2kvdSNx+LUAdDXjGpKJf2j7AQ2ysLbTlhJ42hSWfgdiCc59yK9Ki8L6fFIsitd716E3D8frXkHhnR01r4667KZby2tdPXyIHhuyGlVUVCuVIYKD7nnIoA98orCPhizI+a61Zvrqdwf8A2epJPDWnSxskn2xlJJOb2b/4ugDZorBg8JaNBJ5kdvNv2lQWuZW4PXqxoHhPSAQTBKxHrM5/rQBvUVlxaDp8QISJwDz/AK1v8amGlWm5WMbEqQw3SMcHOe59qAL1FFFABRRVLUbm7tzH9lsmuVbhysiqU98Hr+dAF2isWLVr9hAP7B1H5yQzNJbjaB3IEh4PtmkOuypHK82j6ooQ4AWIOW57AGgDborAj8RPI2F0PWh7tbqo/VqWTX7pXZU8PaxJg4yBCAfpmQUAU/iJai70rT1MjJs1G3kyoz0fpXVVwXi3Wby4s7COXRr2yR7+BfNuJINpy/T5XJya6B9bvUlEZ0HUC3OSrRlfz3UAbtV9RmFvYXMzMyCOJnLKMkYBOQO9Z0WsXTOwk0a+jRQTu+U59gAazdR1+6uNPuYo9C1eMyRsu8xqNuR1+9QB5b8C4hc+O9SujF5saWpFvdb+DGX6YH3mz95j36V7fZ6Rp1lfXV7Z2FrBeXWPPnjiVXlx03MBk/jXgvwW1Se08Va21ppl5dQS20TWsUPlgmMMwaRyWHzFh0H1r2T+3tXI48K6gB6tc24/9qUAdJRWNFqWqPAjvoVxHIeqNcREjn1DY96jOqaxuAGgS4zjJuYvz60AbtFZQv8AUCp/4lThtvygzLyfT/69Rz6pqKFxHos8m0DGJkGfXGfSgDZorCt9V1eRjv8AD80Y9Tcx/wCNQ3Wra+kxW38NNKmBhzexL+maAOjornbPUvEUs2240COCPBO43iMc+mBTmvvEWfk0a2/4Fdj/AAoA6Cg1li71MKxfTo9wXIAnHJ9OlUhquvEceHVH+9fKP/ZaAOgUEAAnJ9aWsUX2tGPP9jRK/wDd+1g/riqsOoeJ3K+ZodpECpJ/00Nhuw4WgDpKKxILnX2hQzWFlHKfvKJyQPxxVf7R4qbpY6Uv1nc/0oA6OisMTeIkjYtZ6bI+0bVWd1APfJKnilju9fZvn0myRcj/AJfSf/ZKANuiucubzxSJ3FtpOmmIH5We8bJH0CVIZ/EptkIs9MWcj5lMzlQc+uKAN+iufgk8UGQedDpKx99rSE1K9zr4JCafYNzjJumGffGw0AbdFY8E+ukt59hYAdtl036/JUV3P4kE2LOw0ox4+9LdODn6BKAN2isNn8RmGPbDpSy4+cGSQgfTgVGv/CUlH3HRg/G3CyEe+eaAOgorCDeJV6x6TJnvukTH86UnxIR9zSF/7aSH/wBloA2vLXzfMwd2NvU9PpTqxifEAjk2ppZfaNmZJMbu+fl6VAp8VEjcmhqOOjyt9ewoAXx54jg8J+E9R1m5K4to8orMBvc8KvPqSK434EeGG0vw8+r6kFl1nUJHlnnwwLbmLHgnuT2rl/GVxqPxD+JEHhG2ubGew0dTc6gixO8DSHGwMdwyUyDgHq3sa9hhg1iCJIopdO8tRgDypOB2/j5oA18nOMHHrS1ibfEe77+klf8AdkBP60Z8RBmAXSmXI2sXkBx34x/WgDbornoh4qMi+a2iKnfaJSf6UskPilm/d3mjIuB1tpGOe/8AGKAOgorHS314p8+oacG8vGVs3+/6/wCs6e361Atj4kym/XNPwD8wXTWGfp++OKAN+iiigAooqre6hZ2Oz7bdwW+/7vmyBd3IHGfcgfiKALVFVl1CzYgLdQEnIGJBzSJqFnJnZd27Y64kHFAFqioUurdwSk8TAcEhwcUn2y2zj7RDn/fFAGL4wH7vSDjpqVv/AOhgV0Nch4/u4DZ6QY723Qrq1k7ZkXlPOXPf0roG1nTFzu1G0GP+my/40AX6juV328qdNyEcfSqser6dKuY762dR3EgNK2q6d9039rzx/rl/xoA8Y+D9okPjGO7iug8Yt5bRyz5Mj7t4ABPAUBhx33Z7V7pXh/w6uzZeJSdUltrWITPCv2iRFmBUcZY9UKkEAd+c8mvWD4o0BZhE2uaWJCCQhu484HXjNAGxRWQfE2hbFf8AtnTdjjKsLlMEe3NZF/8AErwZYPsufEumK/J2rOHPAz0Ge1AHVRQxxGQxrgyNvbnOT/kVJXnp+M3gAb/+Kjt/kG4jy5OPb7vX2qy/xZ8DJLJG3iOzUxv5bsQwVXxkLnHUjPHsaAO5orjofid4KmjZ4/E2mFEIDHzgAMrvH4bQTn0B9DVm1+IPg+7QNbeJ9HlUnHy3aH+tAHUUVzx8a+GAzKfEGl7lJUj7SnBHUdakj8X+HZCgTW9OO8ZX9+oyM4z16UAbtFZUPiPRZnVItVsndjhVEy5JxngZ545qWXXNJikMcup2KODgq1wgIP0zQBoUViXfiXw+qMlxrenRjnP+lop4Jz3/ANk/kaZ/wmPhsojjXNOKyHCEXCnccZ459CKAN6iuWk+IfhFGKt4i03dtDYEwJwTjPHbNNT4ieEXkjjj1+ykeTGxY2LFs9MYHft60AdXRXHN8TfBwETf27blJUDo4RyhBbaPmC468YpsnxQ8GILcnxBZkTsyxkEnJXqDxwfr1GD3oA7OiuJj+KngySJpF122424Qgh23EgbVIyfunpUMvxa8HRztF/aheRX2MEiZtp3bcnA4GaAO8orzOT42eDws7RS6hN5BUOsdm+cnBwM4ycHOOuOgNZz/Gm2uLyOHTfDuuXGWUFvK2hcpvO4YJGMgcZ5znHcA9dorxn/hY/jW9WJrHwillHKWJa/mcGKNR8zOoXggnp3wOeeKi+JPiDq0m2z1HR7CIj90zxZlyc4aRMkKOhIBJ5HfNAHuNFeIXT+No7MwXvjPT47ltoDJbyfvFHDMCq/IemPU5JpRD4t8mZ7fxY8hjZGKTRT4bCqrDIXgGQM2B/Dx3zQB7dRXhN3dfEazSWCz1fzJBv8t2spGU4Y7RxF8qsCPUrt75p9j4l+J8hlC26lS+yNrrSpFIUn7/AMnHC9upb0FAHudc38QfEaeGvCmo36SR/bUiYWsbEHfNj5Rj0zjPoK4CW98aXp2a3rqaNGy7gLCyJlBxx/rOq5JGDg4TP8XFPQvA3hx5pbjXb6/1CXCyMkySOgZX3FwSOSRwR6EigDq/gf4eOjeEVvLlvN1HU3a6u5SOXkLtk57jpXolc3aeLdGIjgtRebVXaqrYzYAA6fd9qm/4SqxzhbbVW/3dOnP/ALLQBvUVjW3iGC4mEaWOqqSCd0lhKi/mVpr+JtPRyrC7BV/Lb/Rn4b06UAbdFYkvifTorZ53NyEQ4IFu5PXHTFJY+J7C9jZ7eO9Kqdp3Wsi/zFAG5RWLceIreEqPsepyZOP3dm7fyFOfXkWFpBp2qNtGdotGyeccCgDYoqPzf9h/++aKAJKZJEkjozjJXpz/AJ9KfSEgEDuaAKEmi6VJdC5k0yxe5BJErW6Fx+OM0g0LSlXamm2aAnJCQquTgjsPc1o0UAZC+G9GWNo1063CMSxULwTUEXg/w9EweLR7JHHRvKBIrd+beem3H40tAHAfEPQtIt9J054dFsXcahZxDFshKp5y5HTpjNdQnhnQl+7oumA+1pH/AIVW8cZGkQMM/LdwH/x8V0FAFGLR9NijMcWnWcaEYKpCoBH4CmLoelJjbp1oMekQrRooA4+L4a+EU1Ge9fQ7OaeZ2kYzJvG5m3FgDwDkD8hU3/CuvBn2doD4W0UxMoUqbKMggEn09ST+NdVRQByLfDTwQ07zHwloRkflj9ij5PPOMY71s2Xh3RLBQtjo+nWwyWxDbInOc54HrzWrRQBVbTrJmLNZ2xJOSTEvP6VCdF0sy+YdOs/M3b93krndjGenXBNaFFAGNP4W0Gdw02i6c7AFQWtkPBGCOnoT+dZ138OvBt3K0k/hjR2kbducWiKTu65IFdVRQBxbfCzwM1wJj4X0vzBG0WRDj5T146dzz15qC7+E3gy5mimbRokli27GQkYCnhcdMDn8zXd0UAee3Hwd8FXF0LifS2klXeUJnfEZbqVGeD/KoJPgn4HkiRH0rcFwMs5YnHrnrmvSaKAPOI/gv4NGoR301lcXF2mB5k9w0hbAwAc9Rjt7CrsHwp8IwQCJNMziJoQ7SMWUMCCQex+YnPvXdUUAcRa/CrwVbBfI0G1VkOUfB3LyDgH0yM46Ulj8KfBtjbJBaaNFEqgLuR2DEAkgE5yeSa7iigDkLL4beE7K4E9vo8Ky/N825jnd17/XHpk46mok+F3g1LeSAaFbmNyCQWbIxngHOQOTxnHOOnFdpRQBzL+AvC7Xgujotr9oGMSAEEYOQBz0B7dKIvBPhwpKjaFaIrMM/KDvwMAn/wCvXTUUAZUHh3Rrf/U6ZaJ+8EvEQ++M4b68mtCO3hjJMcUaknJIUDJ9alooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACkBOTx/wDXpaKACiiigAowMg45FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    What did you do over the weekend? I celebrated Diwali on Friday with my teacher from Balivhar.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_57_29590=[""].join("\n");
var outline_f28_57_29590=null;
var title_f28_57_29591="Endoscopic ultrasound in chronic pancreatitis";
var content_f28_57_29591=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endoscopic ultrasound in chronic pancreatitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/57/29591/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/57/29591/contributors\">",
"     Michael B Wallace, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/57/29591/contributors\">",
"     Massimo Raimondo, MD, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/57/29591/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/57/29591/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/57/29591/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/57/29591/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/57/29591/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic ultrasound (EUS) was developed initially for improving imaging of the pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The close proximity of the pancreas to the gastric and duodenal lumen permits EUS to obtain high resolution imaging without interference by overlying bowel gas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8884?source=see_link\">",
"     \"Endoscopic ultrasound: Normal pancreaticobiliary anatomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The EUS diagnosis of chronic pancreatitis (CP) relies on quantitative and qualitative parenchymal and ductal criteria of which several have been published. It is generally accepted that in the absence of any criteria, CP is unlikely, whereas in the presence of &ge;5 criteria, CP is likely even though endoscopic retrograde cholangiography (ERCP) and standard tests of pancreatic function may still be normal. The clinical significance of fewer (1 to 4) features found on EUS is unclear, particularly when other diagnostic tests such as ERCP and function testing are normal.",
"   </p>",
"   <p>",
"    EUS has allowed for the recognition of several features of CP that had not been appreciated with other imaging modalities. These include hyperechoic margins of the pancreatic duct, subtle lobularity of the parenchyma, small cystic changes in the parenchyma, and side branch duct ectasia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53041 graphicRef53097 \" href=\"UTD.htm?23/33/24087\">",
"     image 1A-B",
"    </a>",
"    ). The ability to detect these subtle changes has raised questions as to how chronic pancreatitis should be defined and whether EUS may be overly sensitive. However, accumulating evidence suggests that these early changes detected by EUS correlate with histologic changes of CP and may predict progression to more overt disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL PANCREATIC EUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several normal sonographic findings of the pancreas have been described, which allow for appreciation of the abnormalities that can be seen on EUS. The following findings were noted in a study involving 130,951 patients who underwent a screening examination with transabdominal ultrasonography (TUS) using a 3.5 or 5 mHz probe [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pancreatic duct diameter, which is measured similarly by TUS and EUS, was dilated (&gt;3 mm) in only 0.49 percent of individuals and was more common in men and in older individuals. There was a strong trend toward increasing duct diameter with age.",
"     </li>",
"     <li>",
"      Cystic lesions were detected in 0.21 percent and calcifications in 0.05 percent of individuals. However, TUS may underestimate the prevalence of these abnormalities compared with EUS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies have evaluated the pancreas with EUS in populations of patients without clinical features or obvious risk factors for chronic pancreatitis such as those undergoing nonpancreatic tumor staging, evaluation of submucosal tumors or portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. However, whether these studies truly reflected findings in a population of patients with a \"normal\" pancreas is unclear. Some patients may have had risk factors for chronic pancreatitis (such as alcoholism) while others with nonpancreatic malignancies had severe cachexia, which can alter the sonographic appearance of the pancreas.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 20 patients, the pancreatic parenchyma was described as having a homogeneous fine granular appearance with smooth margins [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/8\">",
"       8",
"      </a>",
"      ]. The pancreatic duct diameter was 1.9 mm on average (range 1.5 to 2.4 mm).",
"     </li>",
"     <li>",
"      In another series of 25 patients, the pancreatic parenchyma was described as being homogeneous and finely reticulated without evidence of side-branch ectasia [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/7\">",
"       7",
"      </a>",
"      ]. A ventral anlage (echogenic difference between the ventral and dorsal pancreas) was seen in 68 percent of patients. No cysts or stones were described. The main pancreatic duct was uniformly tubular in shape with anechoic walls and a mean diameter (in the pancreatic body at the portal vein confluence) of 1.7 mm (range, 1 to 3 mm). Only two patients had a duct diameter of 3 mm. Side branches were visible in 8 of 25 patients.",
"     </li>",
"     <li>",
"      A third report focused on a group of healthy volunteers without a prior history of abdominal pain or alcohol abuse [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/9\">",
"       9",
"      </a>",
"      ]. The pancreatic parenchyma was described as being uniform and more echogenic than liver. A ventral anlage was detected in 45 percent. No cysts were seen. The main pancreatic duct diameter was 2.4 mm (range, 0.8 to 3.6) in the head, 1.8 mm (0.9 to 3.0) in the body, and 1.2 mm (range, 0.5 to 2.0) in the tail. Side branches were visible but narrow (mean diameter 0.8 mm, head; 0.5 mm, body; 0.3 mm, tail).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     REFERENCE STANDARDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no agreement on an appropriate reference standard for CP, particularly early or minimal change CP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/10\">",
"     10",
"    </a>",
"    ]. Nevertheless, findings on EUS have been correlated with other measures of CP including histology, pancreatic function testing, and other forms of radiologic imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most obvious candidates for a reference standard is histology. However, there is little agreement on the histologic features of CP, and features that have been described are often focally distributed or subtle [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/11\">",
"     11",
"    </a>",
"    ]. Despite these problems, several studies have compared results of EUS with subsequent resection specimens. These studies suggest that EUS detects ductal and parenchymal changes in patients with suspected CP.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study focused on 34 patients who underwent EUS followed by pancreatectomy or open surgical biopsy (21 for CP, 12 for pancreatic cancer) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/12\">",
"       12",
"      </a>",
"      ]. Overall, 68 percent were considered to have CP based upon the histologic findings. The total number of EUS criteria present were predictive of histologic CP. The sensitivity and specificity using a threshold diagnosis for &ge;3 criteria were 87 percent and 64 percent, for &ge;4 criteria 78 percent and 73 percent, for &ge;5 criteria 60 percent and 83 percent, and for &ge;6 criteria 43 percent and 91 percent. The authors concluded that a minimum of four or more criteria was optimal.",
"     </li>",
"     <li>",
"      Two reports evaluated EUS in patients with a heterotopic pancreas [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. Findings confirmed pathologically included small cystic changes, hyperechoic foci (corresponding to adipose tissue), and small duct dilation.",
"     </li>",
"     <li>",
"      Two studies evaluated intraductal ultrasound (IDUS) in freshly excised or snap frozen pancreas specimens. One report compared IDUS with histology in seven \"normal\" pancreas sections post mortem, and one Whipple resection [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/15\">",
"       15",
"      </a>",
"      ]. IDUS criteria for hyperechoic strands corresponded to fibrous bands around cystic structures. Another study compared IDUS with histology in freshly excised pancreatic tissue in 11 patients with CP [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/16\">",
"       16",
"      </a>",
"      ]. IDUS detected lobularity (which corresponded to interlobular fibrosis) and hyperechoic duct margins (which corresponded to periductal fibrosis). All benign areas had preservation of a fine reticular pattern.",
"     </li>",
"     <li>",
"      A study of 27 patients with CP compared the results of EUS with the findings on fine needle aspiration biopsy (FNA) and ERCP [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/17\">",
"       17",
"      </a>",
"      ]. EUS findings correlated with the severity of CP according to the Cambridge classification at ERCP in five of eight patients with grade I, 11 of 13 patients with grade II, and 10 of 10 patients with grade III disease. Furthermore, EUS-FNA increased the negative predictive value to 100 percent and the specificity to 64 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    EUS has also been studied in animal models of CP.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, CP was induced in four dogs by pancreatic duct ligation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/18\">",
"       18",
"      </a>",
"      ]. The dogs underwent EUS before, and 12 weeks after, ligation. In addition, the ex vivo pancreas was examined. At two weeks the main pancreatic duct and side branches were dilated with an irregular duct contour on EUS. The parenchyma showed hyperechoic foci. At four weeks, glandular atrophy occurred and more prominent hyperechoic foci were visible. By 12 weeks, pancreatic acini were replaced with fibrotic duct and fatty tissue. Also noted was an increase in standard deviation of duct diameter (ie, irregularity of caliber). Ex vivo EUS and histologic analysis of the resected specimens showed interlobular and periductal fibrosis and scattered mononuclear cell infiltrates. Other changes included collapse of acinar structures, zymogen granule depletion, and cytoplasmic vacuolization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pancreatography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have compared the results of EUS with ERCP in patients with abdominal pain and suspected CP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/7-9,19-21\">",
"     7-9,19-21",
"    </a>",
"    ]. Four of these [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/7,9,20,22\">",
"     7,9,20,22",
"    </a>",
"    ] used a standardized EUS and ERCP grading system (the Cambridge classification), making them directly comparable. Each evaluated the pancreas for the presence of 9 to 11 described criteria and then considered EUS to be abnormal if the total number of criteria exceeded a threshold number (eg, &ge;3, &ge;4, or &ge;5). EUS and ERCP agreed in approximately 80 percent of cases when the threshold of &ge;3 criteria was considered. In cases where they disagreed, the majority (74 percent) are abnormal by EUS and normal by ERCP. It is unclear if EUS is more sensitive to mild changes of CP than ERCP or if EUS was \"overdiagnosing\" early CP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Functional testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least three studies with a total of 179 patients have compared EUS with pancreatic function studies in which pancreatic juice was analyzed following stimulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/7,9,21\">",
"     7,9,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=see_link\">",
"     \"Clinical features and diagnosis of malabsorption\"",
"    </a>",
"    .) Overall, EUS and functional testing agreed in 75 percent of cases. Similar to the results or pancreatography, the main source of disagreement (71 percent) occurred in patients with an abnormal EUS but a normal functional test. Both EUS and ERCP also appear to correlate well with fecal elastase, a noninvasive measure of pancreatic exocrine function [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natural history may be the most clinically-relevant standard for early CP. A diagnosis of \"mild\" CP based upon EUS, which then progresses to more severe CP as diagnosed by other tests (EUS positive, ERCP positive functional test), is likely to be a correct diagnosis. Unfortunately, there are only limited data on the long-term natural history of \"mild\" CP diagnosed by EUS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cross-sectional study of alcoholic patients with and without abdominal pain showed that EUS diagnosis of CP (&ge;4 criteria) was positive in 89 percent of alcoholics with abdominal pain but also in 58 percent of alcoholics without pain, and 0 percent of control patients (nonalcoholic, no abdominal pain) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another report described the progression of pancreatic disease in 17 asymptomatic alcoholics with an abnormal EUS but a normal ERCP [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/21\">",
"       21",
"      </a>",
"      ]. Follow-up EUS examinations for 12 to 38 months (mean 22 months) did not identify progression to more overt (ERCP positive) disease.",
"      <br/>",
"      <br/>",
"      The follow-up period was notably short considering the natural history of chronic pancreatitis, which typically progresses over many years. Thus, it is not surprising that ductal changes were not detected. On the other hand, another study suggested that ductal changes may be detectable even with such short follow-up. The study focused on 38 patients with a history of chronic alcohol use and recurrent abdominal pain [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/25\">",
"       25",
"      </a>",
"      ]. At the time of enrollment, 32 of 38 patients had an abnormal EUS but a normal ERCP. After a median follow-up of 18 months (range, 6 to 25 months), 22 of 32 patients developed changes of CP at ERCP (12 patients grade I and 10 patients grade II according to the Cambridge classification).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The only significant differences between these two studies appeared to be related to inclusion criteria: patients with alcoholic cirrhosis were included in the first study [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/21\">",
"     21",
"    </a>",
"    ] while the second study focused on patients with abdominal pain and recurrent pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/25\">",
"     25",
"    </a>",
"    ]. Further long-term follow up data are needed to help clarify these relationships.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study focused on 43 patients who had characteristic symptoms of CP but who had normal or equivocal findings on ERCP, CT or TUS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients were treated medically (with enzyme replacement, a low fat diet, and at least three trials of bowel rest with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A pancreatic resection was performed in 16 nonresponding patients. The histologic appearance in the pancreas of these patients showed subtle but distinct evidence of minimal-change chronic pancreatitis. These changes were distributed focally throughout the gland and included lymphocytic cell infiltrates, intralobular and periductal fibrosis, and focal ductal dilation with inspissated protein plugs. Nine of the 16 patients had complete or significant improvement in pain after total pancreatectomy, whereas five did not respond and one died of unrelated causes. The histologic changes and response to pancreatectomy suggest that these patients had CP despite normal imaging and functional testing. However, a placebo response cannot be excluded. Furthermore, unblinded interpretation of the resection specimens may have also introduced bias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INTEROBSERVER RELIABILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interobserver reliability of EUS in the evaluation of CP varies depending upon the specific finding. In a study comparing interpretation among three experienced endosonographers, agreement was 88 percent for hyperechoic foci, 94 percent for focal reduced echogenicity, 94 percent for lobularity, 83 percent for hyperechoic duct margins, and 94 percent for duct irregularity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A similarly-designed study compared the interpretations of 11 highly experienced endosonographers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/26\">",
"     26",
"    </a>",
"    ]. There was moderate overall agreement for the final diagnosis of CP (kappa [k] = 0.45, a perfect test would have a k = 1.00) and for individual criteria of duct dilation (k = 0.60) and lobularity (k = 0.51), but poor for seven other criteria (k &lt;0.4). The expert panel had consensus or near consensus agreement (&gt;90 percent) on 206 of 450 (46 percent) individual examination criteria including 22 of 45 diagnoses of CP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/26\">",
"     26",
"    </a>",
"    ]. To further improve the reliability, an international working group published a set of minimum standard terminology, including definitions, for many of the EUS criteria of CP (",
"    <a class=\"graphic graphic_table graphicRef75105 \" href=\"UTD.htm?24/63/25596\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These estimates of reliability are comparable to other commonly used endoscopic procedures such as bleeding ulcer stigmata (k = 0.34 to 0.66) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/27\">",
"     27",
"    </a>",
"    ], and certain radiologic procedures such as brain CT for stroke localization (k = 0.56 to 0.62) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/28\">",
"     28",
"    </a>",
"    ] and better than the physical diagnosis of heart sounds (k = 0.05 to 0.18) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/29\">",
"     29",
"    </a>",
"    ]. However, reliability in practice is often lower than that observed in controlled trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LINEAR VERSUS RADIAL EUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic ultrasound can be performed with either a linear or a radial echoendoscope. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=see_link&amp;anchor=H109379195#H109379195\">",
"     \"Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract\", section on 'Equipment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endoscopic ultrasound for evaluating chronic pancreatitis is most often performed using linear EUS. However, in a noninferiority study of 100 patients, there was no significant difference between linear EUS and radial EUS with regard to sensitivity or specificity (44 versus 68 percent and 95 versus 95 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/30\">",
"     30",
"    </a>",
"    ]. Accuracy was also similar in the two modalities (74 percent for linear EUS and 84 percent for radial EUS).",
"   </p>",
"   <p>",
"    While radial EUS was not inferior to linear EUS in the study mentioned above, there are potential advantages to linear EUS over radial EUS. Linear EUS has color-flow Doppler capability, the ability to perform fine-needle aspiration, and enhanced tissue resolution. However, newer radial echoendoscopes are starting to incorporate some of these features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     THRESHOLD TO DIAGNOSE OR EXCLUDE CP BY EUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, there are many sonographic features that may indicate the presence of CP. The threshold for diagnosing CP based on EUS can be varied (eg, &ge;3, &ge;4, or &ge;5 criteria). The sensitivity and specificity of EUS compared with other reference standards depends upon which threshold is chosen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=see_link\">",
"     \"Glossary of common biostatistical and epidemiological terms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If a low threshold is used (&gt;1 to 2 criteria) the sensitivity (and negative predictive value) will be high, but the specificity (and positive predictive value) will be low.",
"     </li>",
"     <li>",
"      If a higher threshold is used (&gt;5 to 6 criteria), the sensitivity (and NPV) will be low, but the specificity (and PPV) will be high.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal cutoff depends upon the purpose of the examination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the purpose is to exclude disease, a low threshold will give the best negative predictive value. For example, a patient with only zero to one criteria of CP by EUS has a &gt;90 percent chance of having a normal ERCP [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/20\">",
"       20",
"      </a>",
"      ] (and presumably does not have CP). In such a case, further testing is unlikely to identify CP.",
"     </li>",
"     <li>",
"      If the purpose is to establish the diagnosis with a high degree of certainty, a high threshold such as &ge;6 EUS criteria gives a positive predictive value of &gt;80 percent of having an abnormal ERCP. Those with fewer criteria may require further evidence to establish the diagnosis of CP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two other factors must be taken into account when diagnosing CP based upon EUS criteria. All criteria may not be equally important. As an example, the presence of intraductal calcifications alone is highly suggestive of CP even in the absence of other criteria. In addition, there are age-related changes in the pancreas that may affect the diagnostic threshold. As noted above, the pancreatic duct becomes progressively wider as individuals age [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/5,31\">",
"     5,31",
"    </a>",
"    ]. A 4 mm main pancreatic duct may be normal for a 70-year-old, but abnormal for a 30-year-old. Currently, there is no accepted scoring system that factors in these effects.",
"   </p>",
"   <p>",
"    One common practice is to require a higher threshold (eg, &ge;5 criteria) for older individuals and a lower threshold (eg, &ge;4 criteria) for a younger individual. A lower threshold was suggested in a study of 120 patients (ages 40 to 61) without known pancreatic disease; the authors suggested that age alone was unlikely to be responsible for sonographic changes when at least three criteria suggesting chronic pancreatitis were present [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/31\">",
"     31",
"    </a>",
"    ]. The most common sonographic abnormality in all age groups was hyperechoic stranding. At least one parenchymal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ductular abnormality was identified in 28 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Rosemont classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;An international consensus panel (convened in Rosemont, Illinois, in 2007) developed consensus criteria for EUS features of chronic pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/32\">",
"     32",
"    </a>",
"    ]. Major criteria included: (1) hyperechoic foci with shadowing and main pancreatic duct calculi; (2) lobularity with honeycombing. Minor criteria included cysts, dilated ducts &ge;3.5 mm, irregular pancreatic duct contour, dilated side branches &ge;1 mm, hyperechoic duct wall, strands, nonshadowing hyperechoic foci, and lobularity with noncontiguous lobules. The group proposed a classification scheme based on the combinations of these criteria. Its validity will require additional studies in which the classifications are compared with clinically-relevant reference standards.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUPPLEMENTAL EUS TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several variations of standard EUS techniques have been developed to improve the diagnosis of CP but none is used widely.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intraductal ultrasonography has been useful for discriminating pancreatic duct strictures due to CP from those due to malignancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33353?source=see_link\">",
"       \"Intraductal ultrasound of the pancreaticobiliary ductal system\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Contrast agents such as Albuminex (Shionogi, Osaka, Japan) may help distinguish between pancreatic cancer and CP since the former tends to be hypovascular [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"       Secretin",
"      </a>",
"      stimulation enhances pancreatic duct dilation in patients with CP and has long been used in transabdominal ultrasonography where its benefit remains to be clearly established. Its role during EUS (secretin stimulated EUS or SSEUS) was evaluated in a study that included 120 patients with suspected pancreatic disease who were compared with 20 controls [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/6\">",
"       6",
"      </a>",
"      ]. An increase in the main pancreatic duct of &ge;1 mm which persisted for at least 15 minutes was considered abnormal. SSEUS was compared with a diagnosis of CP based upon an abnormal pancreatogram, calcifications, or bicarbonate secretion.",
"      <br/>",
"      <br/>",
"      The SSEUS had a sensitivity of 80 percent and specificity of 96 percent for the diagnosis of CP when considering the presence of any one of these reference standards. SSEUS also predicted which patients with pancreas divisum would respond to stenting; an abnormal SSEUS had a positive predictive value of 93 percent and a negative predictive value of 62 percent for response to stent therapy. Although stimulating, these results await confirmation by other studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DISCRIMINATION FROM PANCREATIC CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pancreatitis shares clinical and radiologic features with pancreatic cancer. As a result, there may be diagnostic confusion, which can lead to unnecessary resection in those with CP. No test has as of yet proven to be consistently accurate in making this distinction. However, a potential role of EUS has been suggested in several studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study compared EUS findings in 21 patients with pancreatic cancer with 14 patients with focal pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/34\">",
"       34",
"      </a>",
"      ]. The final diagnosis was proven histologically in all patients. The sensitivity, specificity and accuracy of the endosonographers' impression at the time of the EUS examination were 89, 79, and 85 percent respectively. After a blind interpretation of the videotapes, the sensitivity, specificity and accuracy were 73, 100, and 83 percent respectively.",
"     </li>",
"     <li>",
"      EUS fine-needle aspiration (FNA) has been used to obtain biopsies of mucosal and submucosal lesions in which prior conventional endoscopic biopsies have been nondiagnostic. The procedure is most commonly used to sample peri-intestinal structures such as lymph nodes and masses in the pancreas, liver, adrenal gland, and bile duct. Initial studies suggest that the sensitivity of EUS FNA for diagnosis of CP may not be sufficiently high to establish the diagnosis but high specificity may be helpful for exclusion of other diagnoses. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=see_link\">",
"       \"Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In some patients, EUS findings may be unrevealing despite clinical suspicion for pancreatic cancer. One study focused on a group of 80 such patients in whom pancreatic cancer was suspected either because of elevated serum concentrations of CA 19-9 without other definitive evidence of pancreatic cancer, subtle abnormalities on CT, or unexplained abdominal pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      weight loss [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29591/abstract/35\">",
"       35",
"      </a>",
"      ]. Follow-up was available for at least six months in 76 patients (95 percent) after EUS. No patients with a normal EUS developed pancreatic cancer. One patient who was diagnosed with chronic pancreatitis by EUS was subsequently found to have pancreatic cancer at surgery. The authors concluded that pancreatic cancer is unlikely in patients with equivocal clinical suspicion for pancreatic cancer who have a normal pancreatic EUS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies underscore the limitations of EUS in discriminating CP from tumors. Cytopathologists face equivalent challenges when trying to discriminate inflammatory from neoplastic cells. In the future, translational research with application of specific molecular (or tumor) markers to FNA specimens may provide a significant aid in discriminating CP from tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of EUS in the management of patients with chronic pancreatitis is still being determined. EUS detects changes of mild CP that may not be detectable with other imaging modalities or functional testing but can be confirmed by histology. However, controversy remains regarding the diagnosis of \"early\" CP based upon EUS changes alone.",
"   </p>",
"   <p>",
"    There is still a need to improve the definitions and terminology used for the EUS diagnosis of CP and to find better methods for distinguishing focal CP from malignancy. Future studies will need to evaluate the ability of EUS to diagnose CP at early stage by comparison with established clinical criteria, long term follow-up",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    histology.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/1\">",
"      Sivak MV, Kaufman A. Endoscopic ultrasonography in the differential diagnosis of pancreatic disease. A preliminary report. Scand J Gastroenterol Suppl 1986; 123:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/2\">",
"      Lees WR. Endoscopic ultrasonography of chronic pancreatitis and pancreatic pseudocysts. Scand J Gastroenterol Suppl 1986; 123:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/3\">",
"      Kaufman AR, Sivak MV Jr. Endoscopic ultrasonography in the differential diagnosis of pancreatic disease. Gastrointest Endosc 1989; 35:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/4\">",
"      Dancygier H, Classen M. Endosonographic diagnosis of benign pancreatic and biliary lesions. Scand J Gastroenterol Suppl 1986; 123:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/5\">",
"      Ikeda M, Sato T, Morozumi A, et al. Morphologic changes in the pancreas detected by screening ultrasonography in a mass survey, with special reference to main duct dilatation, cyst formation, and calcification. Pancreas 1994; 9:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/6\">",
"      Catalano MF, Lahoti S, Alcocer E, et al. Dynamic imaging of the pancreas using real-time endoscopic ultrasonography with secretin stimulation. Gastrointest Endosc 1998; 48:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/7\">",
"      Catalano MF, Lahoti S, Geenen JE, Hogan WJ. Prospective evaluation of endoscopic ultrasonography, endoscopic retrograde pancreatography, and secretin test in the diagnosis of chronic pancreatitis. Gastrointest Endosc 1998; 48:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/8\">",
"      Nattermann C, Goldschmidt AJ, Dancygier H. Endosonography in chronic pancreatitis--a comparison between endoscopic retrograde pancreatography and endoscopic ultrasonography. Endoscopy 1993; 25:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/9\">",
"      Wiersema MJ, Hawes RH, Lehman GA, et al. Prospective evaluation of endoscopic ultrasonography and endoscopic retrograde cholangiopancreatography in patients with chronic abdominal pain of suspected pancreatic origin. Endoscopy 1993; 25:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/10\">",
"      Forsmark CE. The diagnosis of chronic pancreatitis. Gastrointest Endosc 2000; 52:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/11\">",
"      Walsh TN, Rode J, Theis BA, Russell RC. Minimal change chronic pancreatitis. Gut 1992; 33:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/12\">",
"      Zimmerman MJ, Mishra G, Lewin DN, et al. Comparison of EUS findings with histopathology in chronic pancreatitis [abstract]. Gastrointest Endosc 1997; 45:AB185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/13\">",
"      Fl&eacute;jou JF, Potet F, Molas G, et al. Cystic dystrophy of the gastric and duodenal wall developing in heterotopic pancreas: an unrecognised entity. Gut 1993; 34:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/14\">",
"      Matsushita M, Hajiro K, Okazaki K, Takakuwa H. Gastric aberrant pancreas: EUS analysis in comparison with the histology. Gastrointest Endosc 1999; 49:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/15\">",
"      Menzel J, Foerster EC, Ubrig B, et al. Ex vivo examination of the pancreas by intraductal ultrasonography (IDUS). Endoscopy 1993; 25:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/16\">",
"      Furukawa T, Tsukamoto Y, Naitoh Y, et al. Differential diagnosis of pancreatic diseases with an intraductal ultrasound system. Gastrointest Endosc 1994; 40:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/17\">",
"      Hollerbach S, Klamann A, Topalidis T, Schmiegel WH. Endoscopic ultrasonography (EUS) and fine-needle aspiration (FNA) cytology for diagnosis of chronic pancreatitis. Endoscopy 2001; 33:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/18\">",
"      Morita Y, Takiguchi M, Yasuda J, et al. Endoscopic ultrasonographic findings of the pancreas after pancreatic duct ligation in the dog. Vet Radiol Ultrasound 1998; 39:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/19\">",
"      Buscail L, Escourrou J, Moreau J, et al. Endoscopic ultrasonography in chronic pancreatitis: a comparative prospective study with conventional ultrasonography, computed tomography, and ERCP. Pancreas 1995; 10:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/20\">",
"      Sahai AV, Zimmerman M, Aabakken L, et al. Prospective assessment of the ability of endoscopic ultrasound to diagnose, exclude, or establish the severity of chronic pancreatitis found by endoscopic retrograde cholangiopancreatography. Gastrointest Endosc 1998; 48:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/21\">",
"      Hastier P, Buckley MJ, Francois E, et al. A prospective study of pancreatic disease in patients with alcoholic cirrhosis: comparative diagnostic value of ERCP and EUS and long-term significance of isolated parenchymal abnormalities. Gastrointest Endosc 1999; 49:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/22\">",
"      Stevens T, Conwell DL, Zuccaro G Jr, et al. Comparison of endoscopic ultrasound and endoscopic retrograde pancreatography for the prediction of pancreatic exocrine insufficiency. Dig Dis Sci 2008; 53:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/23\">",
"      Usk&uuml;dar O, Ouz D, Akdoan M, et al. Comparison of endoscopic retrograde cholangiopancreatography, endoscopic ultrasonography, and fecal elastase 1 in chronic pancreatitis and clinical correlation. Pancreas 2009; 38:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/24\">",
"      Bhutani MS. Endoscopic ultrasonography: changes of chronic pancreatitis in asymptomatic and symptomatic alcoholic patients. J Ultrasound Med 1999; 18:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/25\">",
"      Kahl S, Glasbrenner B, Leodolter A, et al. EUS in the diagnosis of early chronic pancreatitis: a prospective follow-up study. Gastrointest Endosc 2002; 55:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/26\">",
"      Wallace MB, Hawes RH, Durkalski V, et al. The reliability of EUS for the diagnosis of chronic pancreatitis: interobserver agreement among experienced endosonographers. Gastrointest Endosc 2001; 53:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/27\">",
"      Lau JY, Sung JJ, Chan AC, et al. Stigmata of hemorrhage in bleeding peptic ulcers: an interobserver agreement study among international experts. Gastrointest Endosc 1997; 46:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/28\">",
"      von Kummer R, Holle R, Gizyska U, et al. Interobserver agreement in assessing early CT signs of middle cerebral artery infarction. AJNR Am J Neuroradiol 1996; 17:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/29\">",
"      Lok CE, Morgan CD, Ranganathan N. The accuracy and interobserver agreement in detecting the 'gallop sounds' by cardiac auscultation. Chest 1998; 114:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/30\">",
"      Stevens T, Zuccaro G Jr, Dumot JA, et al. Prospective comparison of radial and linear endoscopic ultrasound for diagnosis of chronic pancreatitis. Endoscopy 2009; 41:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/31\">",
"      Rajan E, Clain JE, Levy MJ, et al. Age-related changes in the pancreas identified by EUS: a prospective evaluation. Gastrointest Endosc 2005; 61:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/32\">",
"      Catalano MF, Sahai A, Levy M, et al. EUS-based criteria for the diagnosis of chronic pancreatitis: the Rosemont classification. Gastrointest Endosc 2009; 69:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/33\">",
"      Hirooka Y, Goto H, Ito A, et al. Contrast-enhanced endoscopic ultrasonography in pancreatic diseases: a preliminary study. Am J Gastroenterol 1998; 93:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/34\">",
"      Norton ID, Zheng Y, Wiersema MS, et al. Neural network analysis of EUS images to differentiate between pancreatic malignancy and pancreatitis. Gastrointest Endosc 2001; 54:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29591/abstract/35\">",
"      Catanzaro A, Richardson S, Veloso H, et al. Long-term follow-up of patients with clinically indeterminate suspicion of pancreatic cancer and normal EUS. Gastrointest Endosc 2003; 58:836.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2648 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-09444732DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_57_29591=[""].join("\n");
var outline_f28_57_29591=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL PANCREATIC EUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      REFERENCE STANDARDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pancreatography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Functional testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Response to therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INTEROBSERVER RELIABILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LINEAR VERSUS RADIAL EUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      THRESHOLD TO DIAGNOSE OR EXCLUDE CP BY EUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Rosemont classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUPPLEMENTAL EUS TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DISCRIMINATION FROM PANCREATIC CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2648\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2648|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/48/1794\" title=\"diagnostic image 1A\">",
"      Normal pancreas EUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/22/22882\" title=\"diagnostic image 1B\">",
"      Chronic pancreatititis EUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2648|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/63/25596\" title=\"table 1\">",
"      Chronic pancreatitis terms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=related_link\">",
"      Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8884?source=related_link\">",
"      Endoscopic ultrasound: Normal pancreaticobiliary anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=related_link\">",
"      Glossary of common biostatistical and epidemiological terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33353?source=related_link\">",
"      Intraductal ultrasound of the pancreaticobiliary ductal system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_57_29592="Diagnostic cystourethroscopy for gynecologic conditions";
var content_f28_57_29592=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic cystourethroscopy for gynecologic conditions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/57/29592/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/57/29592/contributors\">",
"     Cynthia S Fok, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/57/29592/contributors\">",
"     Kimberly Kenton, MD, MS, FACOG, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/57/29592/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/57/29592/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/57/29592/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/57/29592/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/57/29592/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H12637557\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystourethroscopy is used by urologists, urogynecologists, and gynecologists. It is particularly useful in gynecologic practice for the evaluation of operative lower urinary tract injury. The use of cystourethroscopy to examine the female urethra and bladder was introduced in 1805 by Dr. Philipp Bozzini in Germany and visualization was improved in 1894 by Dr. Howard Kelly, a gynecologist in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29592/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Currently, cystourethroscopy training is provided in most, but not all, United States gynecology residency programs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29592/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The female genital and lower urinary tracts are closely related anatomically and embryologically. Thus, many conditions or procedures affect both of these tracts. Examples of this include: urinary incontinence associated with pelvic organ prolapse, urogenital fistula, metastases of gynecologic malignancies, endometriosis, and hysterectomy or pelvic reconstructive procedures.",
"   </p>",
"   <p>",
"    Cystourethroscopy is commonly referred to as cystoscopy, and this term will be used in this review.",
"   </p>",
"   <p>",
"    Use of cystourethroscopy for evaluation of lower urinary tract injury for gynecologic indications is reviewed here. Prevention, evaluation, and management of lower urinary tract injury in gynecologic surgery, as well as placement or ureteral stents, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14056?source=see_link\">",
"     \"Urinary tract injury in gynecologic surgery: Prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=see_link\">",
"     \"Urinary tract injury in gynecologic surgery: Evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15242?source=see_link\">",
"     \"Placement and management of indwelling ureteral stents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13424516\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gynecologic indications for cystoscopy are discussed in this section. These overlap with some, but not all, urologic indications for cystoscopy.",
"   </p>",
"   <p>",
"    Cystoscopy is performed for women with gynecologic conditions for evaluation of [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29592/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suspected operative urinary tract injury (eg, ureteral injury, cystotomy, intravesical placement or erosion of mesh or suture)",
"     </li>",
"     <li>",
"      Urinary urgency or frequency or urge incontinence in the absence of urinary tract infection",
"     </li>",
"     <li>",
"      Suspected urinary tract involvement by gynecologic malignancies",
"     </li>",
"     <li>",
"      Leakage of urine from the vagina (etiology may be a genitourinary fistula)",
"     </li>",
"     <li>",
"      Suspected involvement of the urinary tract following lower genital tract trauma &nbsp;",
"     </li>",
"     <li>",
"      Postvoid dribbling of urine (etiology may be a urethral diverticulum)",
"     </li>",
"     <li>",
"      Injection of therapeutic agents for urinary incontinence (eg, periurethral bulking agents, botulinum toxin)",
"     </li>",
"     <li>",
"      Verification of suprapubic catheter placement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lower urinary tract injury occurs in approximately 1 percent of all pelvic surgeries in women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29592/abstract/8\">",
"     8",
"    </a>",
"    ]. However, this number rises to 4.3 percent after hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29592/abstract/9\">",
"     9",
"    </a>",
"    ]. Hysterectomy, anti-incontinence procedures, and vaginal apical suspension procedures (uterosacral ligament suspension) are the surgeries most likely to be associated with lower urinary tract injury. Gynecologic surgeons should perform cystoscopy upon suspicion of injury intra- or postoperatively; some experts advise routine cystoscopy following surgical treatment of urinary incontinence, anterior or apical pelvic organ prolapse, and hysterectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14056?source=see_link&amp;anchor=H4#H4\">",
"     \"Urinary tract injury in gynecologic surgery: Prevention\", section on 'Type of procedure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=see_link&amp;anchor=H3#H3\">",
"     \"Urinary tract injury in gynecologic surgery: Evaluation and management\", section on 'Screening for injury with cystoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cystoscopy may also be used to evaluate women who have undergone anti-incontinence procedures or other gynecologic surgery who develop urinary tract symptoms. For these women, new onset of irritative storage symptoms (urinary frequency, urgency, urge incontinence in the absence of urinary tract infection), hematuria, or recurrent urinary tract infections may be symptoms of surgical mesh or suture erosion or genitourinary fistula. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/62/26602?source=see_link&amp;anchor=H34#H34\">",
"     \"Overview of transvaginal placement of reconstructive materials (surgical mesh or biografts) for treatment of pelvic organ prolapse or stress urinary incontinence\", section on 'Graft erosion or extrusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with pelvic organ prolapse often also have irritative storage symptoms. Cystoscopy may be used in these women to exclude urethral diverticula, bladder tumors, bladder stones, bladder scarring, and findings associated with interstitial cystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29592/abstract/10\">",
"     10",
"    </a>",
"    ]. Cystoscopy should also be considered in women with irritative storage symptoms of new onset, not responsive to medications, frequent urinary tract infections, history of prior surgeries, or risk factors such as pelvic radiation or smoking. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical presentation, diagnosis, and staging of bladder cancer\", section on 'Cystoscopy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8330?source=see_link&amp;anchor=H319447#H319447\">",
"     \"Pathogenesis, clinical features, and diagnosis of interstitial cystitis/bladder pain syndrome\", section on 'Role of cystoscopy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26873?source=see_link&amp;anchor=H2637536#H2637536\">",
"     \"Urethral diverticulum in women\", section on 'Urethroscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cystoscopy is used for clinical staging of cervical and vaginal cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link&amp;anchor=H5#H5\">",
"     \"Invasive cervical cancer: Staging and evaluation of lymph nodes\", section on 'Staging procedure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31208?source=see_link&amp;anchor=H10#H10\">",
"     \"Vaginal cancer\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cystoscopic injection of periurethral bulking agents or botulinum toxin is used for select patients with urgency urinary incontinence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19336?source=see_link\">",
"     \"Use of botulinum toxin for treatment of non-neurogenic lower urinary tract conditions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44409?source=see_link\">",
"     \"Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hematuria in the absence of infection may be a symptom of bladder cancer and is an indication for cystoscopy with visual inspection and biopsy, as appropriate, as well as other testing (eg, urine cytology). Cystoscopy for this indication is usually performed by urologists, but may be performed by a gynecologist if there are other gynecologic indications for the procedure. During any cystoscopy procedure, even in the absence of hematuria, any findings suspicious for malignancy should be biopsied. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H13310187\">",
"     'Evaluating bladder lesions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22000641\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few contraindications to cystoscopy for gynecologic conditions; these include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Active urinary tract infection",
"     </li>",
"     <li>",
"      Complete urethral obstruction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cystourethroscopy is rarely performed in pregnant women, but pregnancy is not a contraindication. As with other procedures performed during pregnancy, anesthetic agents must be selected that do not cause fetal harm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22001089\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION AND PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22001097\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should be counseled regarding potential complications and this discussion should be documented on the procedure consent form and in the medical record.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22001105\">",
"    <span class=\"h2\">",
"     Preoperative evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystourethroscopy is a minimally invasive procedure with few potential complications. A focused evaluation should be performed to guide the procedure and to assess procedural risk. This includes eliciting a history of symptoms associated with the indication for the procedure, a personal or family history of urinary tract abnormalities, and any comorbidities that may increase procedural risk. In addition, an abdominal and pelvic examination should be performed, with particular attention to the condition and position of the urethral meatus.",
"   </p>",
"   <p>",
"    In addition, urinary tract infection should be excluded (see",
"    <a class=\"local\" href=\"#H22000641\">",
"     'Contraindications'",
"    </a>",
"    above). One may obtain a urine sample by voiding or straight catheterization on the day of the procedure and perform a dipstick test for leukocyte esterase and nitrite. If the results are positive, send a urine culture and defer the procedure. Some surgeons perform a urine culture several days before the procedure and treat patients with bacteriuria with antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/19/42295?source=see_link&amp;anchor=H13#H13\">",
"     \"Approach to the adult with asymptomatic bacteriuria\", section on 'Urologic intervention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=see_link\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22001134\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest antimicrobial prophylaxis for diagnostic cystourethroscopy only for patients with an indwelling urinary catheter, with risk factors for surgical site infection (eg, neutropenia, immunodeficiency), and when biopsy is performed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29592/abstract/11\">",
"     11",
"    </a>",
"    ]. Randomized trial data are inconsistent regarding whether preoperative antibiotics decrease the risk of bacteriuria or symptomatic urinary tract infection for patients undergoing cystoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29592/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Heart Association (AHA) does not recommend endocarditis prophylaxis for cystourethroscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link&amp;anchor=H14#H14\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\", section on 'Genitourinary and gastrointestinal tracts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If antibiotics are used, the Medical Letter recommends a single dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (oral 500 mg or intravenous 400 mg) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (1 DS tablet orally) administered just prior to urologic procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29592/abstract/14\">",
"     14",
"    </a>",
"    ]. An alternative is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    , which has good specificity for urine and low bacterial resistance rates.",
"   </p>",
"   <p>",
"    These recommendations are consistent with guidelines from professional societies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American College of Obstetricians and Gynecologists (ACOG) recommends prophylactic antibiotics for cystourethroscopy in patients with preoperative bacteriuria, an indwelling catheter, or neutropenia [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29592/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The American Urological Association (AUA) recommends prophylactic antibiotics for diagnostic cystourethroscopy in patients with factors that affect the host response to infection (eg, advanced age, smoking, chronic corticosteroid use, immunodeficiency, externalized catheters, prolonged hospitalization) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29592/abstract/11\">",
"       11",
"      </a>",
"      ]. For procedures with manipulation (eg, biopsy), the AUA recommends antimicrobial prophylaxis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732114\">",
"    <span class=\"h2\">",
"     Thromboprophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystoscopy is typically a brief procedure and prophylaxis is not required. Thromboprophylaxis may be required for the overall procedure when cystoscopy is combined with major gynecologic surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=see_link&amp;anchor=H17332175#H17332175\">",
"     \"Overview of preoperative evaluation and preparation for gynecologic surgery\", section on 'Thromboprophylaxis'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462393\">",
"    <span class=\"h2\">",
"     Operative setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystoscopy for gynecologic conditions may be performed in an office setting or in the operating room as a single procedure or as part of another procedure (eg, hysterectomy, midurethral sling placement).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22001163\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Office cystourethroscopy is well tolerated by most women, including diagnostic procedures, injection of urethral bulking agents, and intravesical botulinum toxin administration.",
"   </p>",
"   <p>",
"    Given that adverse effects of topical anesthetic are minimal and some data show a benefit in decreasing discomfort, we suggest the use of a topical urethral anesthetic gel for women undergoing diagnostic cystourethroscopy who are not under regional or general anesthesia. Randomized studies of rigid cystourethroscopy in women conflict regarding whether perioperative discomfort is decreased with use of anesthetic gel compared with plain lubricating gel [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29592/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We use 2 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    gel, one milliliter drawn up into a tuberculin syringe without a needle attached. The syringe is inserted into the mid-urethra using additional gel as a lubricant. The gel is slowly injected; the procedure can be started after 5 to 15 minutes have elapsed.",
"   </p>",
"   <p>",
"    Sedation or regional or general anesthesia for this procedure may be used, based upon the preferences of the physician or patient and upon whether an operative procedure will be performed. In our practice, we usually do not use sedation for diagnostic procedures, unless biopsies are performed. For collagen injection or intravesical administration of botulinum toxin, we perform a vesical instillation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=see_link\">",
"     \"Procedural sedation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22000705\">",
"    <span class=\"h1\">",
"     INSTRUMENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22000714\">",
"    <span class=\"h2\">",
"     Cystoscope",
"    </span>",
"    &nbsp;&mdash;&nbsp;All cystoscopes include the same basic components:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lens",
"     </li>",
"     <li>",
"      Sheath and bridge",
"     </li>",
"     <li>",
"      Light source",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cystoscope lens may have one of several viewing angles (0&deg;, 30&deg;, or 70&deg;). The degree indicates the deflection of the lens, similar to other endoscopic procedures (",
"    <a class=\"graphic graphic_figure graphicRef58867 \" href=\"UTD.htm?5/54/5985\">",
"     figure 1",
"    </a>",
"    ). The choice of viewing angle impacts the ability to visualize different parts of the bladder and urethra.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 70&deg; lens is usually adequate to fully evaluate the bladder surface, trigone, and ureteral orifices, and is the lens used most commonly to evaluate patients during or after gynecologic procedures.",
"     </li>",
"     <li>",
"      A 30&deg; lens may also be used to assess the bladder and is the best choice if a ureteral procedure is performed (eg, stent placement, retrograde pyelogram).",
"     </li>",
"     <li>",
"      A 0&deg; lens is used to examine the urethra.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cystoscopy can be performed by looking directly into the lens or connecting the lens to a camera attached to a video monitor (",
"    <a class=\"graphic graphic_picture graphicRef83049 \" href=\"UTD.htm?5/6/5221\">",
"     picture 1",
"    </a>",
"    ). The use of a camera and monitor facilitates teaching of surgical trainees. &nbsp;",
"   </p>",
"   <p>",
"    The sheath of the cystoscope holds has channels to allow fluid inflow and outflow (",
"    <a class=\"graphic graphic_picture graphicRef83017 \" href=\"UTD.htm?32/63/33781\">",
"     picture 2",
"    </a>",
"    ). Diagnostic cystoscopy can generally be performed with a size 17 French sheath. This is generally the smallest diameter sheath used in adults and provides optimal patient comfort; however, it is not large enough for an instrument port. The 21 French sheath is the preferred size for most operative procedures performed for gynecologic indications, allowing easy passage of ureteral guidewires and stents, as well as flexible biopsy forceps and electrosurgical instruments.",
"   </p>",
"   <p>",
"    The bridge connects the lens to the sheath and can have one or more ports that allow insertion of operative instruments (eg, biopsy forceps, ureteral guidewires, ureteral stents). The size of the instrument that can be passed is limited by the size of the port. One type of bridge (Albarran bridge) allows deflection of instruments, which facilitates fulguration, biopsy, or passing of a ureteral guidewire, particular for bladder dome lesions or patients with distorted anatomy.",
"   </p>",
"   <p>",
"    The lens is attached to a light source (",
"    <a class=\"graphic graphic_picture graphicRef83018 \" href=\"UTD.htm?39/49/40720\">",
"     picture 3",
"    </a>",
"    ). Various light sources can be used and vary depending upon the equipment available. Most modern light sources allow adjustment of the intensity of the light to permit optimal visualization.",
"   </p>",
"   <p>",
"    Cystoscopy can be performed using either a rigid or flexible cystoscope. Advantages of using a rigid cystoscope (",
"    <a class=\"graphic graphic_picture graphicRef83076 \" href=\"UTD.htm?40/21/41297\">",
"     picture 4",
"    </a>",
"    ) include better optics and larger working and fluid channels. In addition, a rigid cystoscope is easier to orient to ensure complete bladder visualization. Most cystoscopies done for gynecologic office assessment and procedures use a rigid cystoscope. Flexible cystoscopes are advantageous for bedside assessment of hematuria in fresh postoperative or postpartum patients because of their increased ability to be manipulated and less dependence on patient positioning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22000739\">",
"    <span class=\"h2\">",
"     Distending medium",
"    </span>",
"    &nbsp;&mdash;&nbsp;A distention medium is instilled to distend the bladder and improve visualization. The usual distending medium for diagnostic cystoscopy is isotonic saline or sterile water.",
"   </p>",
"   <p>",
"    If electrosurgery is planned, it is necessary to use nonconductive solutions (electrolyte-poor fluids, eg, glycine) since these may result in thermal injury. Use of any distending medium requires monitoring of fluid absorption to avoid volume overload. Use of nonconductive fluids may result in hyponatremia, and therefore, these fluids are reserved for operative procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8858?source=see_link\">",
"     \"Hyponatremia following transurethral resection or hysteroscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Distending media for cystoscopy are the same as for hysteroscopy. Types of distending media are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef71692 \" href=\"UTD.htm?21/17/21789\">",
"     table 1",
"    </a>",
"    ). The use of distending media is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22951?source=see_link\">",
"     \"Hysteroscopy: Managing fluid and gas distending media\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H461325\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystoscopy is typically a brief procedure (5 to 15 minutes), but may be longer if any additional procedures are performed. The surgical technique is similar in many ways to hysteroscopy.",
"   </p>",
"   <p>",
"    Prior to starting the procedure, the surgeon should check that all of the equipment is present, assembled, and functioning properly (see",
"    <a class=\"local\" href=\"#H22000705\">",
"     'Instrumentation'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732323\">",
"    <span class=\"h2\">",
"     Inserting the cystoscope",
"    </span>",
"    &nbsp;&mdash;&nbsp;The steps of a cystoscopy procedure are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient is placed in the dorsal lithotomy position. In an office setting, patients are covered with a sheet and the urethral meatus is cleaned with a sterile solution (eg, iodine). In the operating room, the vagina and perineum are cleaned with a sterile solution and surgical drapes are placed. &nbsp;",
"     </li>",
"     <li>",
"      A sterile lubricant is placed on the cystoscope sheath and the fluid inflow is opened. The cystoscopic lens and sheath are inserted into the urethra with the angle of the lens directed towards the ceiling. Insertion of the cystoscope is usually done under direct visualization, although an obturator may be used if there is difficulty cannulating the urethra meatus such as in a patient with urethral obstruction or tumor. Attention should be given to the angle of the urethra. The normal angle is slightly upward under the pubic bone. For women with pelvic organ prolapse, it is helpful to reduce the prolapse prior to performing cystoscopy.",
"     </li>",
"     <li>",
"      If urethral pathology is suspected, the urethra is examined (see",
"      <a class=\"local\" href=\"#H21999819\">",
"       'Urethra'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      The cystoscope is then advanced past the urethrovesical junction until an air bubble is visualized in the anterior dome of the bladder. The air bubble is oriented at the superior aspect of the bladder and, thus, is useful for establishing orientation. The bladder and urethral orifices are examined and biopsies and other procedures are performed, as appropriate (see",
"      <a class=\"local\" href=\"#H21999826\">",
"       'Bladder'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H21999856\">",
"       'Ureteral orifices'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anterior or apical pelvic organ prolapse or prior pelvic surgery may distort the bladder anatomy, making cystoscopy more difficult. Placing the surgeon&rsquo;s nondominant hand or an obturator in the vagina to support the anterior wall of the vagina will assist in placing the cystoscope and visualizing the urothelium, trigone and ureteral orifices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21999810\">",
"    <span class=\"h2\">",
"     Examining the lower urinary tract",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21999819\">",
"    <span class=\"h3\">",
"     Urethra",
"    </span>",
"    &nbsp;&mdash;&nbsp;First, the urethral meatus is examined. The urethral mucosa is then examined for erythema, pallor, exudate, polyps, condylomata, or diverticula [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29592/abstract/18\">",
"     18",
"    </a>",
"    ]. The presence of an exudate suggests the presence of a diverticulum, although this is rarely visualized during urethroscopy. The urethrovesical junction is also examined for polyps. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26873?source=see_link&amp;anchor=H2637536#H2637536\">",
"     \"Urethral diverticulum in women\", section on 'Urethroscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21999826\">",
"    <span class=\"h3\">",
"     Bladder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The entire urothelial surface should be inspected for perforation, suture or mesh, adhesions, erythema, edema, lesions, or masses [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29592/abstract/18\">",
"     18",
"    </a>",
"    ]. As noted above, a 70&deg; lens is typically used. The cystoscope is rotated and inserted and withdrawn to visualize all areas. Slight suprapubic pressure can facilitate visualization of the anterior bladder wall just behind the bladder neck. (See",
"    <a class=\"local\" href=\"#H22000714\">",
"     'Cystoscope'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21999842\">",
"    <span class=\"h4\">",
"     Identifying bladder injury or erosion",
"    </span>",
"    &nbsp;&mdash;&nbsp;If sutures or reconstructive materials (mesh or biografts) that have eroded or were inadvertently placed in the bladder from incontinence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prolapse surgery are found, these should be removed. The bladder should then be reinspected and any bleeding sites should be cauterized and repaired. Most cystotomies at the time of hysterectomy are located on the bladder base 2 to 3 cm above the trigone. Once a bladder injury is identified, the surgeon must repair the injury. This is ideally done along the same route of access as the initial surgery (ie, vaginal, laparoscopic, or open abdominal approach). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=see_link&amp;anchor=H19#H19\">",
"     \"Urinary tract injury in gynecologic surgery: Evaluation and management\", section on 'Bladder injury'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Cystoscopy can detect most, but not all, bladder injuries. A small proportion of cystotomies are missed and devascularization, denervation, or thermal injuries are not identifiable by cystoscopy. The rate of missed diagnoses of clinically important injuries was illustrated in a systematic review of 17 retrospective studies of women who underwent benign gynecologic surgery with routine intraoperative use of cystoscopy, in which women presented with bladder injury postoperatively following 0.8 per 1000 procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29592/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13310187\">",
"    <span class=\"h4\">",
"     Evaluating bladder lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder biopsy should be performed if lesions are found that are suspicious for a bladder neoplasm or, for patients with potential interstitial",
"    <span class=\"nowrap\">",
"     cystitis/bladder",
"    </span>",
"    pain syndrome, lesions that are associated with this condition (eg, Hunner lesions). If the surgeon is not experienced with bladder biopsy or evaluation of bladder tumors, the patient should be referred to a urologist. Characteristics of bladder tumors include a bubble-like appearance to the trigone, bullous edema, frond-like papillary growths, or shaggy, necrotic tissue (",
"    <a class=\"graphic graphic_picture graphicRef83081 \" href=\"UTD.htm?12/40/12931\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If urothelial malignancy is suspected, a bladder barbotage (repeated injection and aspiration of fluid) to obtain urothelial cells for cytology should be performed. An isotonic fluid should be used (eg, isotonic saline) since hypotonic fluids (eg, sterile water) will cause the cells to lyse, yielding inaccurate cytology. Glycine may also be used for barbotage, if glycine is the medium of choice for the procedure. (See",
"    <a class=\"local\" href=\"#H22000739\">",
"     'Distending medium'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21999849\">",
"    <span class=\"h4\">",
"     Evaluating genitourinary fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystoscopy with simultaneous vaginal examination may be necessary to find extremely small vesicovaginal fistulas and to assess patients who have failed primary attempts at repair. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44792?source=see_link&amp;anchor=H4#H4\">",
"     \"Urogenital tract fistulas in women\", section on 'Cystoscopy and imaging studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21999856\">",
"    <span class=\"h3\">",
"     Ureteral orifices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ureteral orifices are located in the bladder trigone, which is directly in front of the urethra and is identified by locating the interureteric ridge. The cystoscope may need to be rotated to visualize the ureteral orifices. Several minutes of observation may be needed to identify the orifices, which are small, slit-like openings that only become apparent when a burst of urine is released.",
"   </p>",
"   <p>",
"    In women in whom the bladder is distorted by tumor or cystocele, a finger placed in the vagina and pressed upward under the bladder base may facilitate visualization of the ureteral openings. Large cervical tumors can cause distortion of the bladder such that the trigone sits in a valley behind the ridge made by the tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21999863\">",
"    <span class=\"h4\">",
"     Identifying ureteral injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is often helpful to give patients 5 ml of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    approximately 5 to 10 minutes prior to cystoscopy. Indigo carmine colors the urine blue to facilitate identification of ureteral efflux.",
"   </p>",
"   <p>",
"    To evaluate for urinary tract injury with cystoscopy, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    (20 mg) is administered. However, indigo carmine should not be given to patients with a history of anaphylaxis to sulfa medications, since indigo carmine may cross-react with sulfa [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29592/abstract/19\">",
"     19",
"    </a>",
"    ]. Alternatively, 200 mg oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/7/41075?source=see_link\">",
"     phenazopyridine",
"    </a>",
"    can be given immediately prior to surgery.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     Methylene blue",
"    </a>",
"    is not used intravenously for this purpose because it can take up to 45 minutes to be seen in the bladder. In addition, caution is warranted with use of methylene blue because a cumulative dose &gt;7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    can result in methemoglobinemia in susceptible individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of methemoglobinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Administration of a fluid bolus or placing the patient in reverse Trendelenburg position speeds the flow of dye, or a diuretic (eg, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    20 mg) may be used in patients without renal compromise.",
"   </p>",
"   <p>",
"    Flow of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    dye from the ureteral orifice excludes",
"    <strong>",
"     complete",
"    </strong>",
"    ureteral obstruction; lesser degrees of blockage will still allow dye to flow past the injured area. Marked delay between drainage from one ureter or obvious differences in the amount of dye seen coming from each ureter suggests partial obstruction. Blood coming from a ureteral orifice can also point to ureteral injury and must be investigated. Ureters that have been devascularized may appear intact, yet develop fistulas later in the postoperative period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=see_link\">",
"     \"Urinary tract injury in gynecologic surgery: Evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cystoscopy does not detect all ureteral injuries, however. In particular, partial ureteral obstruction or transection or thermal injuries may be missed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29592/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. In the systematic review of 17 studies with routine intraoperative use of cystoscopy described above, women presented with ureteral injury postoperatively in 1.0 per 1000 procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29592/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of operative ureteral injury is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=see_link&amp;anchor=H18#H18\">",
"     \"Urinary tract injury in gynecologic surgery: Evaluation and management\", section on 'Ureteral injury'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/40/43655?source=see_link\">",
"     \"Surgical repair of an iatrogenic ureteral injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12637599\">",
"    <span class=\"h2\">",
"     When to call for consultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative or postoperative consultation by a urogynecologist or urologist may be required if a urinary tract injury is discovered that cannot be repaired by the primary surgeon. In addition, if urinary tract malignancy is suspected, consultation may be required for biopsy and follow-up evaluation and management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462087\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of cystoscopy are rare. This was illustrated in a retrospective study of 101 women who underwent cystoscopy immediately following pelvic surgery, which reported only one complication associated with operative cystoscopy (a thermal injury) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29592/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3741216\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of bacteriuria following cystourethroscopy is 5 to 8 percent; the incidence of symptomatic urinary tract infection is approximately 2 to 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29592/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Bacteremia is possible after cystoscopy, but reports of sepsis following cystoscopy are rare and involve patients with risk factors for urinary tract infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29592/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For women with postoperative symptoms of urinary tract infection, a urine culture should be sent and infection appropriately treated. Asymptomatic women who have findings on cystoscopy suggestive of infection (eg, exudate) should be treated with antibiotics after the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3741223\">",
"    <span class=\"h2\">",
"     Urethral or bladder injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data regarding the incidence of urethral or bladder injury in diagnostic cystourethroscopy. Minor injuries with a small amount of bleeding can be controlled with electrosurgery. Perforation of the bladder or urethra may require placement of a bladder catheter or abdominal or laparoscopic surgery for repair; however, this is extremely rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3741230\">",
"    <span class=\"h2\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemorrhage after cystoscopy is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29592/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732095\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients experience mild postprocedure urinary urgency or dysuria and a small amount of hematuria that should clear within three voids. The patient may resume most normal activities as soon as anesthetic effects, if used, have resolved. We advise patients to call their surgeon if they have urethral bleeding that is heavy or lasts for more than five days or if they develop persistent suprapubic pain, dysuria, urinary urgency, urinary frequency, or fever.",
"   </p>",
"   <p>",
"    We review the results with patients immediately after the procedure if only topical or regional anesthetic was used. We see patients for a follow-up visit two weeks postoperatively if they were under sedation or general anesthesia or have biopsy results pending.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732104\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diagnostic cystoscopy is an endoscopic technique for examining the internal aspect of the urethra and bladder and assessing ureteral patency. (See",
"      <a class=\"local\" href=\"#H12637557\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gynecologic indications for cystoscopy include: evaluation of urogynecologic symptoms, assessment of bladder and ureteral involvement by gynecologic malignancies, and identification of urinary tract injuries during or after gynecologic procedures. (See",
"      <a class=\"local\" href=\"#H13424516\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest prophylactic antibiotics for women undergoing diagnostic cystoscopy who have an indwelling urinary catheter or risk factors for surgical site infection (eg, neutropenia, immunodeficiency) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Antibiotic prophylaxis is not required for other patients. (See",
"      <a class=\"local\" href=\"#H22001134\">",
"       'Prophylactic antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women undergoing cystoscopy who do not receive regional or general anesthesia, we suggest the use of a topical urethral anesthetic prior to the procedure rather than no topical anesthetic (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22001163\">",
"       'Anesthesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An electrolyte-containing irrigation fluid or sterile water is used for diagnostic cystoscopy. If barbotage is done, sterile water is not appropriate. (See",
"      <a class=\"local\" href=\"#H22000739\">",
"       'Distending medium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cystoscopy does not detect all bladder or ureteral injuries; approximately 1 injury will be missed for every 1000 procedures, depending on the type of gynecologic procedure performed. (See",
"      <a class=\"local\" href=\"#H21999810\">",
"       'Examining the lower urinary tract'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following cystoscopy, mild postprocedure hematuria and dysuria are normal and should clear within several voids. Potential complications include urinary tract infection and injury to the urethra or bladder. (See",
"      <a class=\"local\" href=\"#H732095\">",
"       'Postoperative care'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H462087\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/1\">",
"      Morgenstern L. The 200th anniversary of the first endoscope: Philipp Bozzini (1773-1809). Surg Innov 2005; 12:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/2\">",
"      Dwyer PL. In the footsteps of Kelly and Robertson; revival of the art of cystourethroscopy in gynecology. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:713.",
"     </a>",
"    </li>",
"    <li>",
"     CREOG's Educational Objectives. A Core Curriculum in Obstetrics and Gynecology, 9th Ed. file://www.acog.org/departments/dept_web.cfm?recno=1 (Accessed on March 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/4\">",
"      Hibbert ML, Salminen ER, Dainty LA, et al. Credentialing residents for intraoperative cystoscopy. Obstet Gynecol 2000; 96:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/5\">",
"      Bowling CB, Greer WJ, Bryant SA, et al. Testing and validation of a low-cost cystoscopy teaching model: a randomized controlled trial. Obstet Gynecol 2010; 116:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/6\">",
"      American College of Obstetricians and Gynecologists. ACOG Committee Opinion. Number 372. July 2007. The Role of cystourethroscopy in the generalist obstetrician-gynecologist practice. Obstet Gynecol 2007; 110:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/7\">",
"      Gilmour DT, Das S, Flowerdew G. Rates of urinary tract injury from gynecologic surgery and the role of intraoperative cystoscopy. Obstet Gynecol 2006; 107:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/8\">",
"      Bai SW, Huh EH, Jung da J, et al. Urinary tract injuries during pelvic surgery: incidence rates and predisposing factors. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/9\">",
"      Ibeanu OA, Chesson RR, Echols KT, et al. Urinary tract injury during hysterectomy based on universal cystoscopy. Obstet Gynecol 2009; 113:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/10\">",
"      Ramahi AJ, Richardson DA, Ataya KM. Urethral stones in women. A case report. J Reprod Med 1993; 38:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/11\">",
"      Bootsma AM, Laguna Pes MP, Geerlings SE, Goossens A. Antibiotic prophylaxis in urologic procedures: a systematic review. Eur Urol 2008; 54:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/12\">",
"      DasGupta R, Sullivan R, French G, O'Brien T. Evidence-based prescription of antibiotics in urology: a 5-year review of microbiology. BJU Int 2009; 104:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/13\">",
"      Wolf JS Jr, Bennett CJ, Dmochowski RR, et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol 2008; 179:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/14\">",
"      Antimicrobial prophylaxis for surgery. Treat Guidel Med Lett 2009; 7:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/15\">",
"      Goldfischer ER, Cromie WJ, Karrison TG, et al. Randomized, prospective, double-blind study of the effects on pain perception of lidocaine jelly versus plain lubricant during outpatient rigid cystoscopy. J Urol 1997; 157:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/16\">",
"      Choe JH, Kwak KW, Hong JH, Lee HM. Efficacy of lidocaine spray as topical anesthesia for outpatient rigid cystoscopy in women: a prospective, randomized, double-blind trial. Urology 2008; 71:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/17\">",
"      Stein M, Lubetkin D, Taub HC, et al. The effects of intraurethral lidocaine anesthetic and patient anxiety on pain perception during cystoscopy. J Urol 1994; 151:1518.",
"     </a>",
"    </li>",
"    <li>",
"     Cundiff, GW, Bent, AE. Endoscopic evaluation of the lower urinary tract. In: Urogynecology and Reconstructive Pelvic Surgery, 3rd ed, Walters, MD, Karram, MM (Eds), Mosby Elsevier, Philadelphia 2007. p. 114.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/19\">",
"      Graziano S, Hoyte L, Vilich F, Brubaker L. Life-threatening reaction to indigo carmine--a sulfa allergy? Int Urogynecol J Pelvic Floor Dysfunct 2005; 16:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/20\">",
"      Ferro A, Byck D, Gallup D. Intraoperative and postoperative morbidity associated with cystoscopy performed in patients undergoing gynecologic surgery. Am J Obstet Gynecol 2003; 189:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/21\">",
"      Almallah YZ, Rennie CD, Stone J, Lancashire MJ. Urinary tract infection and patient satisfaction after flexible cystoscopy and urodynamic evaluation. Urology 2000; 56:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/22\">",
"      Clark KR, Higgs MJ. Urinary infection following out-patient flexible cystoscopy. Br J Urol 1990; 66:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/23\">",
"      Turan H, Balci U, Erdinc FS, et al. Bacteriuria, pyuria and bacteremia frequency following outpatient cystoscopy. Int J Urol 2006; 13:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/24\">",
"      Arpi M, Werner C, Timmermann B. Bacteremia following transurethral instrumentation. The predictive value of a serum bactericidal activity test. Scand J Urol Nephrol 1986; 20:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/25\">",
"      Bavetta S, Olsha O, Fenely J. Spreading sepsis by cystoscopy. Postgrad Med J 1990; 66:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/26\">",
"      Honma I, Takagi Y, Shigyo M, et al. Massive hematuria after cystoscopy in a patient with an internal iliac artery aneurysm. Int J Urol 2002; 9:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29592/abstract/27\">",
"      Montie JE, Stewart BH. Massive bladder hemorrhage after cystoscopy in a patient with secondary systemic amyloidosis. J Urol 1973; 109:49.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3288 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-50E636C042-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_57_29592=[""].join("\n");
var outline_f28_57_29592=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H732104\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12637557\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13424516\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22000641\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22001089\">",
"      PREOPERATIVE EVALUATION AND PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22001097\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22001105\">",
"      Preoperative evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22001134\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H732114\">",
"      Thromboprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H462393\">",
"      Operative setting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22001163\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22000705\">",
"      INSTRUMENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22000714\">",
"      Cystoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22000739\">",
"      Distending medium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461325\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H732323\">",
"      Inserting the cystoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21999810\">",
"      Examining the lower urinary tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21999819\">",
"      - Urethra",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21999826\">",
"      - Bladder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21999842\">",
"      Identifying bladder injury or erosion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13310187\">",
"      Evaluating bladder lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21999849\">",
"      Evaluating genitourinary fistula",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21999856\">",
"      - Ureteral orifices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21999863\">",
"      Identifying ureteral injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12637599\">",
"      When to call for consultation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H462087\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3741216\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3741223\">",
"      Urethral or bladder injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3741230\">",
"      Other complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H732095\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H732104\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3288\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3288|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/54/5985\" title=\"figure 1\">",
"      Hysteroscopic viewing angles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3288|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/6/5221\" title=\"picture 1\">",
"      Cystoscopy video monitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/63/33781\" title=\"picture 2\">",
"      Cystoscope components",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/49/40720\" title=\"picture 3\">",
"      Cystoscope camera light source",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/21/41297\" title=\"picture 4\">",
"      Cystoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/40/12931\" title=\"picture 5\">",
"      Cystoscopic view bladder tumor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3288|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/17/21789\" title=\"table 1\">",
"      Hysteroscopy distend media",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/19/42295?source=related_link\">",
"      Approach to the adult with asymptomatic bacteriuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=related_link\">",
"      Clinical features, diagnosis, and treatment of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8858?source=related_link\">",
"      Hyponatremia following transurethral resection or hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22951?source=related_link\">",
"      Hysteroscopy: Managing fluid and gas distending media",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=related_link\">",
"      Invasive cervical cancer: Staging and evaluation of lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=related_link\">",
"      Overview of preoperative evaluation and preparation for gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/62/26602?source=related_link\">",
"      Overview of transvaginal placement of reconstructive materials (surgical mesh or biografts) for treatment of pelvic organ prolapse or stress urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8330?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of interstitial cystitis/bladder pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15242?source=related_link\">",
"      Placement and management of indwelling ureteral stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44409?source=related_link\">",
"      Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/40/43655?source=related_link\">",
"      Surgical repair of an iatrogenic ureteral injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26873?source=related_link\">",
"      Urethral diverticulum in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=related_link\">",
"      Urinary tract injury in gynecologic surgery: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14056?source=related_link\">",
"      Urinary tract injury in gynecologic surgery: Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44792?source=related_link\">",
"      Urogenital tract fistulas in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19336?source=related_link\">",
"      Use of botulinum toxin for treatment of non-neurogenic lower urinary tract conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31208?source=related_link\">",
"      Vaginal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_57_29593="MPGN in mixed cryo Light";
var content_f28_57_29593=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F71702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F71702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Membranoproliferative pattern in mixed cryoglobulinemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph in mixed cryoglobulinemia showing a membranoproliferative pattern with increased cellularity and thickening of the glomerular capillary walls. The pathognomonic finding is PAS-positive microthrombi composed of precipitated cryoglobulins that are occluding some of the capillary loops (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_57_29593=[""].join("\n");
var outline_f28_57_29593=null;
var title_f28_57_29594="Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues";
var content_f28_57_29594=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/57/29594/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/57/29594/contributors\">",
"     Jeffrey Zonder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/57/29594/contributors\">",
"     Charles A Schiffer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/57/29594/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/57/29594/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/57/29594/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/57/29594/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/57/29594/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/57/29594/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between cancer and venous thromboembolic events (VTE) has been well documented. There are several possible mechanisms involved, including acquired abnormalities involving clotting factors and the coagulation cascade, extrinsic vessel compression by tumor masses, immobility, surgery, the presence of indwelling central venous catheters, as well as the simultaneous presence of an inherited hypercoagulable state (eg, factor V Leiden). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link\">",
"     \"Hypercoagulable disorders associated with malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1224?source=see_link\">",
"     \"Pathogenesis of the hypercoagulable state associated with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with multiple myeloma (MM) or the precursor lesion monoclonal gammopathy of undetermined significance (MGUS) have an increased incidence of venous thromboembolism (VTE). In addition, a few studies have suggested an increased risk of arterial thromboembolism (ATE) in these populations as manifested by stroke, transient ischemic attack, myocardial infarction, or symptomatic peripheral artery disease. The increased rate of VTE appears to be both a result of the malignancy itself and the therapy given. In particular, the rate of VTE is particularly high for patients with MM treated with combination chemotherapy that contains",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or a thalidomide analog such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The thrombotic risk associated with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    and its analogues as treatment for MM will be discussed here. Thrombotic risk following the use of other antineoplastic agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , L-asparaginase) and issues related to the treatment of VTE are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6730?source=see_link&amp;anchor=H3#H3\">",
"     \"Drug-induced thrombosis and vascular disease in patients with malignancy\", section on 'L-asparaginase'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6730?source=see_link&amp;anchor=H10#H10\">",
"     \"Drug-induced thrombosis and vascular disease in patients with malignancy\", section on 'Tamoxifen and raloxifene'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link\">",
"     \"Treatment of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"     \"Treatment of lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H642162287\">",
"    <span class=\"h1\">",
"     POTENTIAL MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with multiple myeloma are at increased risk of having comorbidities known to be risk factors for the development of venous thromboembolism (VTE) in the general population. In addition, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    and its analogs has been associated with high rates of VTE. Thalidomide has a wide spectrum of biological effects, including immune modulation, alteration of adhesion molecule and cytokine expression, and inhibition of angiogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H642162566\">",
"     'General risk factors'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=see_link&amp;anchor=H117146124#H117146124\">",
"     \"Overview of angiogenesis inhibitors\", section on 'Imunomodulatory drugs (IMiDs)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the exact mechanism by which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    contributes to thrombosis is not known, the following mechanisms have been postulated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum levels of the anticoagulant pathway cofactor thrombomodulin transiently drop during the first month of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      therapy, with gradual recovery over the following two months [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/2\">",
"       2",
"      </a>",
"      ]. It is not known whether surface thrombomodulin expression on endothelial cells is similarly reduced.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       Thalidomide",
"      </a>",
"      increases endothelial cell expression of protease activated receptor-1 (PAR-1) after exposure to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      or other anthracyclines [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/3\">",
"       3",
"      </a>",
"      ]. This could result in increased thrombin binding to the vascular endothelium, and explain, in part, the increased risk of thrombosis seen when thalidomide is used in conjunction with an anthracycline (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Thalidomide plus anthracycline'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Active treatment for MM has been associated with resistance to activated protein C (APC) in the absence of factor V Leiden and response to APC appears to normalize following treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. In one of these reports, the risk of VTE was highest in those patients with both APC resistance and treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/4\">",
"       4",
"      </a>",
"      ]. However, other investigators have not been able to confirm this observation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/2,6\">",
"       2,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one study, patients with MM treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      had extremely high levels of von Willebrand factor antigen and factor VIII, factors known to be associated with an increased risk of VTE in the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H18#H18\">",
"       \"Overview of the causes of venous thrombosis\", section on 'Factor VIII'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genetic analysis of single nucleotide polymorphisms (SNPs) noted that the set of SNPs associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      -related VTE events in patients with MM was enriched in genes and pathways important in drug",
"      <span class=\"nowrap\">",
"       transport/metabolism,",
"      </span>",
"      DNA repair, and cytokine balance [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/8-10\">",
"       8-10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Down-regulation of PU.1 by immunomodulatory derivatives such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      leads to arrest of myeloid maturation with resultant accumulation of promyelocytes, with high levels of cathepsin G contained in their azurophilic granules [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/11\">",
"       11",
"      </a>",
"      ]. Cathepsin G, a platelet function agonist, may contribute to risk of VTE.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H642162558\">",
"    <span class=\"h1\">",
"     INCIDENCE AND RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H642162566\">",
"    <span class=\"h2\">",
"     General risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with multiple myeloma are at increased risk of having comorbidities known to be risk factors for the development of venous thromboembolism (VTE) in the general population. These include immobilization related to bone involvement and pathologic fractures, renal disease due to kidney involvement, diabetes due to glucocorticoid use, acute infection due to immunosuppression, the use of erythropoietin, and central venous catheter placement for treatment. Other risk factors for VTE include obesity (body mass index &ge;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    previous VTE, pacemaker placement, cardiac disease, hormone therapy, and inherited thrombophilias. The impact of these risk factors in the general population is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Thalidomide-based therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of VTE among patients with multiple myeloma taking single-agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    does not appear to be increased over that of patients with myeloma not taking thalidomide. In contrast, the risk of VTE increases substantially when thalidomide is administered in conjunction with glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/12\">",
"     12",
"    </a>",
"    ]. While the majority of thrombotic events described in patients treated with thalidomide have been venous, arterial thrombotic events have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Single agent thalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    is not associated with a significantly increased risk of thrombosis, as attested to in the following studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report in which 84 patients with relapsed or refractory myeloma were treated with 200 to 800",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      , no definite thromboembolic events were reported [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study reported three nonfatal thromboembolic events and one case of transient ischemic attacks occurring among 75 patients with multiple myeloma treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      , with or without concomitant interferon [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third study observed one thromboembolic event during",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      monotherapy in 28 previously untreated patients with multiple myeloma [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The thrombosis incidence of approximately 1 to 5 percent in trials using single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    is similar to the background rate of such events in patients with multiple myeloma not receiving treatment with this agent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. As such, VTE prophylaxis is generally reserved for patients taking single agent thalidomide that also have two or more individual or myeloma-related risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H642163521\">",
"     'Risk stratification'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Thalidomide plus dexamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported frequency of thrombotic events has been as high as 26 percent when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    is used in combination with high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    <span class=\"nowrap\">",
"     (thal/dex)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study reported six thromboembolic events, one of which was fatal, among 40 previously untreated patients (15 percent) receiving treatment with",
"      <span class=\"nowrap\">",
"       thal/dex",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/17\">",
"       17",
"      </a>",
"      ]. The same group reported a DVT rate of 8 percent in 28 patients receiving the same treatment for relapsed myeloma [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second study observed thrombotic complications in 6 of 50 patients with newly diagnosed myeloma (12 percent) treated with",
"      <span class=\"nowrap\">",
"       thal/dex",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Results of a large Eastern Cooperative Oncology Group randomized trial are consistent with the above findings [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/27\">",
"       27",
"      </a>",
"      ]. Among 102 patients treated with",
"      <span class=\"nowrap\">",
"       thal/dex,",
"      </span>",
"      there were 17 episodes of deep vein thrombosis (17 percent), compared with three such episodes in the 102 patients (3 percent) receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      alone.",
"     </li>",
"     <li>",
"      In another study, 43 previously untreated patients with myeloma received two to three courses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      <span class=\"nowrap\">",
"       (dox/dex),",
"      </span>",
"      followed by two months of treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      and dexamethasone",
"      <span class=\"nowrap\">",
"       (thal/dex)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/28\">",
"       28",
"      </a>",
"      ]. All patients received thromboprophylaxis with 81 mg of",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"        aspirin",
"       </a>",
"       /day",
"      </span>",
"      PO. There were five episodes of VTE documented among 42 evaluable patients, three during initial treatment with",
"      <span class=\"nowrap\">",
"       dox/dex,",
"      </span>",
"      and two during the subsequent treatment with",
"      <span class=\"nowrap\">",
"       thal/dex.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Thalidomide plus melphalan and prednisone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (MPT) in patients with multiple myeloma results in a risk of thrombosis of up to 20 percent in those not receiving thromboprophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An interim analysis of a randomized French study with 200 accrued patients observed a higher rate of DVT with MPT treatment (9 percent), compared with 6 percent with MP alone, and 3.5 percent with high-dose IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another French study of similar design in patients 75 years of age or older, the incidence of VTE in the MP (3 percent) and MPT (6 percent) arms was not statistically different. Thromboprophylaxis was not pre-specified, but the authors note that heightened vigilance due to prior trial experience led to greater thromboprophylaxis usage [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third phase III study reported a 20 percent incidence of DVT in 65 patients randomly assigned to treatment with MPT and no thromboprophylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/31\">",
"       31",
"      </a>",
"      ]. In the 126 patients receiving MP and no thromboprophylaxis, the incidence of VTE was 1.6 percent (see",
"      <a class=\"local\" href=\"#H362987974\">",
"       'Low molecular weight heparin'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      In a trial adding a lower dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      (100 to 200",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      to pulses of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , only 2 of 62 patients (3 percent) developed DVT [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, the results of these trials suggest that the risk of thrombosis during treatment with the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , steroids, and an alkylating agent (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    ) is similar to that seen following the use of thalidomide and steroids alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Thalidomide plus anthracycline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regimens utilizing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    in combination with cytotoxic chemotherapy appear to be associated with the highest risk of VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/14\">",
"     14",
"    </a>",
"    ]. This is particularly true when thalidomide is used in combination with an anthracycline [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/33-38\">",
"     33-38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study treated 31 newly diagnosed patients with myeloma with the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      (400",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/33\">",
"       33",
"      </a>",
"      ]. Eight of 31 patients (26 percent) experienced VTE. The authors postulated that the relatively high dose of thalidomide may have accounted for part of the excess risk, since, in a separate report, only 4 of 39 patients (10 percent) treated with vincristine, adriamycin, and dexamethasone (VAD) plus a lower dose of thalidomide (200",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      experienced DVT [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report, 100 patients with myeloma underwent four cycles of induction chemotherapy with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      (400 mg daily). Cycles one (VAD) and three (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , adriamycin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ) included adriamycin, whereas cycles two and four consisted of dexamethasone, cyclophosphamide,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (DCEP). Fourteen of 50 patients (28 percent) randomly assigned to receive thalidomide had thrombotic complications compared with only 2 of 50 (4 percent) receiving chemotherapy alone [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study compared the frequency of VTE among 40 patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      plus DCEP (\"T-DCEP\") and 192 patients treated with \"DT-PACE,\" a regimen similar to T-DCEP except for the addition of adriamycin [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/36\">",
"       36",
"      </a>",
"      ]. Thrombosis occurred in 2.5 percent (1 of 40) and 16 percent (31 of 192) in the T-DCEP and DT-PACE groups, respectively. Although this was not a randomized trial, it provides compelling evidence that the inclusion of anthracyclines may have more of an impact on risk of thrombosis than the thalidomide dose, which was 400",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in each regimen.",
"     </li>",
"     <li>",
"      A study of 19 patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      plus DVd (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"       pegylated liposomal doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ) and no thrombosis prophylaxis reported VTE in 11 of 19 patients (58 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study employing lower dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"       pegylated liposomal doxorubicin",
"      </a>",
"      , the incidence of VTE was 14 percent despite the use of low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      prophylaxis (1.25",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/39\">",
"       39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18282?source=see_link&amp;anchor=H4997000#H4997000\">",
"       \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\", section on 'Thalidomide with or without dexamethasone'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Thalidomide analogues",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased risk of thrombosis has also been seen when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    analogues, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/33/33303?source=see_link\">",
"     pomalidomide",
"    </a>",
"    , are used in combination with steroids. The thrombogenic potential of these agents is less well-defined than that of thalidomide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Lenalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , the risk of venous thromboembolism (VTE) among patients with multiple myeloma taking single-agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    does not appear to be increased over that of patients with myeloma not taking lenalidomide. In contrast, the use of lenalidomide in combination with high-dose glucocorticoids is associated with an at least threefold increased risk of clotting events [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/12,14\">",
"     12,14",
"    </a>",
"    ]. The risk of VTE appears to be considerably lower when lenalidomide is combined with low-dose glucocorticoids or with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    . While VTE is the most common form of thrombosis in this population, arterial thrombotic events have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No increased risk of clotting events was apparent in phase I and II studies of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      as monotherapy for multiple myeloma [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/41,42\">",
"       41,42",
"      </a>",
"      ] or myelodysplastic syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/43\">",
"       43",
"      </a>",
"      ]. Similarly, in a post-marketing study of the use of lenalidomide in 7764 patients with myelodysplasia, VTE was reported in 0.53 percent during the first two years of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two large randomized phase III studies (MM-009 and MM-010) compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      (25",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      PO on days 1 through 21 of a 28-day cycle) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      PO on days 1 to 4, 9 to 12, and 17 to 20 for the first four cycles then on days 1 to 4 only for subsequent cycles) versus dexamethasone plus placebo in a total of 704 patients with relapsed or refractory multiple myeloma [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. Both studies were stopped by their data safety monitoring boards due to significantly better response rates and time to progression with lenalidomide plus dexamethasone compared with dexamethasone alone. However, the lenalidomide plus dexamethasone group had significantly higher rate of VTE (approximately 11 versus 4 percent).",
"     </li>",
"     <li>",
"      In a multivariate analysis of MM-009 and MM-010, the odds ratio for development of VTE in patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (versus those receiving placebo plus dexamethasone) was 3.5 (95% CI 1.8-7.0) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/47\">",
"       47",
"      </a>",
"      ]. Concomitant use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"       recombinant human erythropoietin",
"      </a>",
"      was also an independent contributor to the risk of development of VTE (odds ratio 3.2; 95% CI 1.7-6.0).",
"     </li>",
"     <li>",
"      A Southwest Oncology Group (SWOG) study comparing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      plus high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      to dexamethasone alone found a significantly increased risk of VTE when lenalidomide was given with high-dose dexamethasone (23.5 versus 5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of VTE appears to be at least partially associated with the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    that is combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An Eastern Cooperative Oncology Group (ECOG) randomized trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      plus either high-dose or reduced-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      for newly-diagnosed multiple myeloma patients was temporarily halted because of an increased incidence of VTE in the absence of routine thromboprophylaxis with rates of VTE of 18 and 3.7 percent in patients receiving high-dose and low-dose dexamethasone, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial in 445 patients with newly diagnosed myeloma found a significantly lower rate of VTE with the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      plus a lower dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (40 mg PO on days 1, 8, 15, and 22 of each 28-day cycle) compared with lenalidomide plus the standard high-dose dexamethasone (40 mg days 1 to 4, 9 to 12, 17 to 20 every 28 days) of 12 versus 26 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of VTE prophylaxis can decrease the risk of thrombotic disease among patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . As an example, an expanded access program of lenalidomide plus dexamethasone in 1438 patients with relapsed myeloma that recommended VTE prophylaxis for all enrollees reported VTE in 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/40\">",
"     40",
"    </a>",
"    ]. Similarly, a study of lenalidomide and dexamethasone plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    in patients with newly diagnosed multiple myeloma that required VTE prophylaxis with at least",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    reported an incidence of VTE of 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Pomalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of data regarding the risk of venous thromboembolism (VTE) among patients with multiple myeloma treated with the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    -analog",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/33/33303?source=see_link\">",
"     pomalidomide",
"    </a>",
"    (CC-4047). In a phase I study of pomalidomide involving 24 patients with",
"    <span class=\"nowrap\">",
"     relapsed/refractory",
"    </span>",
"    multiple myeloma, four patients (17 percent) developed VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/51\">",
"     51",
"    </a>",
"    ]. One clot occurred three weeks into therapy in the lower extremity of a patient subsequently recognized as having malignant melanoma-associated adenopathy, whereas the others occurred after four, nine, and 11 months of pomalidomide therapy. In a study conducted at the Mayo Clinic, only one of 60 patients treated with pomalidomide plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    developed VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Phase II, multicenter trials investigating the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/33/33303?source=see_link\">",
"     pomalidomide",
"    </a>",
"    plus low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    have routinely included thromboprophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or other agents [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. Rates of VTE in these trials have been approximately 3 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     VENOUS THROMBOEMBOLISM PROPHYLAXIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H642162808\">",
"    <span class=\"h2\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, patients with multiple myeloma treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    in combination with other agents (eg, glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , or erythropoietin) have a rate of venous thromboembolism (VTE) greater than 20 percent. In comparison, the rate of VTE decreases to less than 10 percent when VTE prophylaxis is administered. As a result, we recommend the routine use of VTE prophylaxis for patients with multiple myeloma who are treated with a combination therapy regimen that contains thalidomide or lenalidomide. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Thalidomide-based therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are no randomized trials comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    treatment with or without VTE prophylaxis; most of the data consist of comparisons of single arm trials with historical controls in which prophylaxis was not used. Numerous variables can influence such nonrandomized studies. As an example, the incidence of thrombosis in myeloma is higher during treatment of newly diagnosed disease compared with relapsed or refractory disease. Other risk factors have been identified, such as the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    and high doses of corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/47,49,56\">",
"     47,49,56",
"    </a>",
"    ]. In addition, the incidence of VTE is almost certainly affected by the degree of physician vigilance in identifying such events (eg, mandatory ultrasound monitoring versus clinical observation alone).",
"   </p>",
"   <p>",
"    Despite the above caveats, the incidence of thrombotic complications appears to be reduced in patients receiving combination therapy that contains",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , using one of the following three strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      , either fixed dose or full dose with a target INR of 2.0 to 3.0",
"     </li>",
"     <li>",
"      Therapeutic or prophylactic dose of low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      (81 to 325",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A choice among these strategies may be based upon the baseline risk of VTE associated with a given regimen and patient population. Given the potential for gastric irritation with or without thrombocytopenia, we suggest concurrent use of either an H2-blocker or a proton pump inhibitor when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    is used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , corticosteroids,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H642163521\">",
"    <span class=\"h3\">",
"     Risk stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to give one of the above drugs and the choice of drug for thromboprophylaxis needs to consider the baseline risk of VTE associated with a given regimen and the presence or absence of risk factors for thromboembolism. Our approach is similar to that proposed by the International Myeloma Working Group [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should be assessed for the following risk factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Body mass index &ge;30",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=see_link\">",
"       calculator 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Previous VTE",
"     </li>",
"     <li>",
"      Central venous catheter or pacemaker",
"     </li>",
"     <li>",
"      Cardiac disease (eg, symptomatic coronary artery disease, congestive heart failure, or history of stent",
"      <span class=\"nowrap\">",
"       placement/CABG)",
"      </span>",
"     </li>",
"     <li>",
"      Chronic kidney disease (eg, estimated glomerular filtration rate less than 30",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Acute infection",
"     </li>",
"     <li>",
"      Immobilization",
"     </li>",
"     <li>",
"      Use of erythropoietin",
"     </li>",
"     <li>",
"      Inherited thrombophilia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using these risk factors, patients can be divided into three categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients receiving either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      or a thalidomide analogue as a single agent are at lower risk for VTE and do",
"      <strong>",
"       not",
"      </strong>",
"      require VTE prophylaxis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Single agent thalidomide'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Lenalidomide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with no or one VTE risk factor who are",
"      <strong>",
"       not",
"      </strong>",
"      being treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , multiagent chemotherapy, or high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      are considered to be at standard risk for VTE and should receive VTE prophylaxis. (See",
"      <a class=\"local\" href=\"#H642162822\">",
"       'Standard risk setting'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with two or more risk factors and any patients being treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , multiagent chemotherapy, or high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (&ge;480 mg per month) are considered at higher risk for VTE and require VTE prophylaxis. (See",
"      <a class=\"local\" href=\"#H642162830\">",
"       'High risk setting'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific recommendations for the prevention of VTE in cancer patients who are hospitalized or are undergoing surgery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=see_link&amp;anchor=H5137695#H5137695\">",
"     \"Prevention of venous thromboembolic disease in medical patients\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H642162815\">",
"    <span class=\"h3\">",
"     Lower risk setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of thrombosis in patients at lower risk, defined as those treated with single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , is approximately 1 to 5 percent, which is similar to the background rate of VTE in patients with multiple myeloma not receiving treatment with one of these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. Thus, in the absence of other indications for VTE prophylaxis, patients taking single agent thalidomide or lenalidomide do",
"    <strong>",
"     not",
"    </strong>",
"    require VTE prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H642162822\">",
"    <span class=\"h3\">",
"     Standard risk setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with no or one VTE risk factor who are",
"    <strong>",
"     not",
"    </strong>",
"    receiving high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , or multiagent chemotherapy are considered to be at standard risk for VTE. For example, a patient without risk factors being treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    , and weekly dexamethasone would be considered &ldquo;standard risk.&rdquo; In such patients, we suggest VTE prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or prophylactic dose low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (LMWH). This preference is largely based upon the lower cost and ease of administration of aspirin and randomized trials that demonstrated similar rates of serious thromboembolic events with each of these agents, as described below.",
"   </p>",
"   <p>",
"    An open-label phase III trial included 667 patients with previously untreated myeloma who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    -containing induction therapy and had no clinical indication or contraindication to specific antiplatelet or anticoagulant therapy; the patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (100 mg daily), fixed low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (1.25 mg daily), or LMWH (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    40 mg once daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/58\">",
"     58",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of a composite endpoint of serious thromboembolic events (symptomatic DVT, pulmonary embolism, or arterial thrombosis), acute cardiovascular events (myocardial infarction or stroke), and sudden death during the first six months of therapy was not significantly different in the three groups (6.4, 8.2, and 5.0 percent, respectively), although the trial was not powered to detect a difference as large as 3.2 percent.",
"     </li>",
"     <li>",
"      There was no statistically or clinically significant difference in adverse events. Major bleeding occurred during the first six months in three patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , but in no patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      or LMWH. Minor bleeding occurred in 2.7, 0.5, and 1.4 percent of patients, respectively.",
"     </li>",
"     <li>",
"      The rate of serious thromboembolic events was lower with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      than rates reported with these agents in other trials. In comparison, the rate of thromboembolism with LMWH was similar to that reported in other trials.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a second phase III trial, 342 younger adults (median age 58 years) with previously untreated myeloma received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    plus low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (Rd) for four cycles followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    for stem cell mobilization and collection before consolidation with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , and lenalidomide (MPR) or melphalan 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/59\">",
"     59",
"    </a>",
"    ]. Patients with no clinical indication or contraindication to specific VTE prophylaxis were randomly assigned to receive either low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or LMWH (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    40 mg daily) during treatment with Rd and MPR. When compared with LMWH, low-dose aspirin resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A similar incidence of the primary composite endpoint of confirmed symptomatic DVT, pulmonary embolism, arterial thrombosis, any acute cardiovascular event, or sudden otherwise unexplained death in the first six months after random assignment (2.27 versus 1.20 percent, respectively).",
"     </li>",
"     <li>",
"      A similar rate of confirmed symptomatic DVT (1.14 versus 1.20 percent). All three cases of pulmonary embolism occurred in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      treated group.",
"     </li>",
"     <li>",
"      There were no acute cardiovascular events, arterial thromboses, or sudden deaths in either group.",
"     </li>",
"     <li>",
"      There were no major bleeding episodes in either group. The one minor bleeding episode (gastrointestinal bleeding) was seen in a patient receiving LMWH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These trials suggest that low, fixed-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , prophylactic dose LMWH, and low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    are all acceptable choices of VTE prophylaxis in standard risk patients. All three options lowered the incidence of VTE to less than 5 percent compared with an expected rate of more than 20 percent. It is unknown how these regimens would compare with VTE prophylaxis with therapeutic adjusted-dose warfarin (INR 2.0 to 3.0) or therapeutic dose LMWH. Use of aspirin is simpler and less expensive than LMWH. Of importance, these trials excluded patients thought to be at higher risk of thromboembolic events due to a history of VTE, severe cardiac disease, immobilization, uncontrolled diabetes, recent surgery, or ongoing infections. Such patients should be considered for more intensive VTE prophylaxis. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Thalidomide-based therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H642162830\">",
"    <span class=\"h3\">",
"     High risk setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving immunomodulatory drugs who have two or more risk factors or are receiving concomitant high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (&ge;480 mg per month),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , or multiagent chemotherapy are considered at higher risk of VTE. The ideal agent for VTE prophylaxis in this setting is unknown and clinical practice varies widely. For patients at higher risk of VTE treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    - or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    -containing therapy, we suggest the use of prophylactic dose of low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (LMWH) or therapeutic anticoagulation with either LMWH or adjusted-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    with a target INR of 2.0 to 3.0 rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . This preference is largely based upon the data suggesting efficacy of full dose warfarin and LMWH and the uncertainty of the efficacy of aspirin in this setting. The choice of prophylactic LMWH versus full anticoagulation in this setting may be based in part on the patient&rsquo;s risk for bleeding complications (see",
"    <a class=\"local\" href=\"#H642162838\">",
"     'Patients at high risk of bleeding'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The choice between LMWH and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is made based upon the clinical circumstances. As an example, LMWH may be preferred in patients who are likely to develop thrombocytopenia (such as those receiving chemotherapy) because of its short half-life and suggested lower risk of secondary bleeding. In contrast, warfarin might be preferred in patients with an estimated glomerular filtration rate below 30",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    If LMWH is given in this setting, dose reduction is suggested. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     \"Enoxaparin: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There have been no randomized trials comparing VTE prophylaxis strategies in this higher risk population. Single-arm studies suggest that the use of either full-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or prophylactic dose LMWH reduces the incidence of VTE associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    therapy. Data on the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in this setting have been mixed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362987967\">",
"    <span class=\"h4\">",
"     Warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Full-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , with a target INR of 2.0 to 3.0, may be used for VTE prophylaxis in high-risk patients with multiple myeloma being treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    combinations. The potential benefit of full-intensity anticoagulation with warfarin, in comparison to a fixed low-dose warfarin, is suggested by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, VTE prophylaxis with a fixed, low dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      was inadequate to prevent VTE in patients undergoing myeloma induction therapy with chemotherapy plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      (400",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/18\">",
"       18",
"      </a>",
"      ]. Eleven of 35 patients (31 percent) treated in this fashion developed VTE. In an update of the experience from this center, the incidence of VTE among 162 patients receiving low-dose warfarin as prophylaxis during combined chemotherapy and thalidomide induction therapy was 34 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second report, prophylaxis with low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      was not effective in preventing VTE in myeloma patients being treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/17\">",
"       17",
"      </a>",
"      ]. Six of 24 patients given low-dose warfarin developed VTE (25 percent), compared with none of 16 patients treated with full dose warfarin (target INR 2.0 to 3.0) or low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      In a retrospective review in 131 patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      , VTE was noted in 18 of 76 patients (24 percent) not receiving anticoagulation and 3 of 55 patients (5 percent) receiving either low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (1 of 37, 3 percent) or conventional-dose warfarin (2 of 18, 11 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/22\">",
"       22",
"      </a>",
"      ]. The effectiveness of low-dose warfarin in this report may be explained by the lower",
"      <span class=\"nowrap\">",
"       mean/median",
"      </span>",
"      dose of thalidomide (200",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      used in these patients, although there are no data clearly demonstrating a dose-effect relationship for thalidomide and thrombosis risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, full dose prophylactic anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    appears effective in reducing the incidence of VTE associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    therapy, although only a small number of patients have been evaluated. More data are needed to determine the relative efficacies of low-dose versus full-dose warfarin prophylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362987974\">",
"    <span class=\"h4\">",
"     Low molecular weight heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of prophylactic doses of the low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (LMWH)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    SQ) appears to reduce the frequency of thrombotic events in myeloma patients receiving immunomodulatory therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the context of a randomized trial of more than 400 patients, the incidence of VTE among patients at high risk for VTE treated with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      containing regimen plus daily LMWH prophylaxis was not statistically different from that seen in patients treated with a chemotherapy regimen that did not contain thalidomide and who were not given VTE prophylaxis (9 versus 5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      , the first 65 patients assigned to treatment with thalidomide did not receive prophylaxis and had an incidence of VTE of 20 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/31\">",
"       31",
"      </a>",
"      ]. Because of this high incidence, the next 64 patients received thromboprophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      SQ) for the first four cycles (months) of therapy, with an incidence of VTE of 3.1 percent (two patients). These two patients developed VTE within two months of discontinuation of enoxaparin.",
"     </li>",
"     <li>",
"      In a randomized trial of high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      with autologous hematopoietic cell rescue with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      therapy, VTE was diagnosed in 34 percent of the initial 162 patients randomly assigned to receive thalidomide in the absence of VTE prophylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/60\">",
"       60",
"      </a>",
"      ]. The subsequent 152 patients randomly assigned to thalidomide received prophylactic LMWH, but still demonstrated an incidence of VTE of 24 percent, a concerning rate of thrombosis. Therapeutic anticoagulation might be considered during induction therapy with the intensive, anthracycline-containing regimen used in this particular report.",
"     </li>",
"     <li>",
"      A single institution retrospective study reported that only one in 45 patients with relapsed refractory myeloma treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      given in conjunction with LMWH developed VTE [",
"      <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the data are mixed, these results suggest that LMWH decreases the rate of VTE among the patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    -containing regimens to less than 10 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362988005\">",
"    <span class=\"h4\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    appears to be an acceptable form of VTE prophylaxis among patients with multiple myeloma at standard risk of developing VTE during treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    -containing combination therapy. However, low dose aspirin has not been directly compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or LMWH in the treatment of patients at high risk of developing VTE. (See",
"    <a class=\"local\" href=\"#H642162822\">",
"     'Standard risk setting'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Investigators at the Cleveland Clinic evaluated the effectiveness of low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (81",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in reducing the risk of thrombosis following the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/37\">",
"     37",
"    </a>",
"    ]. In contrast to the high rate of VTE (58 percent) in myeloma patients treated with DVd (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ) plus thalidomide alone, only 15 of 84 patients (18 percent) treated with the same regimen plus 81 mg or aspirin daily developed DVT. While the risk of DVT using low-dose aspirin was lower in this non-randomized comparison (ie, 18 versus 58 percent), it was not completely protective against the development of thrombosis.",
"   </p>",
"   <p>",
"    It is not clear whether the risk of thrombosis can be further reduced using a higher dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (eg, 325",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or whether aspirin may be sufficient for patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . Prospective studies of lenalidomide plus high-dose dexamethasone reported VTE rates in the range of 20 percent when aspirin was used as thromboprophylaxis during therapy regimens containing high-dose dexamethasone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/48,63\">",
"     48,63",
"    </a>",
"    ]. In contrast, in a report of a phase II trial of lenalidomide plus high-dose dexamethasone induction therapy in 34 patients with newly-diagnosed myeloma, there was one thrombotic event (3 percent) when 80 to 325",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of aspirin (physicians' discretion) was used as thrombosis prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H642162838\">",
"    <span class=\"h3\">",
"     Patients at high risk of bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are at high risk of complications due to bleeding on anticoagulation may not be candidates for pharmacologic VTE prophylaxis. This includes patients with a known bleeding lesion, such as a peptic ulcer, or a recent intracranial hemorrhage. Mechanical methods of thromboprophylaxis, such as graduated compression stockings, intermittent pneumatic compression devices and the venous foot pump reduce stasis within the leg veins and reduce the frequency of VTE in other patient populations. Such methods may be considered for hospitalized patients at standard or high risk of VTE who are also at high risk of complications from bleeding on anticoagulation. When used in all of these circumstances, it is recommended that consideration be given to the use of a pharmacologic agent, such as LMWH, as soon as the bleeding risk becomes acceptably low or when the bleeding lesion or bleeding risk has been reversed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=see_link&amp;anchor=H24#H24\">",
"     \"Prevention of venous thromboembolic disease in medical patients\", section on 'Mechanical methods of thromboprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H642162846\">",
"    <span class=\"h2\">",
"     Length of prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not known whether VTE prophylaxis can be safely discontinued in patients receiving prolonged therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    -containing regimens. VTE prophylaxis is generally administered as long as active therapy is continued [",
"    <a class=\"abstract\" href=\"UTD.htm?28/57/29594/abstract/14\">",
"     14",
"    </a>",
"    ]. The risk of VTE appears to be greatest in the first 6 to 12 months of treatment. The risk appears to decrease after this and is lower among patients treated for relapsed disease than for patients with previously untreated myeloma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H642162936\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND MANAGEMENT OF VENOUS THROMBOEMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of VTE is suspected in patients who develop calf or thigh pain, unilateral edema, or swelling with a difference in calf diameters; warmth, tenderness, or erythema of the skin,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    superficial venous dilation; a palpable cord; chest pain, shortness of breath, or tachycardia. The diagnosis of VTE is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=see_link\">",
"     \"Diagnosis of suspected deep vein thrombosis of the lower extremity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of VTE in patients with multiple myeloma is similar to the management of VTE in the general population. Therapeutic (full dose) anticoagulation is indicated for patients with VTE and should be started immediately. There have been no studies investigating whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    should be temporarily held at the time of VTE diagnosis while therapeutic anticoagulation is being achieved. Given the prothrombotic effects of thalidomide and lenalidomide, we suggest holding these agents until therapeutic anticoagulation is achieved.",
"   </p>",
"   <p>",
"    For patients with VTE, therapeutic anticoagulation should be continued for the total duration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    therapy. If there have been no further VTE episodes while receiving thalidomide or lenalidomide plus therapeutic anticoagulation, we suggest that anticoagulation be stopped one month after these agents have been discontinued, provided that the patient has been receiving therapeutic anticoagulation for a minimum of three months. This differs somewhat from general recommendations related to the duration of anticoagulation for VTE in cancer patients, in which longer (or indefinite) anticoagulation is common. Since stoppage of the immunomodulatory drug modifies the overall VTE risk of the patient, we feel that indefinite anticoagulation should be considered only in myeloma patients who have recurrent VTE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H25#H25\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Length of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who have developed a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    - or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    -associated venous thromboembolism (VTE) and are receiving therapeutic anticoagulation, as well as patients who are receiving anticoagulation for other reasons (eg, atrial fibrillation, prior VTE), can be cautiously treated with thalidomide or lenalidomide, with an acceptable risk of subsequent episodes of VTE (approximately 10 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with multiple myeloma treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      or a thalidomide analogue such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      in combination with other agents (eg, glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , or erythropoietin) have a rate of venous thromboembolism (VTE) greater than 20 percent. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Thalidomide-based therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with multiple myeloma treated with a combination chemotherapy regimen that contains",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      , we recommend the routine use of VTE prophylaxis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). VTE prophylaxis should be continued for as long as the patient is receiving treatment with thalidomide or lenalidomide.",
"     </li>",
"     <li>",
"      The choice of thromboprophylaxis needs to consider the baseline risk of VTE associated with a given regimen and patient population. Our approach stratifies patients into one of three groups based upon 10 risk factors (body mass index &ge;30",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      previous VTE, central venous catheter or pacemaker, cardiac disease, chronic renal disease, diabetes, acute infection, immobilization, use of erythropoietin, and inherited thrombophilia) (see",
"      <a class=\"local\" href=\"#H642163521\">",
"       'Risk stratification'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients being treated with immunomodulatory drugs who have two or more risk factors or are receiving concomitant high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (&ge;480 mg per month),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , or multiagent chemotherapy are considered to be at higher risk for VTE. For patients at higher risk of VTE treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      - or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      -containing therapy, we suggest the use of prophylactic dose low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (LMWH) or therapeutic adjusted-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      with a target INR of 2.0 to 3.0 rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H642162830\">",
"       'High risk setting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with no or one risk factor who are not receiving high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , or multiagent chemotherapy are considered to be at standard risk for VTE. For patients at standard risk for VTE, we suggest VTE prophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      or prophylactic dose LMWH (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). &nbsp;(See",
"      <a class=\"local\" href=\"#H642162822\">",
"       'Standard risk setting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients receiving either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      or a thalidomide analogue as a single agent are at lower risk for VTE and do not require VTE prophylaxis. (See",
"      <a class=\"local\" href=\"#H642162815\">",
"       'Lower risk setting'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VTE prophylaxis is generally administered as long as combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      is continued. (See",
"      <a class=\"local\" href=\"#H642162846\">",
"       'Length of prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis and management of VTE in patients with multiple myeloma is similar to the diagnosis and management of VTE in the general population. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=see_link\">",
"       \"Diagnosis of suspected deep vein thrombosis of the lower extremity\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"       \"Diagnosis of acute pulmonary embolism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"       \"Treatment of lower extremity deep vein thrombosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link\">",
"       \"Treatment of acute pulmonary embolism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who develop VTE and continue treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      , we suggest that therapeutic anticoagulation continue for the duration of their treatment with these agents (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If there have been no further VTE episodes while receiving thalidomide or lenalidomide plus therapeutic anticoagulation, we suggest that anticoagulation be stopped one month after these agents have been discontinued, provided that the patient has been receiving therapeutic anticoagulation for a minimum of three months and has no other indication for anticoagulation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H642162936\">",
"       'Diagnosis and management of venous thromboembolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the potential for gastric irritation with or without thrombocytopenia, we suggest concurrent use of either an H2-blocker or a proton pump inhibitor when",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      is used in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , corticosteroids,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/1\">",
"      Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol 2003; 21:4444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/2\">",
"      Corso A, Lorenzi A, Terulla V, et al. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol 2004; 83:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/3\">",
"      Kaushal V, Kaushal GP, Melkaveri SN, Mehta P. Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J Thromb Haemost 2004; 2:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/4\">",
"      Zangari M, Saghafifar F, Anaissie E, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 2002; 13:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/5\">",
"      Elice F, Fink L, Tricot G, et al. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006; 134:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/6\">",
"      Deitcher SR, Choueiri T, Srkalovic G, Hussein MA. Acquired activated protein C resistance in myeloma patients with venous thromboembolic events. Br J Haematol 2003; 123:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/7\">",
"      Minnema MC, Fijnheer R, De Groot PG, Lokhorst HM. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003; 1:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/8\">",
"      Johnson DC, Corthals S, Ramos C, et al. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood 2008; 112:4924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/9\">",
"      Tewari P, Kenny E, Staines A, et al. Genetic variants in XRRC5 may predict development of venous thrombotic events in myeloma patients on thalidomide. Blood 2009; 113:5691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/10\">",
"      Cini M, Zamagni E, Valdr&eacute; L, et al. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. Eur J Haematol 2010; 84:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/11\">",
"      Pal R, Monaghan SA, Hassett AC, et al. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood 2010; 115:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/12\">",
"      Carrier M, Le Gal G, Tay J, et al. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 2011; 9:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/13\">",
"      Scarpace SL, Hahn T, Roy H, et al. Arterial thrombosis in four patients treated with thalidomide. Leuk Lymphoma 2005; 46:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/14\">",
"      Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/15\">",
"      Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/16\">",
"      Mileshkin L, Biagi JJ, Mitchell P, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003; 102:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/17\">",
"      Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/18\">",
"      Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004; 126:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/19\">",
"      Srkalovic G, Cameron MG, Rybicki L, et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004; 101:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/20\">",
"      Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006; 132:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/21\">",
"      Prince HM, Schenkel B, Mileshkin L. An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2007; 48:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/22\">",
"      Ikhlaque N, Seshadri V, Kathula S, Baumann MA. Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol 2006; 81:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/23\">",
"      Rajkumar SV. Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clin Proc 2005; 80:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/24\">",
"      Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007; 82:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/25\">",
"      Anagnostopoulos A, Weber D, Rankin K, et al. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003; 121:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/26\">",
"      Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20:4319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/27\">",
"      Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/28\">",
"      Hassoun H, Reich L, Klimek VM, et al. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Haematol 2006; 132:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/29\">",
"      Facon T, Mary JY, Hulin C, et al. Randomized clinical trial comparing melphalan-prednisone (MP), MP-thalidomide (MP-thal), and high-dose therapy using melpalan 100 mg/m(2) (MEL100) for newly-diagnosed myeloma patients aged 65-75 years. Interim analysis of the IFM 99-06 trial (abstract). Blood 2004; 104:63a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/30\">",
"      Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009; 27:3664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/31\">",
"      Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/32\">",
"      Williams CD, Byrne JL, Sidra G, et al. Combination chemotherapy with cyclophosphamide, thalidomide, and dexamethasone achieves a high response rate in patients with newly-diagnosed, VAD-refractory and relapsed myeloma (abstract). Blood 2004; 104:419a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/33\">",
"      Sch&uuml;tt P, Ebeling P, Buttkereit U, et al. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Eur J Haematol 2005; 74:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/34\">",
"      Zervas K, Dimopoulos MA, Hatzicharissi E, et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol 2004; 15:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/35\">",
"      Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/36\">",
"      Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/37\">",
"      Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005; 80:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/38\">",
"      Hussein MA, Baz R, Srkalovic G, et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc 2006; 81:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/39\">",
"      Offidani M, Corvatta L, Piersantelli MN, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 2006; 108:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/40\">",
"      Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 2009; 146:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/41\">",
"      Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100:3063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/42\">",
"      Barlogie B. Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience. Semin Hematol 2003; 40:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/43\">",
"      List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/44\">",
"      Yang X, Brandenburg NA, Freeman J, et al. Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques. Clin Drug Investig 2009; 29:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/45\">",
"      Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/46\">",
"      Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/47\">",
"      Rajkumar SV, Blood E. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006; 354:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/48\">",
"      Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010; 116:5838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/49\">",
"      Rajkumar SV, Jacobus S, Callender N, et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group (abstract). J Clin Oncol 2007; 25:968s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/50\">",
"      Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/51\">",
"      Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004; 22:3269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/52\">",
"      Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009; 27:5008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/53\">",
"      Richardson PG, Siegel D, Baz R, et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 2013; 121:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/54\">",
"      Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02. Blood 2013; 121:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/55\">",
"      Jagannath S, Hofmeister CC, Siegel DS, et al. Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis (abstract 450). Blood 2012; 120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/56\">",
"      Menon SP, Rajkumar SV, Lacy M, et al. Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer 2008; 112:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/57\">",
"      Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25:5490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/58\">",
"      Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 2011; 29:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/59\">",
"      Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 2012; 119:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/60\">",
"      Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/61\">",
"      Minnema MC, Breitkreutz I, Auwerda JJ, et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004; 18:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/62\">",
"      Klein U, Kosely F, Hillengass J, et al. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol 2009; 88:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/63\">",
"      Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/64\">",
"      Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106:4050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/57/29594/abstract/65\">",
"      Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:381S.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1332 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-8913731101-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_57_29594=[""].join("\n");
var outline_f28_57_29594=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H642162287\">",
"      POTENTIAL MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H642162558\">",
"      INCIDENCE AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H642162566\">",
"      General risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Thalidomide-based therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Single agent thalidomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Thalidomide plus dexamethasone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Thalidomide plus melphalan and prednisone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Thalidomide plus anthracycline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Thalidomide analogues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Lenalidomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Pomalidomide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      VENOUS THROMBOEMBOLISM PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H642162808\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H642163521\">",
"      - Risk stratification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H642162815\">",
"      - Lower risk setting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H642162822\">",
"      - Standard risk setting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H642162830\">",
"      - High risk setting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H362987967\">",
"      Warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H362987974\">",
"      Low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H362988005\">",
"      Aspirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H642162838\">",
"      - Patients at high risk of bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H642162846\">",
"      Length of prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H642162936\">",
"      DIAGNOSIS AND MANAGEMENT OF VENOUS THROMBOEMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body mass index (BMI; Quetelet's index)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=related_link\">",
"      Diagnosis of suspected deep vein thrombosis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6730?source=related_link\">",
"      Drug-induced thrombosis and vascular disease in patients with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=related_link\">",
"      Enoxaparin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18282?source=related_link\">",
"      Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=related_link\">",
"      Overview of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1224?source=related_link\">",
"      Pathogenesis of the hypercoagulable state associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=related_link\">",
"      Prevention of venous thromboembolic disease in medical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_57_29595="Frequency appendiceal neoplasms";
var content_f28_57_29595=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of appendiceal neoplasms found in 7970 appendectomy specimens",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Neoplasm",
"       </td>",
"       <td class=\"subtitle1\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Carcinoid",
"       </td>",
"       <td>",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Benign tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mucinous cystadenoma",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Villous adenoma",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Malignant tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\" rowspan=\"1\">",
"        Primary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Adenocarcinoma",
"       </td>",
"       <td class=\"sublist_other\">",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Lymphoma",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Secondary",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Total",
"       </td>",
"       <td>",
"        74",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Connor SJ, Hanna GB, Frizelle FA. Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7970 appendectomies. Dis Colon Rectum 1998; 41:75.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_57_29595=[""].join("\n");
var outline_f28_57_29595=null;
var title_f28_57_29596="Management of hypocalcemia after thyroid surgery";
var content_f28_57_29596=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F59019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F59019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Management of hypocalcemia after thyroid surgery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"25%\">",
"     </colgroup>",
"     <colgroup width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Postoperative day",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serum tests",
"       </td>",
"       <td class=\"subtitle1\">",
"        Therapy",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Night of surgery",
"       </td>",
"       <td>",
"        Calcium in the evening (approximately 8 PM)",
"       </td>",
"       <td>",
"        <strong>",
"         Ca &lt;7.5 mg/dL:",
"        </strong>",
"        Calcitriol 0.5 mcg three times daily x three days and calcium gluconate 3 g/L D5 1/2 normal saline IV at 100 mL/hour",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Day 1",
"       </td>",
"       <td>",
"        Calcium and phosphorus in the morning (approximately 6 AM); if Ca &lt;7.5 mg/dL, add magnesium",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Ca &lt;7.5 mg/dL:",
"         </strong>",
"         Calcitriol 0.5 mcg twice daily x three days and adjust depending upon calcium response and calcium gluconate 3 g/L D5 1/2 normal saline IV at 100 mL/hour and calcium carbonate (1 to 4 g elemental calcium) by mouth daily in divided doses depending upon calcium response",
"        </p>",
"        <p>",
"         <strong>",
"          Ca 7.5 to 8.0 mg/dL:",
"         </strong>",
"         Calcitriol 0.5 mcg twice daily x three days and adjust depending upon calcium response and calcium carbonate (1 to 4 g elemental calcium) by mouth daily in divided doses depending upon calcium response",
"        </p>",
"        <p>",
"         <strong>",
"          Ca &gt;8.0 mg/dL:",
"         </strong>",
"         Calcium carbonate (1 g elemental calcium) by mouth twice daily",
"        </p>",
"        <strong>",
"         Mg &lt;2 mg/dL:",
"        </strong>",
"        Magnesium sulfate 4 g in 100 mL normal saline IV at 33 mL/hour and magnesium oxide 400 mg by mouth twice daily x one month",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Day 2 to 4",
"       </td>",
"       <td>",
"        If day 1 Ca &le;8.0 mg/dL, total calcium and phosphorus",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Ca &lt;7.5 mg/dL and symptomatic:",
"         </strong>",
"         Calcitriol 0.25 mcg three times daily and calcium gluconate 3 g/L D5 1/2 normal saline IV at 100 mL/hour and calcium carbonate (1 to 4 g elemental calcium) by mouth daily in divided doses and modify based upon calcium response",
"        </p>",
"        <p>",
"         <strong>",
"          Ca &lt;7.5 mg/dL and asymptomatic:",
"         </strong>",
"         Calcitriol 0.25 mcg three times daily and calcium carbonate (1 to 4 g elemental calcium) by mouth daily in divided doses and modify based upon calcium response",
"        </p>",
"        <p>",
"         <strong>",
"          Ca 7.5 to 8.4 mg/dL or P &ge;4.5 mg/dL:",
"         </strong>",
"         Calcitriol 0.25 mcg daily and calcium carbonate (1 to 4 g elemental calcium) by mouth daily in divided doses and modify based upon calcium response",
"        </p>",
"        <p>",
"         <strong>",
"          Ca 8.5 to 9.4 mg/dL and P &le;4.5 mg/dL:",
"         </strong>",
"         Calcium carbonate (1 to 4 g elemental calcium) by mouth daily in divided doses and modify based upon calcium response",
"        </p>",
"        <strong>",
"         Ca &ge;9.5 mg/dL:",
"        </strong>",
"        No therapy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    To convert serum calcium to mmol/L, divide by 4. To convert serum phosphorus to mmol/L, divide by 3.1.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_57_29596=[""].join("\n");
var outline_f28_57_29596=null;
var title_f28_57_29597="Meta analysis ACEI in HF";
var content_f28_57_29597=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ACE inhibitors reduce mortality in patients with left ventricular dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 336px; height: 245px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A meta-analysis of five trials involving 12,763 patients with left ventricular dysfunction who were followed for 35 months found that therapy with an angiotensin converting enzyme (ACE) inhibitor significantly reduced mortality (23 versus 26.8 percent, odds ratio 0.80, p &lt;0.0001). There is continuing divergence in the mortality curves during the follow-up that exceeds four years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Flather MD, Yusuf S, Kober L, et al. Lancet 2000; 355:1575.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_57_29597=[""].join("\n");
var outline_f28_57_29597=null;
var title_f28_57_29598="Screen quest future injury";
var content_f28_57_29598=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Violence victims screening questions risk of future injury due to violence",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Protective factors",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Percent",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Odds of association with violence perpetration if protective factor not present",
"         <br/>",
"         (OR 95% CI)",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        p value",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        1. Do your parents expect you to do well at school?",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        6.1 (1.1-33.83)",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        0.02",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Most of the time",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sometimes",
"       </td>",
"       <td>",
"        6.1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rarely/never",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        2. Are your grades mostly:",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        5.8 (1.7-19.2)",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        0.002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A/B average",
"       </td>",
"       <td>",
"        77.9",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C average",
"       </td>",
"       <td>",
"        16.6",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        D/F average",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\">",
"        Risk factors",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent positive",
"       </td>",
"       <td class=\"subtitle1\">",
"        Odds of association with future violence perpetration if risk factor present",
"        <br/>",
"        (OR 95% CI)",
"       </td>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        3. Have you been suspended from school in the last year?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Yes",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        47 (11.1-201)",
"       </td>",
"       <td>",
"        0.000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        4. How many fights have you been in during the last year?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1-5",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        10.7 (3.2-35.6)",
"       </td>",
"       <td>",
"        0.000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        5. Have you ever smoked marijuana or used other drugs?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Yes",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        4.6 (1.5-14.2)",
"       </td>",
"       <td>",
"        0.005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        6. Have you or your friends ever been in trouble with the law?*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Yes",
"       </td>",
"       <td>",
"        38.2",
"       </td>",
"       <td>",
"        2.1 (0.72-6.2)",
"       </td>",
"       <td>",
"        0.13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Males",
"       </td>",
"       <td>",
"        40.8",
"       </td>",
"       <td>",
"        8.6 (1.4-54.2)",
"       </td>",
"       <td>",
"        0.02",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Females",
"       </td>",
"       <td>",
"        36.2",
"       </td>",
"       <td>",
"        0.85 (0.19-3.8)",
"       </td>",
"       <td>",
"        0.56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        7. Are you or your friends involved with a gang or tagging crew?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Yes",
"       </td>",
"       <td>",
"        7.0",
"       </td>",
"       <td>",
"        4.6 (0.93-23.0)",
"       </td>",
"       <td>",
"        0.04",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        8. Do you feel you are hyperactive, or have you ever been diagnosed with ADHD?*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Yes",
"       </td>",
"       <td>",
"        14.8",
"       </td>",
"       <td>",
"        3.0 (0.88-10.3)",
"       </td>",
"       <td>",
"        0.07",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Males",
"       </td>",
"       <td>",
"        15.9",
"       </td>",
"       <td>",
"        0.83 (0.08-8.5)",
"       </td>",
"       <td>",
"        0.69",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Females",
"       </td>",
"       <td>",
"        14.0",
"       </td>",
"       <td>",
"        6.4 (1.3-30.7)",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        9. Have you had any friends that have committed suicide?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Yes",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        3.7 (0.93-14.4)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        10. Have you ever been injured in a fight?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Yes",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        4.3 (1.1-17.6)",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        11. When was the last time you hurt someone else in a fight?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        In the past month",
"       </td>",
"       <td>",
"        4.3",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Between 1-6 months ago",
"       </td>",
"       <td>",
"        6.7",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Between 6-12 months ago",
"       </td>",
"       <td>",
"        3.7",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Over 1 year ago",
"       </td>",
"       <td>",
"        11.6",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Never",
"       </td>",
"       <td>",
"        73.8",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Positive if &le;12 months ago",
"       </td>",
"       <td>",
"        14.6",
"       </td>",
"       <td>",
"        24.6 (4.3-138.7)",
"       </td>",
"       <td>",
"        0.000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        12. When was the last time you watched a fight?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        In the past month",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Between 1-6 months ago",
"       </td>",
"       <td>",
"        13.4",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Between 6-2 months ago",
"       </td>",
"       <td>",
"        11.6",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Over 1 year ago",
"       </td>",
"       <td>",
"        22.6",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Never",
"       </td>",
"       <td>",
"        27.4",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Positive if &le;12 months ago",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        6.1 (1.6-22)",
"       </td>",
"       <td>",
"        0.004",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        13. How many times has someone beat you up in the last 6 months:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td>",
"        91.2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1-6",
"       </td>",
"       <td>",
"        9.8",
"       </td>",
"       <td>",
"        6.2 (1.1-34.2)",
"       </td>",
"       <td>",
"        0.02",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        14. How many times has someone asked you to fight in the last 6 months:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1-6",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        3.6 (1.1-11.7)",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent.",
"     <br/>",
"     * Questions 6 and 8 display gender differences, since these two questions reveal statistically-significant differences between genders.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Sigel E, Hart J, Hoffenberg A, Dodge M. \"Development and psychometric properties of a violence screening tool for primary care.\" J Adolesc Health 2011; 48:358. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_57_29598=[""].join("\n");
var outline_f28_57_29598=null;
var title_f28_57_29599="Arteriovenous malformation";
var content_f28_57_29599=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Arteriovenous malformation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right uterine angiography on a 42-year-old woman who presented with sudden uterine bleeding. Angiogram shows very dilated uterine artery and veins with nidus of dilated tangled blood vessels within the uterine wall consistent with arteriovenous malformation (AVM).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_57_29599=[""].join("\n");
var outline_f28_57_29599=null;
